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UN i VERS
A b s t r a c t
The synthesis of two inositol phosphates (part I) and a range of PEGylated polyamines (part II) 
is described. D-myo-Inositol 1,4,5-trisphosphate was prepared in five steps from myo-inositol in a 
synthesis involving a novel protection step - the incomplete hydrolysis of an orthoacetate 
orthoester to yield acetate protection. A sample was found to be equipotent for calcium release 
at the D-myo-Inositol 1,4,5-trisphosphate receptor compared to a commercial sample. DL- 
(l,3,5/2,4,6)-6-Hydroxymethylcyclohexane-l,2,3,4,5-pentol 1,2,4,7-tetrakisphosphate, a novel 
jcy/fo-inositol-based analogue of D-myo-inositol 1,3,4,5-tetrakisphosphate bearing a 
hydroxymethylphosphate at the pseudo 3-position, was synthesised from myo-inositol. It was 
found to be inactive at D-wzyo-inositol 1,4,5-trisphosphate receptors and was used as a standard 
in studies involving the biology of D-myo-inositol 1,4,5-trisphosphate 3-kinase. The polyanionic 
nature of biological phosphates such as inositol phosphates and DNA means it is difficult for 
these molecules to cross cell membranes; this is a particular problem for the delivery of DNA in 
gene therapy. For the second part of this thesis, attention is turned to the delivery of DNA. A 
range of polyamines conjugated to mPEGs were synthesised as potential gene delivery vectors. 
A number of compounds based on the linear tetramine thermine were constructed by coupling 
mPEG glycidyl ethers (of mPEG 550 and mPEG 2000) to Boc-protected thermine derivatives. 
Ethidium bromide assays suggested these conjugates formed complexes with DNA with weak 
interactions. A linear hexamine was synthesised by a cyanoethylation/reduction strategy from 
thermine and coupled to mPEG 550 again using the glycidyl ether. Two branched polyamines 
were synthesised, one pentamine and one triamine, and coupled to mPEG 550 via a spacer on 
their central nitrogen, using the mPEG 550 chloroformate. A stronger interaction with DNA 
was demonstrated for the hexamine based conjugates and the branched pentamine. The ability 
of three of the conjugates to transfer reporter genes to mouse muscle and tumour tissue in vivo 
was evaluated in tumour-bearing mice. Two of the conjugates were found to enhance reporter 
gene transfer to tumours compared to naked DNA.
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PA R Tl: 
Sy n t h e s is  o f  I n o s it o l  P o l y p h o s p h a t e s
The physiological significance of the stimulation by acetylcholine o f the turnover ofphosphate and phosphoryl units 
in the phospholipids o f pancreas and brain remains unknown, although these and earlier studies do point to the 
phospholipids as participating in the physiobgical events throzvn into pby by acetylcholine.
[Hokin and Hokin, 1955]
Micromobr concentrations o f inositol 1,4,5-trisphosphate release Ca2+ from a non-mitochondrial intracellular 








Communication between cells in a  multicellular organism is essential for all physiological 
processes. A range of substances, from small molecules to proteins mediate this intercellular 
communication. The majority of these substances (hormones, neurotransmitters, cytokines, 
growth factors, eicosanoids), so-called first messengers, are charged hydrophilic molecules and are 
unable to pass through the lipid bilayer of the plasma membrane. Therefore, in order to exert 
their effect on cells they stimulate extracellular receptors causing the release or production of a 
substance within the cell, a so called second messenger. It is the second messenger that elicits the 
cellular response. This arrangement also provides a  means of amplifying the signal across the 
cell membrane, one molecule of extracellular 
agonist leads to the production of many molecules 
of second messenger. Further, the same agonist 
may elicit different responses in different tissues 
through its receptors utilising different second 
messengers. There are a number of second 
messengers. The first part of this thesis is 
concerned with the second messenger D-myo-inositol
2 Calcium ions
One o f the most versatile and universal signalling agents in the human body is the calcium ion.
[Berridg eeta l, 1998]
Calcium ions are used as an intracellular signal in many processes including muscle contraction, 
secretion, metabolism, neuronal excitability and proliferation. When intracellular Ca2+ 
concentration is low (10-lOOnM range) cells remain quiescent. With an increase in C a2+ 
concentration (500-1000nM range), cells are activated to perform their particular functions via 
Ca2+ sensors such as calmodulin or troponin C, which transduce the signal into specific cellular 
responses. Therefore, the activity of a  cell depends upon the balance between Ga2+ “O N ” 
mechanisms and Ca2+ “O F F ’ mechanisms. Intracellular Ca2+ concentration may rise by Ca2+ 
entry from outside the cell or by release of Ca2+ from intracellular stores. Ca2+ concentration
* This style of abbreviation for inositol phosphates shall be used throughout. The numbers in brackets 
refer to the positions on the inositol ring of the phosphate groups, and compounds are D-myo 
stereoisomers unless indicated otherwise.
2
Figure 1 D-myo-mositol 1,4,5-tnsphosphate
1,4,5-trisphosphate [Ins( 1,4,5)P3* Figure 1],
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outside the cell is 10000 times greater than that inside and, as the inside is also negatively 
charged, there is a  strong electrochemical gradient in favour of Ca2+ entry.
The plasma membrane may contain a number Ca2+ channels, including voltage-operated 
channels found mainly in excitable cells, which open in response to membrane depolarisation, 
receptor-operated channels activated by extracellular agonists and calcium-release activated 
channels (CRACs) activated by emptying of intracellular Ca2+ stores through a mechanism 
called capacitative Ca2+ entry. When the endoplasmic reticulum Ca2+ store is full, entry of Ca2+ 
through CRACs is inhibited but, when it discharges, the CRACs open. The mechanism by 
which this modulation occurs is not known. It has been suggested [Randriamampita and Tsien, 
1993] that the empty Ca2+ stores release a messenger calcium influx factor that diffuses to the 
membrane and opens the CRACs.
Release of Ca2+ from intracellular stores occurs via two 
main types of Ca2+ channels; the Ins(l,4,5)P3 receptor 
and the ryanodine receptor. Ca2+ release involving the 
Ins(l,4,5)P3 receptor will be considered in detail later.
Cyclic adenosine diphosphate-ribose (cADP-ribose,
Figure 2), a metabolite of nicotinamide adenine 
dinucleotide (NAD), is the endogenous Ca2+ releasing 
ligand for the ryanodine receptor; its main signalling 
function is modulation of Ca2+ induced Ca2+ release 
[Lee, 1997]. The metabolic signals that regulate cADP- 
ribose production and the termination of its action are 
unknown and our knowledge of its metabolic enzymes is 
limited. NAD is converted to cADP-ribose by ADPR cyclase and it is metabolised by cADP- 
ribose hydrolase, an enzyme that may have other functions. Recently, a third molecule capable 
of releasing Ca2+ from intracellular stores has been described, nicotinic acid adenine 
dinucleotide phosphate (NAADP) [Genazzani and Galione, 1997; Lee, 1997]. The release 
mechanism, which is not known, and the stores on which NAADP acts are distinct from those 
of cADP-ribose and Ins(l,4,5)P3.
Once intracellular Ca2H' concentration has risen and the cell has responded, the cell must return 
to its original state in order to receive further signals. There are a  number of Ca2+ “O F F ’ 
mechanisms. Plasma membrane Ca2+ ATPases utilise the energy of ATP to extrude Ca2+ from 
the cell against the electrochemical gradient; in addition, excitable cells use a Na+/C a 2+ 




Figure 2 Cyclic adenosine 
diphosphate-ribose
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3 P hosphoinositide signalling
3.1 Introduction
The membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) is cleaved by 
phospholipase C (PLC) releasing Ins(l,4,5)P3 into the cytosol (scheme 1). The other product of 
this pathway is diacylglycerol (DAG). Both DAG and Ins(l,4,5)P3 act as second messengers. 
Ins(l,4,5)P3 stimulates Ca2+ release from intracellular stores, DAG activates protein kinase-C 
(PKC).
fatty acid chains in inner 
lipid monolayer o f plasma 
membarane
CO CO CO CO
CYTOPIASM




0 - P = 0  
HO |
H? »I O P032'
0 P 0 32'
D-myo-INOSITOL 1,4,5-TRISPHOSPHATE
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Schem e 1 Hydrolysis of phosphatidylinositol 4,5-bisphosphate by phospholipase C.
3 .2  Diacylglycerol
The cellular response to DAG is mediated via the activation of PKC* which phosphorylates 
serine and threonine residues in many target proteins and is implicated in a diverse range of 
cellular processes. The regulation of PKC is the subject of a recent review [Liu and Heckman, 
1998]. Some PKC isozymes are activated by the tumour-promoting phorbol esters and are thus 
thought to affect some aspects of cell cycling. DAG is metabolised by two major pathways. In
* In fact, a family of 11 different PKC isozymes are now known, not all of which are activated by DAG 
[Liu and Heckman, 1998].
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the first, phosphorylation by a kinase enzyme to phosphatidic acid is followed by combination 
with cytidine 5'-monophosphate (CMP) to form CMP-phosphatidate, this in turn is coupled to 
myo-inositol to form phosphatidyl inositol and ultimately PtdIns(4,5)P2. In the second, hydrolysis 
by a lipase leads to the formation of monoacylglycerol and arachidonate, the latter of which is 
used for the synthesis of various eicosanoids.
3.3 Cellular Production of D-myo-Inositol 1,4,5-Trisphosphate
In 1983, Ins(l,4,5)P3 was identified as the phospholipid derived mediator of increased 
intracellular Ca2+ levels [Streb etal, 1983], The events that lead to Ins(l,4,5)P3 production have 
subsequendy been extensively studied and are now well established [Berridge, 1993]. 
Ins(l,4,5)P3 is produced when an agonist binds to an extracellular receptor, causing activation of 
PLC. Many isoforms of PLC have been identified and have been classified into three main 
groups P, y and 8. Activation of PLC occurs through two major types of receptor; those coupled 
to GTP-binding proteins (G-proteins) and those linked to tyrosine kinase. There are numerous 
G-protein coupled receptors and most have seven transmembrane domains. Agonist stimulation 
induces a conformational change in the receptor which causes the heterotrimeric G-protein to 
dissociate into Ga and Gpy subunits, both of which can activate different PLC isoforms. For 
example PLC pi is activated by the a  subunit of the G-protein Gq. The tyrosine kinase-linked 
receptors relay information through a direct interaction between the receptor and PLCyl. 
Upon agonist stimulation, the receptor dimerises and undergoes autophosphorylation of specific 
tyrosine residues. This provides a binding site for PLCyl, which is then phosphorylated and 
begins to hydrolyse PtdIns(4,5)P2. It is not known which receptors or transducers are coupled to 
PLC8 members [Rhee and Choi, 1992]. Some examples of receptors that are now known to 
utilise Ins(l,4,5)P3 are listed in table 1.
ViaPLC-P Via PLC-y
Adrenoceptors: (Xia  c tm  otiD Epidermal growth factor receptor
Angiotensin: ATi Fibroblast growth factor receptor
Bradykinin: BBi BB2 Platelet-derived growth factor receptor
Cholecystokinin: CCKa CCK b T  cell antigen receptor
Histamine: Hi
5 -H T 2A 5-HT2b5-H T 2c
Glutamate: mGlui mGlu5
Muscarinic: Mi M 3 Ms
Thrombin
Table 1 Examples of receptors coupled to PtdIns(4,5)P2 turnover
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3.4 D-myo-Inositol 1,4,5 Trisphosphate Receptors
The Ins(l,4,5)P3 receptors are tetramers. Each subunit consists of three domains: an Ins(l,4,5)P3 
binding N-terminal domain, a regulatory domain containing ATP-binding and phosphorylation 
sites and a C-terminal domain containing six membrane-spanning regions. Both the N-terminal 
and regulatory domains lie free in the cytosol and the C-terminal regions co-operate to form the 
Ca2+ channel. The highly conserved N-terminal region incorporates some 650 amino acid 
residues, rich in positively charged arginine and lysine that may have a role in binding the 
phosphate groups. Upon binding Ins(l,4,5)P3, the receptor undergoes a large conformational 
change leading to Ca2+ channel opening.
Three isoforms have so far been firmly identified, designated type I, II and III; all three have 
been cloned and sequenced. Based on rat sequences, type II has 69% identity with type I, type 
III has 62% [Joseph, 1996]. Fourth and fifth isoforms have been reported based on partial 
sequence information, both having a high degree of identity with type II. Studies using isoform- 
specific antibodies suggest that all cells contain multiple receptor isoforms but that one isoform 
may predominate in a particular tissue or cell type. For example, type I receptors are the major 
isoform found in the brain, particularly enriched in cerebellar Purkinje cells. Furthermore, a 
recent study indicates that these receptors are essential for proper brain function [Matsumoto et 
al, 1996]. In this study, mice lacking type I Ins(l,4,5)P3 receptors were generated by gene 
targeting. Most of the mice died in utero; those that survived had severe ataxia and tonic or tonic- 
clonic seizures and died by the weaning period. Electroencephalography showed that the mice 
suffered from epilepsy. Gross examination of the brain found a reduced size but an apparently 
normal structure; the gross structure of various peripheral tissues appeared normal. Light- 
microscopic examination of the brain and various peripheral tissues showed no significant 
difference from normal mice.
Ins(l,4,5)P3 receptors are largely located in the endoplasmic reticulum membrane as would be 
expected, although they have been shown to be present in the plasma membrane in a number 
of experimental systems [Joseph, 1996]. They have also been found in the outer nuclear 
membrane although, given the contiguity of this membrane with the endoplasmic reticulum 
membrane, this is not surprising.
3.5 Structure-Activity Relationships at Ins(l,4,5)P3 Receptors
A large number Ins(l,4,5)P3 analogues have now been synthesised and it has become obvious 
that the Ins(l,4,5)P3 receptor shows considerable stereo- and regio-specificity in its structural 
requirements for binding and Ca2+ release. The stereospecificity of the receptor is clearly 
demonstrated by the fact that L-Ins(l,4,5)P3 does not release Ca2+ and its binding is 2000 times
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weaker than that of Ins(l,4,5)P3. Further, this collection of analogues has allowed a picture to be 
built up of what substituents on the ring are conducive to binding and Ca2+ release [Potter and 
Lampe, 1995]. It is the 4,5-bisphosphate arrangement that is accepted as the essential 
pharmacophore; deletion of either the 4- or the 5-phosphate abolishes activity. Vicinal 
phosphates at other positions on an inositol ring can mimic this 4,5-bisphosphate arrangement 
to varying degrees. The 6-hydroxyl is important for binding, probably via H-bond interactions 
a nd /o r fixing the conformation of the 5-phosphate. Least important is the 2-hydroxyl; this can 
be changed to equatorial or even deleted with little loss of activity and introduction of large 
substituents at this position is tolerated.
Most modifications of the Ins(l,4,5)P3 molecule 
have resulted in reduced potency in terms of Ca2+ 
release. However, in 1994, the discovery of the 
adenophostins (figure 3) was reported [Takahashi 
et al, 1994]. These molecules, isolated from the 
culture broth of Pemcillium brevicompactum, were 
reported to be around 100-fold more potent 
agonists at the Ins(l,4,5)P3 receptor than 
Ins(l,4,5)P3 itself in cerebellar microsomes.
Although at first glance the molecule looks 
markedly different to Ins(l,4,5)P3, it does bear the 
essential pharmacophore, the vicinal phosphates, 
and they are in a six-membered ring. Further, it 
has a hydroxyl at the position next to the phosphates, mimicking the 6-hydroxyl of Ins(l,4,5)P3 
and its third phosphate may enhance binding in the same way that the 1-phosphate of 
Ins(l,4,5)P3 is thought to. The steric bulk of the adenosine moiety suggests that the receptor has 
a vacant area in this region. At what position this may be analogous to in Ins(l,4,5)P3 itself 
depends upon the orientation in which adenophostin binds. The adenophostins are resistant to 
5-phosphatase and 3-kinase and have prolonged activity as a result.
3.6 Ins(l,4,5)P3 Receptor Antagonists
At present, only a small number of Ins(l,4,5)3 receptor antagonists are known. Most potent are 
the polysulfated polysaccharide heparin and decavanadate (VioC>286') [Potter and Lampe, 
1995], both however have low specificity. Most inositol phosphate analogues that have shown 
any antagonistic activity have also shown some Ca2+ releasing activity, the exception being the





Figure 3 The adenophostins (R= H  
adenophostin A, R =  Ac adenophostin B)
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The polyamines putrescine 1, spermidine 2 and spermine 3 (Figure 4), naturally present in all 
cells, have been shown to inhibit Ins(l,4,5)P3-induced Ca2+ release in rat cerebellar microsomes, 
[Sayers and Michelangeli, 1993] possibly by an effect on the Ins(l,4,5)P3 receptor.
Figure 4 Putrescine, Spermidine, Spermine
Their potency in inhibiting Ca2+ release was related to the number of amino groups (and hence 
the number of charges), the order being spermine > spermidine > putrescine. This paralleled 
their ability to inhibit [3H]Ins(l,4,5)P3 binding. Under the conditions used for the Ca2+ release 
experiments, the inhibition of Ca2+ release was shown not to be due to the formation of a 
complex between Ins(l,4,5)P3 and spermine as, at Im M , spermine inhibited Ins(l,4,5)P3-induced 
C a2+ release by 50%, but spermine-agarose bound essentially no Ins(l,4,5)P3 at that 
concentration. This suggested that the effect of spermine on Ins(l,4,5)P3-induced Ca2+ release 
was due to an effect on the Ins(l,4,5)P3 receptor. However, the study could not show that 
inhibition of [3H]Ins(l,4,5)P3 binding was not due to the formation of a complex between the 
negatively charged phosphates and the positively charged amines.
3.7 Metabolism of Ins(l,4,5)P3
The action of Ins(l,4,5)P3 must be terminated so that the cell is free to respond to further 
signals. Its metabolism (summarised in scheme 2) is complex, generating many other inositol 
phosphates, the roles of which are the subject of much debate. The two most important 
enzymes involved in Ins(l,4,5)P3 metabolism are inositol polyphosphate 5-phosphatase and D- 
myo-Inositol 1,4,5-trisphosphate 3-kinase. A recent study [Sims and Allbritton, 1998], suggests 
that the rate and route of metabolism of Ins(l,4,5)P3 in Xenopus lams oocytes is dependent upon 
Ins(l,4,5)P3 concentration and intracellular free Ca2+ concentration. The rate and route of 
metabolism of [3H]-Ins(l,4,5)P3 was measured in whole oocytes (by microinjection) and in 
cytoplasmic extracts. At low Ins(l,4,5)P3 concentration (lOOnM) and high Ca2+ concentration 
(>lpM), Ins(l,4,5)P3 was metabolised predominantly by 3-kinase, whereas at high Ins(l,4,5)P3 
concentration (8 pM or greater) 5-phosphatase was dominant irrespective of Ca2+ concentration. 
At Ins(l,4,5)P3 and Ca2+ concentrations below 400nM the activities of 5-phosphatase and 3- 
kinase were comparable.
8




























Li+ 1  monophosphatase






Schem e 2 Summary of inositol polyphosphate metabolism
In o sito l P o lyph osph a te  5 -P hosphatases
Inositol polyphosphate 5-phosphatases are a group of isoenzymes that dephosphorylate 
Ins(l,4,5)P3 to inactive Ins(l,4)P2 and can, therefore, be regarded as an effective way of 
deactivating the Ins(l,4,5)P3 signal. There seem to be both cytosolic and membrane-bound 
forms of these enzymes [Verjans et al, 1994]. They appear to be relatively non-selective; many 
inositol phosphates are a substrate for these enzymes including inositol phospholipids, although 
different isoforms may show different degrees of substrate specificity. The first known example 
of an inborn defect in inositol polyphosphate metabolism involves the 5-phosphatases. The gene 
defective in Lowe’s oculocerebrorenal syndrome, an X-chromosome linked condition 
characterised by protean manifestations including mental retardation, numerous eye 
abnormalities and impaired renal function, was found to encode a protein highly homologous 
to an isoform of 5-phosphatase [Attree et al, 1992]. This protein was subsequently produced
9
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recombinantly [Zhang et al, 1995] and, was indeed, found to carry out the reactions of 5- 
phosphatase. Interestingly, it hydrolyses the phospholipid substrate (ie. PtdIns(4,5)P2 to 
PtdIns(4)P) 10- to 30-fold better than 5-phosphatase II, an isoform from human platelets; hence 
the protein is mainly a lipid 5-phosphatase.
There has been success in the synthesis of potent, selective, non-Ca2+ mobilising inhibitors of 5- 
phosphatase, some examples of which are shown in figure 5. The most potent 5-phosphatase 
inhibitor to date is L-c/?iro-2,3,5-trisphosphorothioate 4 (Ki = 230nMt) [Safrany et al, 1994] 
however it is also a partial agonist at the Ins(l,4,5)p3 receptor and a potent inhibitor of 3-kinase. 
L-myo-InositoI 1,4,5-trisphosphorothioate inhibits 5-phosphatase 5 (Ki = 430nM) showing 250- 
fold selectivity over 3-kinase and the m^o-compound myo-inositol 1,3,5-trisphosphorothioate 6 
(Ki = 520nM) shows 475-fold selectivity. More potent, however, is L-cAiro-inositol 1,4,6- 
trisphosphorothioate 7 (K = 300nM) and this compound is also the most selective; it interacts 















Figure 5 Inhibitors of Inositol Polyphosphate 5-Phosphatase 
Insflj 4}5)Ps 3-kinase
D-myo-Inositol 1,4,5-trisphosphate 3-kinase catalyses the phosphorylation of Ins(l,4,5)P3 to 
Ins(l,3,4,5)P4. The roles of 3-kinase and its product, Ins(l,3,4,5)P4, are pertinent to the work 
described in chapter 3 and will be discussed in detail in that chapter.
M ultiple Inositol Polyphosphate Phosphatase (MIPP)
Ins(l,3,4,5)P4 and higher inositol phosphates are metabolised by MIPP. The enzyme can 
hydrolyse the 6-phosphate of Ins(l,3,4,5,6)P5 and Ins(l,4,5,6)P4, and the 3-phosphate of
 ^Human erythrocyte ghost 5-phosphatase-catalysed breakdown of [3H]-Ins(l,4,5)P3 [Safrany et al, 1994].
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Ins(l,3,4,5)P4. Ins(l,3,4,5,6)Ps can be formed independently of phospholipase C by direct 
phosphorylation of inositol [Stephens and Irvine, 1990] and M IPP may function to produce 
Ins(l,4,5)P3, independently of phospholipase C activity. This has been demonstrated in 
Dictyostelium cell homogenates and by a single enzyme purified from rat liver [Van Dijken et al, 
1995]. The presence of MIPP in cell preparations used to study the actions of Ins(l,3,4,5)P4 may 
lead to misleading results, since some observed effects may be due to Ins(l,4,5)P3 produced by 
the action of MIPP on applied Ins(l,3,4,5)P4. This problem has been overcome by using the 3- 
phosphorothioate analogue of Ins( 1,3,4,5)P4 that is resistant to MIPP [Wilcox et al, 1993b], by 
using a MIPP inhibitor such as InsP6 [Wilcox et al, 1993b] or by conducting experiments at 4°C 
which arrests this metabolism [Gawler et al, 1990].
Inosito l 1 ,3 ,4-trisphosphate 5 /6 -k in ase
Ins(l,3,4)P3 is phosphorylated at the 5- or 6-position by inositol 1,3,4-trisphosphate 5/6-kinase. 
The enzyme, which has been purified and characterised from rat liver, has a  high affinity for 
Ins(l,3,4)P3 and is about 5 times more active towards the 6-phosphate than towards the 5- 
phosphate [Abdullah et al, 1992]. The enzyme is not affected by Ca2+/calmodulin or protein 
kinase A or C. It is not known whether its products have signalling functions or whether they are 
just precursors to inositol pentakisphosphates and hexakisphosphate.
4 Aims and objectives of this work
The aim of the work within the first part of this thesis was the synthesis of Ins(l,4,5)P3 via a 
rapid, novel route and the synthesis of an Ins(l,3,4,5)P4 analogue for use in biological studies. It 
was intended to explore the partial hydrolysis of the orthoacetate orthoester of myo-inositol to 
yield acetate ester-protected intermediates. The reaction would be carried out on camphanate 
derivatives that allow a chiral desymmetrisation of the molecule, such that the natural 
enantiomer of Ins(l,4,5)P3 would be obtained. The goal was to see if the reaction could be 
controlled in such a way that a useful yield of a direct precursor to Ins(l,4,5)P3 could be 
obtained. Emphasis was placed upon ease and rapidity of synthesis and consideration given to 
the possibility of obtaining other useful products of the orthoester partial hydrolysis. The second 
overall target was the Ins(l,3,4,5)P4 analogue having a hydroxymethyl phosphate at the 3- 
position. This was to be used as a standard in biological studies involving Ins(l,4,5)P3 3-kinase. 
The molecule may have interesting properties as an Ins(l,3,4,5)P4 surrogate and may prove 
useful in the synthesis of a potential multisubstrate analogue inhibitor of Ins(l,4,5)P3 3-kinase.
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Chapter 2: 
Synthesis of D-myo-Inositol 1,4,5-Trisphosphate
1 Introduction
Chapter 1 gave an overview of the significance of Ins(l,4,5)P3 in animal cell physiology. It can 
be seen that we still have much to learn about the details of this ubiquitous pathway. Thus there 
is continuing demand for supplies of pure homochiral Ins(l,4,5)P3. Many synthetic routes to 
Ins(l,4,5)P3 have been published; they are generally time-consuming, long, linear sequences 
involving extensive chromatography. Hence, a practical, expeditious synthesis would be 
welcome.
2 Synthesis of Inositol Phosphates: General Considerations
When one is designing a synthesis of an inositol phosphate from myo-inositol consideration must 
be paid to a number of key points, namely:
♦ The selective protection of hydroxyl groups. Much attention has been paid to this and there 
are now a large number of protection strategies.
♦ Different enantiomers may show vastly different biological action, so the preparation of 
homochiral material is highly desirable. Resolution usually involves preparation of a  pair of 
diastereoisomers at a convenient point in the synthesis and separation of these by 
chromatography or recrystallisation. This is usually relatively straightforward, although it 
may involve additional protection and deprotection steps.
♦ Once a suitably protected derivative has been prepared, the free hydroxyls are 
phosphorylated. Phosphorylation can be performed using phosphorus-V reagents or 
phosphorus-III reagents. Phosphorus-V reagents are more stable but less reactive and more 
likely to form cyclic phosphates when phosphorylating vicinal diols. Phosphorus-III 
chemistry involves phosphitylation followed by oxidation.
♦ Protected hydroxyls and phosphates must be deprotected in a manner that avoids 
phosphate migration. This may require a one or two step process.
♦ Purification of the final compound is of great importance since many inositol phosphates 
are active at very low concentrations. A tiny contamination with a  more active isomer may 
give misleading biological results. Final purification by HPLC or ion-exchange 
chromatography is highly desirable.
These points will be illustrated by the chemistries described within this chapter.
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3 Previous Syntheses of Ins(l,4,5)P3
The first total synthesis of Ins(l,4,5)P3 was by Ozaki and co-workers in 1986 [Ozaki et al, 1986]. 
The synthesis is illustrated in scheme 3. DL-l,2:4,5-Di-O-cyclohexylidene-»ry0-inositol 9, 
prepared from myo-inositol 8, was benzylated and the frmf-4,5-acetal was cleaved selectively to 
yield diol 11. Allylation, then hydrolytic removal of the remaining acetal, gave diol 13. The 
authors chose to resolve the molecule at this stage by making the L-menthoxyacetate ester at the 
1-position. The diastereoisomers were separated by recrystallisation, followed by 
chromatography of the mother liquor, to afford D-14 in 39% yield. The menthoxyacetate ester 
was cleaved and the diol was allylated regioseiectively. Benzylation followed by deallylation 
gave the key intermediate D-2,3,6-tri-O-benzyl-m)>0-inositol 17. Although long (10 steps), the 
synthesis to this point is relatively efficient and straightforward; subsequent phosphorylation and 
deprotection, however, are low yielding. The triol 17 was phosphorylated with dianilido- 
phosphoric chloride to yield 18 in ca. 41% yield. Treatment of 18 with isoamyl nitrite in 
pyridine/ACOH/AC2O removed the protecting groups from phosphorus, then hydrogenolysis 
over Pd removed the benzyl groups to give Ins(l,4,5)P3 19. No indication as to the purity of the 
final product is given in the paper.
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Scheme 3 The synthesis of Ins(l,4,5)P3 by Ozaki etal [Ozaki etal, 1986],
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A synthesis of racemic Ins(l,4,5)P3 from racemic 17, using an improved phosphorylation 
strategy [Cooke and Potter, 1987], was soon developed; this is illustrated in scheme 4. The triol 
17 was treated with diisopropylamino(2-cyanoethyl)chlorophosphine to give the phosphite 
triester 21 in 90% yield. This was converted to the di-(2-cyanoethyl)phosphite derivative 22, 
then quantitatively oxidised to the protected phosphate 23 using £-butyl hydroperoxide. All the 
protecting groups were removed in one step, employing sodium in liquid ammonia, to afford 
racemic Ins(l,4,5)P3 after ion exchange chromatography.
DL-17
f o B n  N(P^)2 
V ^ -^ r 'O P O C H 2CH2CN 




V -^ ^ r-O P (O C H 2CH2CN)2





M V ° ^ T OP(OCH2CH2CN)2
(NCCH2CH20)2P 0 ~ \ ^ - - ^ \ ^ 0 P ( 0 C H 2CH2CN)2
OBn U
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Scheme 4 Synthesis of racemic Ins(l,4,5)P3 from racemic 17.
DL-Ins(l,4,5)P3
These syntheses illustrate the typical approaches to inositol polyphosphate synthesis from myo­
inositol. O ther starting materials can be employed. For example, the need for optical resolution 
can be negated by the use of chiral starting materials, such as L-quebrachitol or (-)-quinic acid. 
Interestingly, a synthesis of Ins(l,4,5)P3 was devised starting from benzene [Ley et al 1990]. The 
synthesis starts with oy-l,2-dihydroxycyclohexa-3,5-diene 24, a product of the microbial 
oxidation of benzene (scheme 5).
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Pseudomonas putida




The remaining hydroxyls were introduced by stereoselective epoxidation of the alkenic bonds 
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Scheme 6 The synthesis of racemic Ins(l,4,5)P3 via stereoselective oxidation of alkenic bonds.
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Thus the cyclic carbonate 25 was prepared from 24 with sodium methoxide and dimethyl 
carbonate. Epoxidation with 3-chloroperoxybenzoic acid (MCPBA) gave the a-epoxide 26 in 
4.6:1 excess over its 3-isomer. Regioselective ring opening of the epoxide of 26 with benzyl 
alcohol under camphorsulfonic acid catalysis gave 27 which was benzylated. Basic hydrolysis of 
the cyclic carbonate gave diol 29 where the hydroxyl groups are placed for directed 
epoxidation. Thus epoxidation with MCPBA proceeded to give 30 and 31 in a 9:1 ratio. The 
authors found it more convenient to make acetonides 32 and 33 before separating the a- and 13- 
epoxides by flash chromatography. The epoxide was opened with alcohol 34 (which was 
synthesised in two steps) as its sodium salt in hexamethylphosphoramide/THFt . This gave the 
required regioisomer 35 in 43% yield. Hydrogenolysis removed the benzyl groups to give 36 
which was phosphorylated with w-butyllithium/tetrabenzylpyrophosphate to give 37. 
Hydrogenolysis, then acidic hydrolysis removed the protecting groups to give racemic 
Ins(l,4,5)P3. This is a long synthetic sequence involving extensive chromatography (7 of the 11 
steps from diol 24 involve chromatography, in addition, both steps for production of 34 
required chromatography) that provides racemic Ins(l,4,5)P3 only. However, the route was 
readily modified to provide homochiral material by a method that did not add any more steps 












Scheme 7 Epoxide ring opening using a chiral nucleophile gives diastereoisomers 38 and 39, 
intermediates for the synthesis of both enantiomers of Ins(l,4,5)P3.
Epoxide 26 was treated with (R)-(+)-l-phenylethanol with HBF*.OEt2 catalysis to give 
diastereoisomeric alcohols 38 and 39 which were separated by HPLC. These led to D- and L- 
Ins(l,4,5)P3 via similar methods employed to those for the racemic route. The absolute
* The use of this reagent as a hydroxide equivalent allowed deprotection by acidic hydrolysis of the acetal; 
this generates a (3-alkoxy aldehyde which spontaneously undergoes 3-elimination to yield the free 
hydroxyl group.
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configuration of 38 and 39 was determined by X-ray crystallography of a later derivative. In 
addition to the synthesis of Ins(l,4,5)P3, intermediates in this synthesis were useful in the 
synthesis of other inositol polyphosphates (scheme 8). Notably, epoxide 33 was opened with 
LiAlH* to furnish 40, which was transformed into 6-deoxy-Ins(l,4,5)P3 41; ring opening with 
tris(dimethylamino)sulfur (trimethylsilyl)difluoride gave 42, which was transformed into another













Scheme 8 Compound 33, a versatile intermediate for the synthesis of 6-position modified 
Ins(l,4,5)P3 analogues.
There are at least 15-20 more reported syntheses of Ins(l,4,5)P3. Probably the shortest route is 
that of Salamonczyk and Pietrusiewicz [Salamonczyk and Pietrusiewicz, 1991; Pietrusiewicz et 
al, 1992] which is illustrated in scheme 9.
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Scheme 9 The synthesis of Ins(l,4,5)P3 by Salamonczyk and Pietrusiewicz [Salamonczyk and 
Pietrusiewicz, 1991]
The first step was a difficult precipitation-driven equilibration reaction, where the complex 
mixture of mono- and bis- acetals, formed from myo-inositol 8 and D-camphor dimethyl acetal 
under sulfuric acid catalysis in DM SO, was subjected to hydrolytic conditions 
(CH C U /M eO H /H ^O  50:5:1 and PTSA) leading to the formation of the single product 44 
which precipitated gradually from the reaction mixture in 65% yield. The conditions for this 
reaction undoubtedly require very careful control. The authors claim that only tiny amounts of 
free inositol or other monoacetals are detectable in the product. The absolute configuration was 
determined by converting 44 to its tetrabenzyl derivative, a known compound, as well as by X- 
ray analysis of intermediate 46. Treatm ent of 44 with 4 equivalents of pivaloyl chloride gave 
the tripivaloyl derivative 45 in 48% yield after chromatography. Benzylation, then basic 
hydrolysis of the pivaloate esters, gave triol 47 in 46% yield from 45. Phosphitylation then 
oxidation gave the protected phosphate 48. Deprotection was carried out in two stages. 
Hydrogenolysis of the benzyl groups, then acid hydrolysis of the acetal with acetic acid, gave 
Ins(l,4,5)P3, which was isolated by precipitation in methanol as its sodium salt. It was not 
indicated whether or not further purification was carried out or whether the Ins(l,4,5)P3 was 
evaluated biologically.
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4 A Rapid and Practical Synthesis of D-m^o-Inositol 1,4,5- 
Trisphosphate
4.1 Overview
The triol 49 was proposed as the key intermediate for the rapid synthesis of Ins(l,4,5)P3.
CamphO
I OH
v ^ A l^ ^ V * O C am p h  
OH 5
49
This intermediate was chosen for two reasons:
(i) A colleague had previously synthesised diastereoisomeric di-camphanates of wryo-inositol 
orthoformate 50 and 53, separable by chromatography, and utilised these for a rapid synthesis 










0H 53 54 55
Scheme 10 Synthesis of both enantiomers of Ins( 1,3,4,5)P4, Riley et al [Riley etal, 1997].
It can be seen that additional protection at the 3-position in 51 would yield an intermediate 
such as 49 that would yield Ins(l,4,5)P3 upon phosphorylation and deprotection.
{it) During routine hydrolysis (using H C l/M eO H  at reflux for example) of intermediates with
orthoformate protection, small amounts of formate esters as products of partial deprotection
had often been observed on TLC. These intermediates usually disappeared as the reaction
progresses and, if not, are easily lost upon treatment with concentrated aqueous ammonia.
Orthoformate hydrolysis under milder conditions allowed the formation of enough formate
ester to allow convenient isolation by flash chromatography [Lampe, 1993]. 2,4,6-Tri-O-
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butanoyl-myo-inositol orthoformate 56 was treated with 80% aqueous trifluoroacetic acid (TFA) 
and 2,4,6-tri-O-butanoyl-l-O-formyl-myo-inositol 57 was formed as a minor product (14%), this 
is shown in scheme 11.
Scheme 11 Orthoformate hydrolysis to yield a formate ester
Although these formate esters were not sufficiently stable to be useful synthetically, this finding 
did suggest that a different, more stable orthoester, such as an orthoacetate, might be useful as 
an intermediate protecting group that could be later transformed by partial hydrolysis into an 
acetate ester of defined regiochemistry.
Thus, considering these two points, the strategy for the synthesis of 49 was first to synthesise 59 
(scheme 12) from myo-inositol orthoacetate, then to establish reaction conditions that allow only 
partial hydrolysis of the orthoacetate functionality, such that acetate protection is retained at the





















Scheme 12 Partial hydrolysis of myo-inositol orthoacetate derivative 59
This reaction would probably proceed via the mechanism shown in scheme 13.
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Scheme 13 Mechanism of partial hydrolysis of a  myo-inositol orthoacetate derivative. Only one 
of the potentially similar pathways is shown for simplicity.
Examining this mechanism, it is reasonable to assume that the reaction should yield a  mixture 
of 1-, 3-, and 5-acetate esters 60, 49 and 61 (Figure 6).
CamphO CamphO CamphO
I OAc [H O  I OH
v^^^V^OCam ph v^\-^^V"OCamph Y'A'^^V'OCamph
H O - X ^ ^ ^ -O H  A c O -\^ ^ -< ^ O H  H O - \^ ^ \ - - O A c
OH 49 OH 61 OH60
Figure 6 Possible regioisomers from partial hydrolysis of 59.
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Scheme 14 Synthesis of camphanate esters of wyo-inositol orthoacetate from myo-inositol
The first unambiguous synthesis of an orthoester of myo-inositol was the synthesis of the 
orthoformate orthoester, reported in 1985 [Lee and Kishi, 1985]. Subsequently, this 
intermediate has found wide application in inositol phosphate synthesis [for example: Baudin et 
al, 1988; Billington et al, 1989; Ozaki et al 1994]. Orthoformate protection is relatively easy to 
introduce by treatment of wiyo-inositol with triethyl orthoformate in DM F with PTSA as a 
catalyst, it is stable under many reaction conditions and it is easily removed by acidic hydrolysis. 
Thus it would be expected that using triethyl orthoacetate in place of triethyl orthoformate in 
an analogous reaction would give rise to orthoacetate protected myo-inositol. Indeed, this is the 
case and myo-inositol orthoacetate 62 (scheme 14) was easily prepared from myo-inositol. 
Triethyl orthoacetate was added to a suspension of myo-inositol and PTSA in DM F and heated 
at 140°C for three hours. Flash chromatography eluting with acetonitrile followed by 
recrystallisation from methanol gave 62 as colourless crystals in 57% yield. As already noted, 
the synthesis of diastereoisomeric di-camphanates of myo-inositol orthoformate has been 
reported [Riley et al, 1997]. It was found, not surprisingly, that the orthoacetate also underwent 
such chemistry. Treatment of 62 with 2 equivalents of (lS)-(-)-camphanoyl chloride and a 
catalytic amount of DMAP in dichloromethane gave the two diastereoisomeric di-camphanates
23
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59 and 63 as well as some unwanted tri-camphanate 64. These products were separated by 
flash chromatography and further purified by recrystallisation. At this stage, it was not possible 
to determine the regiochemistry of these diastereoisomers, ie. which was the 2,6-diester and 
which was the 2,4-diester. Therefore, it was necessary to convert one of them to a known 
reference compound and to measure its optical rotation (or gain an X-ray crystal structure). A 
convenient reference compound was available [Riley et al, 1997]. In the synthesis of the 
enantiomers of Ins( 1,3,4,5)P4, Riley et al had determined the X-ray structure of 50 (scheme 15) 
and subsequently converted it to 51. By hydrolysing the orthoacetate functionality of one of the 
diastereoisomers 59 or 63 it would be possible to compare the optical rotation of the resulting 
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Scheme 15 Tetrol 51 is a convenient reference compound to determine the absolute 
configuration of 59.
This proved to be more difficult than anticipated and was achieved in only 9% yield by treating 
59 in M eOH/aqueous HC1 heated to reflux for 14 hours. The formation of considerably more 
polar products as shown by TLC, before complete orthoacetate removal, suggested that the low 
yield was due to extensive loss of camphanates. This illustrated the more robust nature of the 
orthoacetate compared to orthoformate. Orthoformate protection would typically be lost in less 
than one hour in M eOH/aqueous HG1 under reflux. Hence, it would appear that the 
conditions required to cleave the orthoacetate completely are conditions that also cleave 
camphanate esters. However, despite the low yield, enough 51 was recovered to measure the 
optical rotation of the product and confirm the absolute configuration of the original compound 
59.
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The reaction in scheme 14 yielded an excess of the 2,6-diester 59 over the 2,4-diester 63 when 
carried out in C H 2CI2. Carrying out the reaction in pyridine, however, gave an excess of the 
2,4-diester (table 2); this is in agreement with the findings of Riley [Riley, 1996] who carried out 
analogous reactions on the diesters of the orthoformate.
Dichloromethane Pyridine
2,4-diester 63 24% 37%
2,6-diester 59 34% 20%
Table 2 Yields of the diastereoisomeric dicamphanates in CH 2CI2 and in pyridine.
4.3 Synthesis of the key intermediate: lD-3-Acetyl-2,6-Di-0-(-)- 
Camphanoyl myo-Inositol
The next stage was to attempt the synthesis of the key Ins(l,4,5)P3 precursor 49, from 59. 
Repeating the conditions employed by Lampe [Lampe, 1993] in the synthesis of a formate ester 
by-product of orthoformate hydrolysis (scheme 11), ie. 80% aqueous trifluoroacetic acid, 4 
hours at room temperature, had virtually no effect on the molecule. Elevation of the reaction 
temperature to reflux resulted in complete hydrolysis and loss of camphanates and, as described 
earlier, using aqueous HC1 in M eOH gave similar results. Returning to 80% aqueous TFA at 
room temperature and lengthening the contact time proved to be more promising. It was found 
that treatment of 59 with 80% aqueous TFA at room temperature for 7 days gave 3 products as 
shown by TLC. One was the product of complete orthoacetate deprotection 51, the other two 
having an R f between that of 51 and that of the starting material, suggesting partial 
deprotection products. These were separated with some difficulty by flash chromatography 
eluting with EtOAc, then recrystallised. The !H  NM R spectrum of the first product (figure 7) 
showed 3 inositol ring proton signals shifted downfield suggesting that 3 hydroxyl groups were 
esterified. The inositol-H signal of one of the esterified positions (at 8 4.9) is a doublet of 
doublets (after D 2O exchange) showing a small axial-equatorial coupling and a larger axial- 
axial coupling. This must be position 1 or 3, since the only equatorial proton on the myo-inositol 
ring is at position 2; therefore the 1 or 3 acetate has formed. Further evidence was a singlet at 5 
2.02, integrating for three protons; this is consistent with an acetate methyl signal. O f the other 
two signals corresponding to esterified positions, the signal at 5 5.3 is a broad triplet (after D 2O 
exchange), suggesting that this must correspond to position 6, as the signal for the proton at 
position 2 would show smaller equatorial-axial coupling only. Knowing the signal 
corresponding to the proton at position 6 it was possible to assign all the other signals from the 
coupled COSY spectrum (figure 8) and thus define the regiochemistry of this first
25
Chapter 2: Synthesis of D-z/p'o-Inositol 1,4,5-Trisphosphate
product. The structure was confirmed as the 3-acetate ester, 49. Note that the 'H  NMR 
spectrum of 49, shown in figure 7, illustrates beautifully, after D2O exchange, the typical 











5.5 5.0 4.5 4.0
5.5 5.0 4.5 4.0
Figure 7 Section of the JH NMR spectrum of 49 showing the inositol ring protons (a) normal 
spectrum (b) D2O exchange (400MHz, [2H]7-DMF)
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5.5 5.0 4.5 3.54.0
Figure 8  'H - 'H  C O SY  spectrum  of 49 (400M Hz, [2H]7-DMF).
T h e  next product was therefore expected to be either the 1-acetate 60 or the 5-acetate 61. 
Analysis o f its 'H  N M R  spectrum  and 'H - 'H  coupled C O S Y  spectrum  in a  similar m anner to 
that described for the 3-acetate showed it to be the 1-acetate ester 60. No 5-acetate 61 form ed 
in this reaction. This is in agreem ent with the findings of Lam pe [Lampe, 1993] who saw no 5- 
form ate in the partial hydrolysis o f 2,4,6-tri-O-butanoyl-wp'O-inositol orthoform ate. T he reason 
for this cannot be predicted with certainty. It could be argued that in 59 the 5-oxygen is always 
the first to be protonated upon treatm ent with acid and therefore will always lose its orthoester 
bond. H ow ever there appears to be no obvious reason as to why this should be the case as there 
is probably no difference in the p K a  values of these oxygens. T h e  reason could be related to the 
energy requirem ents in form ing one o f the possible interm ediates, in tha t the energy of the 
transition state going to a particu lar interm ediate may be lower than the others. For exam ple 
figure 9 shows the three possible interm ediates that may form in the first step of the mechanism.
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Figure 9 Intermediates during orthoacetate hydrolysis.
Note that formation of both 1- and 3-acetate may result from intermediate A, but not the 5- 
acetate. If the formation of intermediate A was favoured over the other two on energetic 
grounds for example, then no 5-acetate could form during the reaction. It is more feasible that 
the formation of one intermediate may be favoured over two others, than the protonation of 
two oxygens being favoured over the third oxygen. The explanation behind the regioselectivity 
of this reaction is obviously complicated.
4.4 Phosphorylation and Deprotection
Phosphorus-III chemistry was used to introduce the phosphate groups as a phosphorus-V 
approach may have caused problems such as low reactivity and formation of a five-memhered 
cyclic phosphate at the vicinal 4,5-hydroxyls, as described above. Phosphitylation of 49 (scheme 
16) was carried out using bisbenzyloxydiisopropylamino-phosphine in the presence of 1H- 
tetrazole as catalyst (the phosphitylating reagent-tetrazolide was observed by 31P NM R before 
committing the triol to the reaction mixture). This intermediate phosphite triester 65 was not 
isolated but, again, a 31P NM R spectrum (figure 10) was run on a sample of the reaction 
mixture to check that reaction with the alcohols had occurred. This is possible as the 
phosphitylating reagent-tetrazolide is observed at around 5p 127 and a shift downfield to a. 8p 
140 is observed upon formation of the phosphite triester. The trisphosphite triester was 
immediately oxidised to the trisphosphate triester using excess MCPBA at -78°C , yielding the 
dibenzyl protected trisphosphate 66, after flash chromatography, in 72% yield. 31P NMR 
chemical shifts show a marked change upon oxidation of phosphorus; figure 10 shows the 31P 
spectrum of 65, the trisphosphite triester and of the trisphosphate triester 66. Note the 5Jpp 
couplings, in the spectrum of 65, of the 4,5-vicinal phosphites giving rise to doublets. This 
pattern of couplings, an AB system and one singlet, confirms the regiochemistry of 49; an 
acetate at the 1-position would have led to more complex signals upon phosphitylation.
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Schem e 16 Phosphorylation and deprotection of 49 yields Ins(l,4,5)P3
•1.6 - 1.1 - 2.0 - 2.4 - 2 .<
142.0 141.5 141.0 140.5
Figure 10 Proton-decoupled 31P  N M R  spectra o f (a) trisphosphite triester 65 (90MHz) and 
(b) trisphosphate triester 6 6  (162M Hz).
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The benzyl groups were removed by hydrogenolysis over 10% palladium on charcoal at 
atmospheric pressure; then the camphanates and acetate were hydrolysed with ammonia at 
60°C (after removal of the catalyst and solvent) to yield Ins(l,4,5)P3. Deprotection in this order 
ensured that the risk of phosphate migration was minimised. Although the only non-volatile 
impurities at this stage were presumably acetamide and camphanamide, and these could 
presumably be washed out with a  suitable organic solvent, a product of high purity was best 
obtained after ion exchange chromatography. This also removed any traces of palladium ions 
which may have been present after the catalytic hydrogenolysis, which may give rise to poor 
NM R spectra. The Ins(l,4,5)P3 was purified on a strong anion exchanger, Q Sepharose Fast 
Flow resin, eluting with a  gradient of triethylammonium hydrogencarbonate buffer to yield the 
triethylammonium salt. As the product contains no chromophore, it was not possible to detect, 
by UV absorption, which column fractions contain the product. Therefore, the fractions were 
analysed for phosphate content by a method where the compound is broken down to free 
phosphate, which is then detected by formation of a blue complex with molybdate ions. This is 
based upon the assay first described by Briggs [Briggs, 1922]. This assay was then used again, 
quantitatively, to determine how much Ins(l,4,5)P3 had been synthesised. This is necessary, as 
the exact stoichiometry, ie. the number of triethylammonium ions associated with each 
phosphate group, of the triethylammonium salt cannot be predicted with accuracy; therefore, 
one may not simply weigh it. For the quantitative assay, a standard curve was prepared by 
assaying known amounts of potassium dihydrogen phosphate. Thus the amount of phosphate 
contained in samples of Ins(l,4,5)P3 could be calculated and, hence, the amount of Ins(l,4,5)P3 
itself. The triethylammonium salt of Ins(l,4,5)P3 was obtained as a colourless glass in 70% yield, 
figure 11 shows the ]H  NM R and the 1 FI-decoupled 3IP NM R spectra.
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H-2 & H-4
Figure 11 (a) 31P NMR (162MHz, D20) and (b) >H NMR (400MHz, D20 ) spectra of the 
triethyl ammonium salt of Ins(l,4,5)P3.
5 B iological Evaluation
I am grateful to Dr Colin Taylor and co-workers, Department of Pharmacology, University of 
Cambridge who performed these assays.
The ability of this synthetic Ins(l,4,5)P3 to stimulate Ca2+ release was determined in 
permeabilised rat hepatocytes. Hepatocytes were isolated from male Wistar rats and 
permeabilised by incubation with saponin in a cytosol-like medium (CLM). The cells were 
loaded to steady state with 45Ca2+ at 37°C in CLM, then further Ca2+ uptake was prevented by 
treatment with thapsigargin. Appropriate concentrations of Ins(l,4,5)P3 were added and, after
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60 seconds, the preparation was quenched in an ice-cold medium. The 45Ca2+ content of the 
stores was determined using a rapid filtration method. The dose-response curve is shown in 






Figure 12 Effect of synthetic Ins(l,4,5)P3 on Ca2+ mobilisation in permeabilised rat hepatocytes
E C 5 0  (nM)
C om m ercial sam ple 122 ± 8
Synthetic 121 ± 2
Table 3 EC 50 values in permeabilised rat hepatocytes for Ins(l,4,5)P3 made by the route 
described in this chapter compared to a  commercial sample.
6 Conclusions
A rapid, novel route to Ins(l,4,5)P3 from myo-inositol is described. The chemical analyses show 
this route produces material of high purity and this is confirmed by the biological evaluation 
where the synthetic material prepared via this route is indistinguishable in its intracellular C a2+ 
release profile from a commercial sample. This route offers considerable advantages over 
established routes in terms of facility, rapidity and potential for large scale synthesis. Further, 
the route provides intermediates that may find use in the synthesis of other targets. The 2,4- 
diester 63 should provide L-Ins(l,4,5)P3 via an analogous route and the 1-acetate ester 60 may 




Chapter 2: Synthesis of D-myo-Inositol 1,4,5-Trisphosphate
7 Publication
The synthesis of D-myo-inositol 1,4,5-trisphosphate described in this chapter was published as 
the following communication in Journal o f the Chemical Society Perkin Transactions 1.
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Rapid and practical synthesis of D-znyo-inositol 1,4,5-trisphosphate
Shane W. Garrett, Changsheng Liu, Andrew M. Riley and 
Barry V. L. Potter
Wolfson Laboratory o f  Medicinal Chemistry, Department o f  Pharmacy and Pharmacology, 
University o f  Bath, Claverton Down, Bath, UKBA2 7A Y
A  concise synthetic sequence to biologically active d-myo­
inositol 1,4,5-trisphosphate is described involving just 
five steps from myo-inositol and minimal chromatography 
with a key transformation o f orthoacetate Into acetate 
protection.
D-myo-lnositol 1,4,5-trisphosphate [Ins(l,4,5)P,, 1] is a cellular 
second messenger first identified in 1983.* Phospholipase C 
catalyses hydrolysis of phosphatidylinositol 4,5-bisphosphate 
to Ins(l,4,5)P, and diacylglyocrol. Ins(l,4,5)P, interacts specif­
ically with a tetrameric receptor-operated Ca2+ channel on the 
endoplasmic reticulum to mobilise Ca2+ stores in stimulated 
cells.2 Ins(l,4,5)P, mediates the agonist-induced response 
via this rise in intracellular CaJ+ concentration. There is con­
tinuing interest in the biology of Ins(l,4,5)P, and the many 
other related inositol polyphosphates, and in the synthesis of 
analogues that may offer the prospect of pharmacological 
intervention in this signalling pathway.2




Structures of £>In*( 1,4.5)P, 1 and D-In*(l,3,4,5)P41
Since Ozaki and co-workers first prepared optically active 
lns(l,4,5)Pj in 1986/ many routes have been described for the 
synthesis of enantiomerically pure In*(l,4,5)P, from diverse 
starting materials.2 They are generally time-consuming long 
linear sequences involving extensive chromatography. The 
critical strategic points in most routes to chiral inositol phos­
phates are desymmetrisation of /Myoinositol (a meso com­
pound) and resolution of an intermediate. The most rapid route 
to chiral 1 hitherto described is probably that of Salamonczyk 
and Pietrusiewicz.* This route, however, involves a difficult 
precipitation-driven equilibrium and is not readily modified to 
provide materials leading to other inositol phosphate deriv­
atives. Here, we describe a shorter synthetic sequence which 
obviates the need for tedious chromatographic separations and 
long sequences of protecting group manipulations and which, 
by modification of reaction conditions and/or isolation pro­
cedures, can provide material for alternative targets. The route 
is also applicable to relatively large scale preparations.
We have recently published6 a rapid synthesis of D-myo- 
inositol 1,3,4,5-tetrakisphosphate [D-Ins(l,3,4,5)P4, 2] and 
its enantiomer L-Ins(l,3,4,5)P4 by a chiral desymmetrisation 
approach. In arid catalysed deprotection of intermediates utilis­
ing orthoformate protection2 we often observed small quan­
tities of formate esters as products of partial deprotection. 
While these esters were not stable enough to be useful syn­
thetically, this finding did suggest that a different orthoester 
such as an orthoacetate might be useful as an intermediate
f  E-Mail: B.V.L.Pbtter@Batii.ac.uk
protecting group that could be later transformed by partial 
hydrolysis into an acetate ester o f defined rcgiochcmistry such 
as 8$ (Scheme 1). Building upon the above we have now 
developed a synthesis of chiral InsO,4,5)Pt involving only 
five steps from myoinositol. Furthermore, the methodology 
developed has potential application in the synthesis of other 
inositol phosphates, myoinositol orthoacetate 4§ was prepared 
by modifying methodology established for the synthesis of 
the orthoformate orthoester of myo-inositol.* myoinositol was 
treated with triethyl orthoacetate and PTSA in DMF. The arid 
was removed by precipitation as a salt After filtration and 
evaporation in vacuo the residue was dissolved in hot methanol 
and filtered to remove any unreacted myoinositol. Recrystal­
lisation from methanol-chloroform-light petroleum followed 
by further recrystallisation from methanol gave myoinositol 
orthoacetate 4 of sufficient purity for use in the next step, in 60- 
65% yield. Orthoacetate 4 was treated with 2.1 equivalents of 
15-(-)-camphanoyI chloride and a catalytic amount of DMAP 
in dichloromethane to yield the two diastereoisomeric di- 
camphanates 51 and 6. In our synthesis of the enantiomers 
of myoinositol 1,3,4,5-tetrakisphosphate,6 careful chrom­
atography was required to separate the analogous 2,4- and 2,6- 
diastereoisomeric dicamphanate esters of myoinositol ortho- 
formate. As a consequence of the orthoacetate functionally, the 
corresponding diesters 5 and 6 were easier to crystallise and 
thus were separable without chromatography. Crystallisation 
from ethyl acetate gave the required lo-2,6-diester 5 in 37% 
yield. Control over the selectivity of the desymmetrisation could 
be achieved by changing the reaction conditions. An excess
{Data for compound 8: mp 226-229°C; [a)D + 5 2  (c 1.9, DMF)
(Found: C, 57.5; H, 6.5. Calc, for C *H *0I}: C, 57.63; H, 6.74%);
<V400 MHz; pHJjDMF; IM S) 0.96.1.02,1.05,1.10,1.12.1.17 (I8H.
6 x s, camph CH,). 1.55-1.67 (2H, m, camph CHJ. 1.94-2.14 (4H, m, 
camph CH,), 2.02 (3H, s. COCH,), 2.49-2.61 (2H. m, camph CH,), 
3.61 (1H. dt, H-5, J  5.9,9.3 Hz D ,0. exchange gives t, J  9.8 Hz) 3.86 
(IH, dt, H-4, J  4.9,9.8 Hz, D ,0  exchange give* t, J  9.8 Hz), 4.IS-4.17 
(1H, m, H-l, DjO exchange gives dd, / 2 .8 .10.4 Hz), 4.96 (I H, dd. H-3, 
/  2.8,10.1 Hz), 529 (1H, t, H-6, J  10.1 Hz), 5.58 (1H, d, 5-OH, J  5.4 
Hz), 5.60 (IH, m, 4-OH), 5.62-5.63 (1H, m, H-2, D ,0  exchange gives 
t, J  2.8 Hz). 5.75 (1H, d, 1-OH, J  5.9 Hz); mfz (FAB+) [Fbund: 
(M + H)+, 5832394. C »H ,A > requires 583.2391].
J Data for compound 4: mp 185-187 °C (with softening at 165 °C) 
(Found: C, 47.0; H, 6.0. Calc, for C.HiaO*: C, 47.06; H, 5.92%); <5„(400 
MHz; pH]*DMSO) 128 (3H, s, CH,). 3.94-4.0 (4H, m. Ins-H), 4 2 1 -  
427 (2H, m, Ins-H). 5.19 (1H. s. 2-OH), 5.38 (2H, d, 4-OH and 6-OH, 
J 5 2  Hz); 6c(100 MHz; [*H]jDMSO) 24.30 (CH,), 57.70,6724, 6924, 
74.98 (Ins C), 107.66 (CCH,); m/s (FAB+) 205J(M + H)*, 100%].
1 Data for compound 5: mp 228-231 °C; (aJo +17 (c* 1, C H ,C y  
(Found: C. 59.6; H, 6.45. Calc, for C*H*0„: C, 59.59; H, 6.43%); 
<5r(400 MHz; CDa,;TM S) 0.98,0.99,1.08,1.09.1.10,1.11 (18H ,6x s, 
camph CH,), 1.44 (3H, s, 0,CCH,), 1.67-1.76 (2H, m, camph CH,), 
1.91-2.10 (4H, m, camph CH,), 2.39-2.53 (2H. m, camph CH,), 323  
(1H. d, 24)H, J  6 4  Hz). 4.33-4.36(1 H, m, H-3), 4.39-443 (1H. m, H-l), 
4.45-4.50 (IH, m, H-5), 4.57-4.62 (IH, m, H-4), 5.21-525 (1H, m, H- 
2). 5.52-5.57 (IH, m, H-6); dcOOO MHz; CDCI,) 9.59, 9.66. 16.47, 
16.54,16.65 (camph CH,), 23.94 (OsCCH,), 28.76,28.90, 30.44, 30.86 
(camph CH,). 54.41.54.51,54.80,54.89,90.86,91.03 (camph C), 63.72, 
66.78, 68.15, 69.14,69.30. 71.86 0ns C), 108.8 (OtC), 166.15, 166.81, 
177.73,178.02 (camph CO); ntiz (FAB+) 565 [(M + H ) \  100%].
J. Chem, Soc., Perkin Trans. 1 ,1998  1367
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Scheme 1 Reagents and conditions i. Triethyl orthoacetate, PTSA, 
OMF, 90-100 °C, 4 h; ii, 1SA.~ Fcamphanoyl chloride, DM AP, dichloro- 
methane, 0 °C then RT, 2 h; iii, 80% aqueous trifluoroacetic add, 7 days; 
iv (a), (BnOjjPNPr1*, l/Z-tetrazole, dichloromethane, RT, I h; (b), 
MCPBA, dichloromethane, -7 8  °C to RT; v (a), H2, 10% Pd on C, 
MeOH-H A  RT, 12 h; (b), conc. aqueous NH„ 60 °C, 4 h; vi, 5 M H O - 
MeOH 1:11, reflux, 14 h
of the 2,4-diester 6 was gained by omitting the DMAP, and 
crystallisation from methanol gave 6 in 40-45% yield. The 
regiochemistry of the required 2,6-dicamphanate 5 was deter­
mined by removing the orthoacetate completely by refiuxing in 
methanol-HCl to give tetrol 10. The [a]D value of 10 was found 
to be identical to that of authentic material {[a]" - 8  (c 1, 
DMF)} synthesised from the analogous 2,6-dicamphanate 
with orthoformate protection, a compound whose structure 
had been unambiguously determined previously by X-ray 
crystallography.6
Selective transformation of 5 to 8 was required to produce 
the appropriately protected intermediate for the synthesis of 1. 
Whereas acidic hydrolysis of the analogous orthoformate, as 
described in our synthesis of 2, resulted in complete loss of the 
protection afforded by this functionality, treatment of 5 with 
80% aqueous trifluoroacetic arid at room temperature for one 
week yielded the acetate esters 7 and 8. Regioisomer 8, required
to make Ins(l,4,5)P}, could be crystallised directly from the 
mixture in 25% yield using methanol-light petroleum (total 
yield 31%). Pure 7 could be obtained in 40% yield by chrom­
atography of the mother liquor (RP 8 0.32, 7 0.47, (EtOAc]). 
Structure determination of these acetate esters was straight­
forward by ‘H-'H COSY NMR experiments. No derivative 
with a 5-acetate was obtained. Phosphitylation of 8 using 
dibenzyl Af,JV-diisopropyl phosphoramidite9 followed by oxid­
ation of the intermediate phosphite triester with MCPBA gave 
the protected phosphate 9 in 72% yield. One-pot deprotection 
by hydrogenolysis at atmospheric pressure over 10% Pd/C, 
then ester hydrolysis with ammonia at 60 °C gave Ins(l,4,5)P}. 
Deprotection in this manner ensured that any risk of phosphate 
migration was minimised. For biological evaluation, the 
Ins(l,4,5)Pj 1 was further purified by ion exchange chrom­
atography on Q-Sepharose Fast Flow resin eluting with a gradi­
ent of triethylammonium hydrogen carbonate buffer (0-100% 
1 m) to give the triethylammonium salt in 70% yield (quantified 
by Briggs phosphate assay10). A typical preparation generated 
60 mg of this highly active target compound. Clearly the 2,4- 
diester should provide the now well-established biological con­
trol L-Ins(l,4,5)Pjn via an analogous synthetic route. The other 
readily available regioisomeric acetate 7 could find use in the 
synthesis of further inositol polyphosphates or phospholipids.
Biological evaluation using saponin-permeabilised hepato­
cytes showed that synthetic 1 prepared via this route was indis­
tinguishable in its intracellular Ca2* release profile (ECjo= 
121 ± 2 u m )  from a sample of commercially available 
Ins(l,4,5)P} (ECjo -  122 ± 8 nM).
In summary, we have described a novel route to this highly 
potent second messenger in chiral form with considerable 
advantages over currently established routes in terms of facility, 
speed and potential for large scale synthesis.
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Chapter 3: 
Synthesis of an Inositol Tetrakisphosphate Analogue
1 Introduction
This chapter highlights the importance of D-myo-inositol 1,3,4-,5- 2'0 3P 0
tetrakisphosphate, the product of the action of 3-kinase on /
Ins(l,4,5)P3, and describes the synthesis of the tetrakisphosphate 2-rVjprv / OPOj2' 
6 8  in racemic form. The rationale behind the synthesis of the 3- ^  DL-68
deoxy-^cy/fo inositol derivative DL-68 was twofold:
(i) There is currently a high level of interest in Ins(l,3,4,5)P4 and in Ins(l,4,5)P3 3-kinase. 
Compound DL-68 is an interesting Ins(l,3,4,5)P4 surrogate and could be tested for activity at the 
Ins(l,4,5)P3 receptor and against the metabolic enzymes, providing valuable structure-activity 
data.
(it) The Ins(l,4,5)P3 surrogate 6 9  had been synthesised in |_jq
racemic form [Riley et al, 1996; Riley, 1996] and had been )
2'0 3 P 0 '7 r ^ ^ ^ 7 ^ ' 0 H
tested as a substrate for Ins(l,4,5)P3 3-kinase. The enzyme ^ n p n  2-
phosphorylated this molecule; however, it was not certain at HO ^  ^
which position the new phosphate ester had formed.
Phosphorylation of the primary hydroxyl to give D /L -68  would be an unusual and interesting
observation. Synthesis of DL-68 would provide a standard that could be used in HPLC to
determine whether or not D /L -6 8  forms as a result of the action of 3-kinase on DL-69.
The fully protected inositol derivative DL-70 was chosen as the key intermediate for the 
synthesis of DL-68. The synthesis of DL-70 has been demonstrated in excellent yield starting 
from myo-inositol [Riley et al, 1998]. Treatment of DL-70 with acid should remove the 
benzylidene acetal and the 4-methoxybenzyl ether protection to yield DL-71. 
Phosphitylation/oxidation then deprotection of DL-71 would then yield the desired compound 
DL-68 (scheme 17).
OBn





H O - ^ 7 ^ ^ 7 ^ 0 B n
BnO
DL-71
Scheme 17 Acid hydrolysis of fully protected inositol derivative DL-70 would yield key 
intermediate DL-71.
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2 D-myo-Inositol 1,4,5-Trisphosphate 3-Kinase
2.1 Introduction
D-myo-Inositol 1,4,5-trisphosphate 3-kinase catalyses the phosphorylation of Ins(l,4,5)P3 to 
Ins(l,3,4,5)P4. The enzyme was first identified in animal tissues in 1986 [Irvine et al, 1986]. 
Ins(l,3,4,5)P4 had recently been discovered [Batty et al, 1985] and the search was on for the 
metabolic steps that generated it. It was found that 10-20% of [3H]-Ins(l,4,5)P3 microinjected 
into Xenopus oocytes was rapidly converted to a tetrakisphosphate and greater conversion was 
observed with rat tissue homogenates (brain, liver and pancreas). The new tetrakisphosphate 
was identified as Ins(l,3,4,5)P4; thus Ins(l,4,5)P3 3-kinase activity had been demonstrated [Irvine 
etal, 1986].
2.2 There are Different Isoforms of 3-Kinase
Two isoforms of 3-kinase have now been described, referred to as Ins(l,4,5)P3 3-kinase A and B 
[Communi et al, 1995] and a putative third isoform, Ins(l,4,5)P3 3-kinase C, has also been 
suggested. However, care must be taken when identifying and describing different isoforms as 
there has been the suggestion that, although some reported 3-kinase activity of low molecular 
weight cytosolic proteins may indeed correspond to different isoforms, some activity is likely to 
derive from proteolytic* release of the C-terminal region which contains the catalytic domain 
[Soriano and Banting, 1997]. The C-terminal region shows high amino acid identity between A 
and B isoforms [Woodring and Garrison, 1997]. There is little identity at the N-terminal region 
and this region contains many more amino acids in the B isoform. Most studies suggest that the 
enzymes are largely cytosolic. A study, using Northern analysis to detect mRNA complementary 
to Ins(l,4,5)P3 3-kinase cDNA in various rat tissues and human cell cultures, has suggested that 
Ins(l,4,5)P3 3-kinase isoforms are expressed in a  tissue- or cell-specific manner [Vanweyenberg 
et al, 1995]. In rat tissue, isoenzyme A is specifically expressed in brain and testis, whereas 
isoenzyme B is predominantly expressed in lung but also in thymus, heart, testis and brain. In 
the three human cell lines analysed, SH-SY5Y (a neuroblastoma-cell line), HL-60 (a leukaemia­
cell line) and H TB -138 (a glioma-cell line), no signal was observed with the isoenzyme A probe, 
but all three expressed mRNA for isoenzyme B. R at 3-kinase B has been shown to be associated 
with the cytosolic face of the ER membrane [Soriano et al, 1997] via specific, conformation- 
dependent, protein-protein interactions, with the catalytic domain facing the cytosol.
t Ins(l,4,5)P3 3-kinases are reported to be highly sensitive to the calcium-activated protease calpain [Lee et 
al, 1990], and degradation products are commonly found in preparations of 3-kinase.
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2.3 Regulation of 3-Kinases
Various mechanisms may regulate the activity of 3-kinases. Regulation by Ca2+/calmodulin, by 
phosphorylation by PKC or PKA or by phosphorylation by a cAMP-dependent protein kinase 
is known. The 3-kinase from a number of cell types is stimulated by Ca2+/calmodulin to varying 
degrees dependent upon the cell or tissue type. For example, rat brain isoenzyme A is 
stimulated 2-3-fold, whereas an uncharacterised human platelet isoenzyme is stimulated 17-fold 
[Communi et al, 1995]. This suggests that regulation of 3-kinases may be cell or tissue specific. 
However, this cell- or tissue- specific regulation is probably a reflection of dssue-specific 
expression of different isoforms and that regulation is isoform-specific. Further, a recent study 
[Woodring and Garrison, 1997] showed activation of 3-kinases to be highly dependent upon 
the purity of the protein and upon the assay conditions, suggesting that comparison of different 
studies may not be straightforward. There is, however, good evidence for isoform-specific 
regulation. In this study [Woodring and Garrison, 1997], pure A and B isoforms were produced 
recombinantly from a mammalian cell line and the regulation of each by Ca2+/calmodulin and 
by kinases was examined. It was found that each isoform was activated to a different degree by 
Ca2+/calmodulin. The effect of phosphorylation of the enzyme by PKA and PKC showed 
marked differences between isoforms. PKA increased the activity of isoform A in the absence of, 
and to a  lesser extent in the presence of, Ca2+/calmodulin; PKC decreased activity both in the 
presence and absence of Ca2+/calmodulin. Phosphorylation of the B isoform by either of the 
protein kinases had no effect in the absence of Ca2+/calmodulin, and decreased activity in the 
presence of Ca2+/calmodulin suggesting that the interaction of the B isoform with 
C a2+/calmodulin is affected by its phosphorylation state. The picture regarding the expression 
and regulation of 3-kinases is obviously complicated and the enzymes are clearly tightly 
regulated; this suggests that their product, Ins(l,3,4,5)P4, plays an important role in C a2+ 
signalling and inositol phosphate metabolism. This is discussed later.
2.4 Structure-Activity Relationships
Recently Choi et al examined the interaction of all the possible regioisomers of myo-inositol 
phosphates with 3-kinase [Choi et al, 1997]. They examined the ability of all 38 isomers to 
inhibit phosphorylation of D-[3H]-Ins(l,4,5)P3 by rat brain 3-kinase (expressed in E. coli and 
purified). Whilst the study showed nothing particularly striking, it did allow them to build up a 
model for the binding site of the enzyme. Their model is illustrated in figure 13.
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some space 
available 
in the equatorial 
direction
Figure 13 Binding model of Ins(l,4,5)P3 3-kinase for Ins(l,4,5)P3 as proposed by Choi et al 
[Choi et al, 1997].
Other descriptions of the recognition motifs for this enzyme [for example: Potter and Lampe, 
1995] are basically in agreement with the findings of this study. The 1-phosphate seems 
essential for substrate recognition, both Ins(4,5)P2 and Ins(2,4,5)P3 being very poor substrates. 
The 4- and 5-phosphates are also important for binding, possibly to a slightly lesser extent since 
Ins(l,4,5)P3-5S and the equivalent 4,5-bisphosphorothioate are phosphorylated but the 
trisphosphorothioate is not. Steric bulk at the 2-position is well tolerated, with the exception of 
phosphate groups as there appears to be negative charge near the vacant space in the axial 
direction. An interesting 2-position modified analogue is DL-2,2-F2-Ins(l,4,5)P3 [Safrany et al, 
1992]. Upon resolution, the D-isomer is a substrate for 3-kinase, whereas the L-isomer is a 
potent inhibitor and does not mobilise intracellular Ca2+. Modifications of Ins( 1,4,5)P3 at the 3- 
position, the site of enzyme action, can result in inhibition. The 3-deoxy and 3-fluoro analogues 
of Ins(l,4,5)P3 for example are both inhibitors of 3-kinase. It seems that the enzyme 
accommodates ATP in the axial direction at the 3-position and that there is limited space in the 
equatorial direction [Choi et al, 1997]. The 6-OH is not important for binding, 6-deoxy- 
Ins(l,4,5)Ps is a substrate for 3-kinase but stereoinversion or bulky substituents are not tolerated.
2.5 Inhibitors of 3-Kinases
It can be seen that 3-kinase exhibits considerable stereo and positional selectivity for its 
substrates and that, in contrast to 5-phosphatase, there has been limited success in the design of 
selective, potent, non-Ca2+ mobilising inhibitors. Probably the best lead to date is the difluoro 
compound L-2,2-F2-Ins(l,4,5)P3, although, interestingly, the cytotoxic anthracycline antibiotic 
adriamycin appears to be a potent inhibitor of 3-kinase [da Silva et al, 1994]. Heparin is also a 
potent inhibitor of 3-kinase.
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3-Kinase works by transferring a phosphate from ATP to Ins(l,4,5)P3 and, for this, binds both 
these molecules simultaneously. This could possibly be exploited in the design of a 3-kinase 
inhibitor. A molecule that binds at both the Ins(l,4,5)P3 site and the ATP site simultaneously 
may well be a  potent and selective inhibitor of the enzyme, ie. a multisubstrate analogue 
inhibitor. The ideal multisubstrate analogue would be a conjugate of Ins(l,4,5)P3 and ATP as 
shown in figure 14
NH2
“O----- P— O' ■P O.
OH
OH OH
Figure 14 Potentially ideal multisubstrate analogue inhibitor of 3-kinase.
Synthesis of such a molecule would pose many synthetic problems. The coupling of ADP, with 
an activated diphosphate, to Ins(l,3,4,5)Pj. for example, would be possible but obviously would 
result in a mixture of regioisomers. Compound 68 may be a useful intermediate in the synthesis 
of a multisubstrate analogue inhibitor. It is planned to investigate the coupling of 68 to a 
suitably activated AMP derivative such as its morpholidate (scheme 18). The conjugate 73 may 
well be the major, or only product, as the primary phosphate would be expected to be more 
nucleophilic. Compound 73 differs from the ideal lead compound (figure 14) only in that it has 
a methylene in place of one of the phosphates of the triphosphate and would therefore be a 
useful lead.
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Scheme 18 Synthesis of a potential multisubstrate analogue inhibitor of Ins(l,4,5)P3 3-kinase. 
The use of morpholidates is well established in making pyrophosphate bonds [for example: 
Moffatt and Khorana, 1961].
3 Why do Cells Make Ins(l,3,4,5)P4?
3.1 Introduction
It is now 13 years since the first report of the formation of Ins(l,3,4,5)P4 in animal tissue, [Batty 
et al, 1985] but the downstream effects of this molecule in cellular signalling remain ambiguous. 
In particular, two questions remain to be answered;
Can Ins(l,3,4,5)P4 mobilise Ca2+from intracellular stores by acting at Ins(l,4,5)P3 receptors? 
and
Are there specific receptors for Ins(l,3,4,5)P4, and, i f  so, what is their role?
A brief account of the current theories and experimental evidence that addresses these questions 
will be outlined here.
3.2 Ins(l,3,4,5)P4 and Ca2+ Mobilisation
Studies into whether or not Ins(l,3,4,5)P4 can mobilise Ca2+ by a direct action on Ins(l,4,5)P3 
receptors have yielded some conflicting results, and the picture is further complicated by
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potential artifacts. Cells contain a  3-phosphatase enzyme (MIPP); conversion of Ins(l,3,4,5)P4 to 
Ins(l,4,5)P3 is therefore possible. In addition, commercial samples of Ins( 1,3,4,5)P4 have been 
shown to be contaminated with Ins(l,4,5)P3. Gawler et al [Gawler et al, 1990] studied the ability 
of Ins( 1,3,4,5)P* to mobilise Ca2+ from intracellular stores in saponin-permeabilised SH-SY5Y 
human neuroblastoma cells. To avoid the considerable conversion of Ins(l,3,4,5)P4 to 
Ins(l,4,5)P3 (Le. 3-phosphatase activity) that they found occurred at room temperature, they 
performed their experiments at 4°C, which arrests this metabolism. They also found that the 
activity of commercial samples of Ins(l,3,4,5)P4 was reduced if pre-treated with a crude 
Ins(l,4,5)P3 3-kinase preparation, suggesting contamination with Ins(l,4,5)P3. They therefore 
used chemically synthesised Ins(l,3,4,5)P4. The study showed that Ins(l,3,4,5)P4 releases Ca2+ 
from intracellular stores and that Ins(l,3,4,5)P4 appears to act synergistically with sub-maximal 
concentrations of Ins(l,4,5)P3 in releasing Ca2+.
Cullen et al [Cullen et al, 1990], also suggested a synergistic effect between Ins(l,4,5)P3 and 
Ins(l,3,4,5)P4 in Ca2+ release, based on a study using digitonin-permeabilised L1210 mouse 
lymphoma cells. They showed that, in their system, Ins(l,3,4,5)P4 alone caused no mobilisation 
of Ca2+ but that Ins(l,3,4,5)P4 markedly enhanced Ins(2,4,5)P3 induced Ca2+ release when 
Ins(2,4,5)P3 was administered at low concentration (at threshold or just above). At high 
Ins(2,4,5)P3 concentration, Ins(l,3,4,5)P4 had no effect. In a later study, the same group showed 
that the dose-response curve to Ins(l,3,4,5)P4 was not shifted to the left by thimerosal, a 
sensitiser of the Ins(l,4,5)P3 receptor [Loomis-Husselbee et al, 1996]. This suggests that the 
synergistic effect of Ins(l,3,4,5)P4 on Ins(2,4,5)P3-induced Ca2+ release does not appear to 
involve a direct interaction with the Ins(l,4,5)P3 receptor but is more likely to be due to an 
indirect action of Ins( 1,3,4,5)P4 via an Ins(l,3,4,5)P4 receptor.
In contrast, Wilcox et al [Wilcox et al, 1993a,b] suggested that Ins(l,3,4,5)P4 independently 
mobilises Ca2+ via a direct action on Ins(l,4,5)P3 receptors. Their studies, using saponin- 
permeabilised SH-SY5Y cells, showed that Ins(l,3,4,5)P4 acted as a full agonist, albeit weaker 
than Ins(l,4,5)P3 (EC50 2.5pM compared to 52nM). The studies were either conducted in InsP6- 
supplemented buffer to inhibit 3-phosphatase or with the 3-phosphorothioate analogue of 
Ins(l,3,4,5)P4, which is resistant to 3-phosphatase and only a 2-fold weaker agonist. The picture 
is certainly made no clearer by a more recent study [Bird and Putney, 1996] which has 
suggested a possible role for Ins(l,3,4,5)P4 as an inhibitor of the effects of Ins(l,4,5)p3. The 
study, using microinjection into mouse lachrymal acinar cells, showed that Ins(l,3,4,5)P4 was 
able to antagonise the effects of Ins(2,4,5)P3 and that it neither mobilised Ca2+ nor potentiated 
the effect of Ins(2,4,5)P3. They suggest that the contrast shown between their study and the 
findings of Wilcox etal [Wilcox et al, 1993a,b] may be explained by the two cell types expressing 
different forms of the Ins(l,4,5)P3 receptor.
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3.3 Ins(l,3,4,5)P4 Binding Proteins
Suggestions of a specific Ins(l,3,4,5)P4 receptor have evolved from the first report of a  binding 
site for Ins(l,3,4,5)P4 [Bradford and Irvine, 1987]. Binding proteins for Ins(l,3,4,5)P4 have now 
been reported in several tissues [Irvine, 1992; Cullen et al, 1997]. Cullen et al purified and 
characterised such a protein from pig platelets [Cullen et al, 1995b] and studied the binding 
affinities of the 6 enantiomeric pairs and 3 m^o-isomers of the regioisomers of Ins(l,3,4,5)P4 
[Cullen et al, 1995a] The study concluded that phosphorylation of the l-,3- and 5-positions is 
essential for high affinity binding, a  6-phosphate is tolerated but a 2-phosphate is not and a 4- 
phosphate has very little influence. The protein was later cloned and shown to be a GTPase- 
activating protein (GAP), specifically, a member of the GAP1 family [Cullen et al, 1995c]. They 
designated the protein GAP1IP4BP.
A pleckstrin homology (PH) domain constitutes part of the G A Pln>4BP protein [Cullen et al,
1997]. PH domains are a family of modular domains consisting of sequences of around 100 
amino acids originally found in pleckstrin, a major substrate for protein kinase C in platelets. 
PH  domains have been described over 60 different proteins including many involved in cellular 
signalling, such as the phospholipase C family, various protein kinases and G protein regulators 
[Shaw, 1996]. Their function appears to be the regulation of membrane binding of various 
proteins. It is the PH domain of G A Pln>4BP that is the functional Ins(l,3,4,5)Pt binding site, 
deletion mutants of G A Pln>4BP that do not contain the PH domain do not bind Ins(l,3,4,5)P4 
[Cullen etal, 1997]. Moreover it is the PH  domain that appears to be important in determining 
the localisation of the GAP within the cell. The GAP1IP4BP homologue (about 60% identical), 
G A Plm shows a different subcellular distribution to G A Pln>4BP in that it appears to have a 
perinuclear localisation and possibly a small cytosolic component [Lockyer et al, 1997], In 
contrast, G A Pln>4BP is located solely at the plasma membrane. The difference may be a function 
of their respective PH domains, as previously noted, the PH domain of GAP1EP4BP contains the 
Ins(l,3,4,5)P4 binding site, but also mediates association with the plasma membrane. This 
suggests that the localisation and function of G A Pln>4BP may be regulated by the competition 
between phospholipid binding and Ins(l,3,4,5)P4 binding [Lockyer et al, 1997].
Another known binding site for Ins(l,3,4,5)P4 is the PH  domain of Bruton’s tyrosine kinase.
Mutational changes in this enzyme are the cause of X-linked agammaglobulinaemia a condition
in which the function of B cells is disrupted, causing immunodeficiency. Recently, the crystal
structure of the PH domain of Bruton’s tyrosine kinase in complex with Ins(l,3,4,5)P4 has been
published [Baraldi et al, 1999]. This study has provided useful information about the molecular
interactions of Ins(l,3,4,5)P4 and one of its important binding sites. Key interactions involve
hydrogen bonds between the 3-, 4- and 5-phosphates and lysine residues and an arginine
residue. Ins(l,4,5)P3 has considerable lower affinity for this site, it is suggested this is due to the
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absence of the 3-phosphate significantly reducing the number of hydrogen bonds. The 
interaction of Ins( 1,3,4,5)P* directly with the PH domain involves a total of 18 hydrogen bonds. 
There are further hydrogen bonds via water molecules and hydrophobic contacts with the 
cyclohexane ring.
Although a number of proteins that bind Ins(l,3,4,5)4 with high affinity and specificity have 
been described, the role of these proteins [Ins(l,3,4,5)P4 receptors?] in signal transduction is not 
known. It has been suggested for some years that a possible function of Ins(l,3,4,5)P4 is to 
modulate Ca2+ entry across the plasma membrane [Irvine, 1992]. Hence, it would seem 
reasonable that, if G A Pl15455 is indeed an Ins(l,3,4,5)P4 receptor, that, given its membrane 
localisation, it may be involved in this process. In support of the Ca2+ entry hypothesis is the 
identification of an Ins(l,3,4,5)P4 sensitive Ca2+ channel in the plasma membrane of endothelial 
cells [Liickhoff and Clapham, 1992]. Another study, using adriamycin to inhibit 3-kinase (and 
therefore Ins(l,3,4,5)P4 production) inJurkat T-lymphocytes, showed that the markedly reduced 
Ins(l,3,4,5)P4 concentration in the cells did not appear to have an effect on Ca2+ entry [da Silva 
et al, 1994]. More attention now focuses upon the physiological targets of G A Pln>4BP, specifically 
which G-proteins are targets. Both Ras and Rap GAP activity for GAP 111,4511 have been clearly 
demonstrated in vitro [Bottomley et al, 1998]. GAP 115455 and G A Plm function as GAPs on 
various Ras family members, when assayed in the presence of membrane phospholipids. The 
GAP activity is completely dependent on the presence of Ins(l,3,4,5)P4 suggesting that 
G A Pl15455 and G A Plm function as Ins(l,3,4,5)P4-dependent Ras GAPs. G A Pl15455 but not 
G A Plm functions as a Rap GAP and appears not to be regulated by Ins(l,3,4,5)P4. Thus 
G A Pl15455 and G A Plm appear to differ in their specificity as well as their sub-cellular 
localisation.
4 Synthesis of DL-(l,3,5/2,4,6)-6-Hydroxymethylcyclohexane- 
1,2,3,4,5-pentol-1,2,4,7-Tetrakisphosphate
This route starts with the synthesis of mjw-inositol orthoformate 7 4  (scheme 19), using the 
method of Baudin et al [Baudin et al, 1988]. The orthoacetate orthoester utilised earlier, in the 
synthesis of Ins(l,4,5)P3, is not suitable for use here, as there is a requirement later in the 
synthesis to remove the orthoester in the presence of 4-methoxybenzyl ethers, which would 
probably be lost under the conditions required to cleave the orthoacetate. O ther protecting 
groups could be used that would be compatible with the orthoacetate but the advantage of 
using the PMB group is that its instability to acid should allow the conversion of the fully 
protected intermediate DL-70 into the tetrol DL-71 (scheme 17). Thus myo-inositol was treated
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with triethyl orthoformate and PTSA in DM F at 140°C; chromatography and recrystallisation 























Scheme 19 Synthesis of tetrol 79.
The route to the fully protected intermediate DL-70 is that described by Riley et al [Riley et al,
1998]. Treatment of the orthoformate 74 with 2 equivalents of NaH, then with 2 equivalents of
4-methoxybenzyl chloride in DM F at room temperature gave a mixture of di, mono, and tri- 
PMB derivatives. Chromatography of the mixture gave the required 4,6-di-PMB derivative 75 
in 40% yield. A mild and efficient oxidation of 75 was carried out using a Swern procedure. 
Anhydrous dimethyl sulfoxide (DMSO), in dichloromethane, was activated using oxalyl 
chloride at -60°C . This reacts rapidly with the alcohol to form an alkoxysulfonium 
intermediate that is rapidly converted to the ketone upon addition of triethylamine. 
Examination of the IR  spectrum of the reaction product showed 
hydroxyl groups at around 3450cm*1 as well as a characteristic carbonyl 
peak at 1760cm*1, indicating formation of the ketone hydrate 80 during 
the aqueous work up. Boiling a solution of this gem-diol in toluene using 
a Dean and Stark apparatus for azeotropic removal of water, followed 
by careful recrystallisation using dry solvents under nitrogen, gave the 
pure ketone 76 in 90% yield. The ease with which the ketone hydrates is attributed to strain 
effects in this rigid molecule, [Riley et al, 1998] the carbon at position-1 preferring to be sp3- 
hybridised. A cyclohexane ring can accommodate the larger bond angle at an sp2 carbon by a 
small amount of ring distortion, this is obviously not possible in this caged, adamantane-like 
structure. Alkene 77 was prepared using a Wittig reaction. A solution of potassium fert-butoxide 
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was added and the mixture was to be heated to reflux for three hours. The oxaphosphatane 
intermediate in Wittig reactions of this type is usually unstable, decomposing to the desired 
alkene at low temperature. The oxaphosphatane of 76, which presumably has the structure 81a 
or 81b (figure 15), however, was unusually stable and needed to be heated in refluxing TH F in 





Figure 15 Possible structures of the oxaphosphatane intermediate derived from compound 76.
Hydroboration/oxidation of 7 7  using 9-borabicyclononane (9-BBN), then alkaline hydrogen 
peroxide followed by purification by column chromatography, gave exclusively the axial alcohol 
7 8  in 74% yield. This product is preferred as formation of the equatorial alcohol would require 
approach by the bulky 9-BBN on the face of the alkenic double bond hindered by the PMB 
groups. The orthoformate functionality of 78  was hydrolysed by treatment with m ethanol/ 1M 
aqueous HC1 at 50°C. The reaction was followed carefully by TLC as the PMB groups will 
eventually be cleaved under these conditions, so the reaction must be stopped when 
orthoformate hydrolysis is complete. Treatment of the crude product with concentrated 
aqueous ammonia was necessary to cleave a formate ester that formed by incomplete 
orthoformate hydrolysis and was observed by TLC. Chromatography gave the tetrol 79  in 74% 
yield. Note that each compound synthesised to this stage is meso. The next step was to protect 
the primary hydroxyl and its adjacent secondary hydroxyl simultaneously by forming a 
benzylidene acetal. It can be seen that this reaction gives a pair of enantiomers, DL-82 (scheme 















Scheme 20 Treatment of 79 with benzaldehyde dimethyl acetal gives a pair of enantiomers.
Acetal DL-82 was made in 82% yield by treatment of 79 with benzaldehyde dimethyl acetal in 
DM F and a catalytic amount of PTSA at 70°C. The reaction vessel was fitted with an air 
condenser connected to a  water pump to remove methanol formed during the reaction; this 
shortens the reaction time and improves the yield. The remaining two free hydroxyls were 
benzylated in the usual manner (NaH/BnBr in DMF) to give DL-70 in 90% yield (scheme 21). 
The benzylidene acetal and the PMB groups were removed conveniently in one pot by acidic 
hydrolysis. Thus treatment with refluxing ethanol/ lM aqueous HC1 (1:20) gave the tetrol DL-83 
in 71 % yield, after chromatography.











Scheme 21 Benzylation of racemic 82 followed by acid hydrolysis gave the key intermediate 
DL-83.
Figure 16 shows sections of the NM R spectrum of DL-83; a ^ - 'H  COSY spectrum was 
required to assign the inositol ring protons.
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Figure 16 Sections of the >H NMR spectrum of DL-83 (400MHz, [2H]6-DMSO).
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Phosphitylation of DL-83 with bis(benzyloxy)diisopropylaminophosphine (scheme 22) in the 
presence of l//-tetrazole in dichloromethane gave a tetrakisphosphite. This was not isolated but 
the reaction mixture was checked by 31P NMR (90MHz) and signals were observed at 8140.8 
(doublet), 142.3 (singlet), 142.5 (doublet), and 143.0 (singlet). Immediate oxidation with excess 
MCPBA at -78°C, then purification by column chromatography, gave the benzyl protected 








Schem e 22 Phosphitylation, oxidation, then deprotection of DL-83 to yield the target 
tetrakisphosphate DL-68.
Deprotection was achieved by catalytic hydrogenolysis using palladium on charcoal under 40psi 
of hydrogen in MeOH/water (4:1) to yield the tetrakisphosphate DL-68. This was purified by 
ion-exchange chromatography on Q  Sepharose Fast Flow resin eluting with a gradient of 
triethylammonium hydrogencarbonate buffer to yield its triethylammonium salt, 75% as 
quantified by phosphate assay. Figure 17 shows the 3lP NMR spectrum of the final purified 
product.
0.0 - 0.5J.O 0.5
F igure 17 'H-decoupled 31P NMR spectrum of the tetrakisphosphate DL-68
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5 Biological Work
5.1 Ca2+ Release
I am grateful to D r Colin Taylor and co-workers, Department of Pharmacology, University of 
Cambridge who performed the Ca2+ release assay.
The ability of compound DL-68 to stimulate Ca2+ release was determined in permeabilised rat 
hepatocytes using the assay conditions described in chapter 2. It was found to be inactive. The 3- 
hydroxyl of Ins(l,4,5)P3 is thought to enhance binding to the receptor, probably via H-bond 
interactions. Compound DL-69 was found to be equipotent with Ins(l,4,5)P3 itself in releasing 
45Ca2+ from permeabilised rabbit platelets [Riley et al, 1996b]. Thus the receptor tolerates the 
equatorial C H 2O H  at this pseudo 3-position. Furthermore, this |_jq
an Ins(l,4,5)P3 surrogate, the result obtained for Ca2+ release
indicates that the steric bulk of a phosphate attached to the C H 2O H  is not tolerated by the 
receptor. From this study, little can be concluded when considering DL-68 as an Ins(l,3,4,5)P4 
mimic. If Ins( 1,3,4,5)P* does cause Ca2+ release, then this result would suggest that the change 
from secondary to primary phosphate at position 3 is not tolerated (although DL-68 also differs 
from Ins(l,3,4,5)P4 in terms of the 2-hydroxyl being equatorial as opposed to axial, the 2- 
hydroxyl is not important for Ca2+ release).
5.2 Use as a Standard in Studies Involving 3-Kinase
These studies were performed by G. Mayr and co-workers, University of Hamburg.
As described early in this chapter, DL-69 had been tested as a substrate for 3-kinase. A product 
with a  retention time in HPLC corresponding to a tetrakisphosphate, or possibly a 
pentakisphosphate, was observed. The chromatogram* in figure 18 shows that the major 
phosphorylation product that is obtained has a longer retention time than DL-68. A small peak 
does appear to correspond to DL-68, this is indicated by the red arrow and suggests that DL-68 
may form as a minor product. Figure 19 illustrates the possible products of phosphorylation of 
DL-69; both tetrakisphosphates and pentakisphosphates may have formed in this experiment. If
* The chromatography utilises a metal-dye detection system [Mayr, 1988] as the inositol phosphates 
possess no chromophore. This is based on the complexation of transition metal ions with both the inositol 
phosphates and a dye, 4-(2-pyridylazo)resorcinol, at the same time in a so-called “two-ligand one-metal” 
system. The dye acts as a reporter substance allowing spectrophotometric detection at 546nm.
arrangement may even enhance activity, since the compound 
tested was racemic and presumably only one enantiomer was 
responsible for the observed activity. Considering DL-68 as HO DL-69
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the enzyme has, indeed, phosphorylated the prim ary hydroxyl and possibly phosphorylated the 
m olecule twice, this is anom alous to its apparen t high substrate specificity discussed earlier in 
terms of the lack of success with the design and synthesis o f inhibitors o f 3-kinase.
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Figure 18 H PL C  trace of phosphorylation products of DL-69 with DL-68 as a  standard.
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Figure 19 Possible phosphory lation products of DL-69 other than DL-68, new phosphates are 
shown in red.
As described earlier, the possible phosphorylation of a  prim ary hydroxyl by 3-kinase is a  
significant and highly interesting result and further experim ents were perform ed in an attem pt 
to gain further inform ation about the phosphorylation of DL-69. Figure 20 illustrates the result 
o f an  experim ent using a  lower 3-kinase concentration and a  lower A T P concentration.
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Figure  20 HPLC traces of phosphorylation products of DL-69 at various timepoints showing 
formation of DL-68.
These data suggest that DL-68 does form by the action of 3-kinase on DL-69. However, this 
appears to be dependent upon concentration of enzyme and ATP, as a different product, either 
a pentakisphosphate or a different tetrakisphosphate, forms at higher ATP concentration.
6 C onclusions
The synthesis of a novel inositol tetrakisphosphate is described. Although inactive at the 
Ins(l,4,5)P3 receptor, this does make a small contribution to our understanding of the structure- 
activity relationships of the receptor. The molecule may have use as a probe for the various 
Ins(l,3,4,5)P4 binding sites. The molecule has proved useful in a standard in the studies 
involving 3-kinase and may prove to be useful in the synthesis of a lead compound as a 
multisubstrate analogue inhibitor of 3-kinase.
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P a r t  I I :  
Sy n t h e s is  o f  imP E G -P o l y a m in e  C o n ju g a t e s
We can even be somewhat optimistic on the long-range possibility o f therapy by the isolation or design, ynthesis, 
and introduction of new genes into defective cells ofparticular organs.
[Tatum, 1966]
The idea that human genetic disease and even some degenerative and infectious disease will become amenable to 
correction at the genetic level has cleared its initial conceptual and technical obstacles and has now become widely 
accepted in most molecular genetic, medical and public policy circles. Thefirst phase o f human gene therapy — the 
emergence and acceptance o f the general concept — is over. We are now in an explosive second phase — one of 
technical implementation.
[Friedmann, 1992]
Mtrogen is the element o f faction neatly dividing organic chemists into camps. Those who have mastered its 
vagaries are undaunted by the prospect o f contending with its reactivity. Then there are those in the minority 
antipodal camp who suspect that nitrogen is best confined to a cylinder and used to shield precious reactions and 
reagentsfrom the ravages o f air and moisture.
[Kocienski, 1994]
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Chapter 4: 
An Introduction to the Science of Gene Therapy
1 Introduction
The second part of this thesis is concerned with the synthesis of polyethylene glycol)-polyamine 
conjugates. It is thought that such constructs may have use in the development of formulations 
for the delivery of nucleic acids to cells in vivo. Such formulations would have application within 
the field of gene therapy. This chapter will present an introduction to the science behind the 
well-established concept of gene therapy and highlight the fact that the major obstacle to success 
in this field is largely a technical one, that of delivering the gene to its site of action, the nuclei of 
the target cells. A brief overview of how gene therapy has evolved and which diseases it may 
tackle will be presented, followed by consideration of more technical issues, including the routes 
by which gene medicines may be administered and what vectors or techniques are available to 
mediate this delivery.
2 Gene Therapy, an Overview
2.1 What is Gene Therapy?
There are a  number of diseases known to be caused by a defect in a specific gene; these 
conditions are termed monogenic diseases. Such diseases have an obvious cure. Identify the 
defective gene, produce a functional copy that will produce the correct protein and then 
administer it to the patient for expression in the required tissue. Thus the synthesis of the 
missing/defective protein is restored and the genetic defect is corrected. This is the original 
concept of gene therapy. As research progressed and techniques such as gene sequencing and 
PC R became commonplace, and much was learned about the molecular basis of disease, the 
concept of gene therapy broadened to have application in diseases other than those with a 
purely genetic cause. In this case, the delivered gene would encode a protein that is not missing 
or dysfunctional in the patient but that provides some therapeutic benefit. Some examples 
might be a tumour suppresser gene to treat cancer or a gene for a cytotoxic protein to kill 
cancer cells, the tyrosine hydroxylase gene to treat Parkinson’s disease, or a gene encoding an 
immunostimulatory protein for treatment of cancer or infection.
Thus the concept is a simple one. Putting this into practice, however, is far from simple and this 
will become apparent in the following discussion. Although identification and cloning of
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potentially therapeutically useful genes has been highly successful, delivery of the genes to the 
cell remains a major limiting factor. Delivery vectors are broadly divided into viral and non- 
viral; the discussion here will be mainly concerned with non-viral vectors.
2.2 A Brief History
The concept of gene therapy is widely thought to have come about relatively recently. In fact,
the idea that one could manipulate genes to treat human disease has been around for some
decades now. In 1944, Avery et al found that a non-virulent form of Pneumococcus could be
transformed into an infective form using extracted nucleic acids from a virulent form [Avery et
al, 1944]. This was essentially the first suggestion of a link between DNA and genetic
information, and this revelation is widely cited as the foundation-stone of molecular genetics
and, as such, of the concept of gene therapy. Over the decade following this discovery, nucleic
acids moved from being considered as largely uninteresting molecules to being the most likely
candidate for the gene [Lederberg, 1994] culminating in the elucidation of the structure of
DNA [Watson and Crick, 1953]. Even so, the possibility of molecules other than DNA playing
a significant role in genetics had not been entirely dismissed [Lederberg, 1994] and it could be
argued that rigorous proof came only in the 1960’s when DNA synthesised in vitro was shown to
be biologically active [Lederberg, 1994]. Throughout the 1950’s and 60’s the ability of viruses
to stably transform inheritable changes was observed, first by bacteriophages, and later by
animal viruses including Rous Sarcoma virus, and the papovaviruses SV40 and polyoma [Wolff
and Lederberg, 1994], By the mid to late 1960’s, forward-looking researchers were beginning to
see the use of these viruses as a mechanism to deliver therapeutically useful genes as a possibility
[Friedmann, 1992], in particular, Tatum provided an explicit account of the concept of viral
gene therapy in 1966 [Tatum, 1966]. At this stage, though the concept of gene therapy was
inviting, not only in the treatment of monogenic disease, but also in cancer [Tatum, 1966], the
existent technology precluded the possibility of integrating therapeutically useful genes into a
virus vector. The 1970s saw a technological revolution in molecular biology with the discovery
of restriction enzymes at last providing the tools needed for genetic engineering, and allowing
gene therapy to become a serious possibility. In 1973, a new calcium phosphate transfection
procedure was developed which allowed DNA to be introduced efficiently and functionally into
human cells in vitro [Graham and Van der Eb, 1973]. In 1980, Cline reported the successful
introduction of the human globin gene into the bone marrow of mice using an ex vivo technique
involving calcium phosphate transfection [Cline et al, 1980]. At the time this experiment
received much media attention and was described as “revolutionary” [Marx, 1980], Cline
followed up the study with the first human gene therapy trial. Bone marrow cells from
thalassaemia patients were transfected in vitro with the human globin gene, and reintroduced
into the patients [Friedmann, 1992]. The trial failed to induce any change in the patients. It was
severely criticised on scientific, administrative and ethical grounds [Friedmann, 1992] and
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sparked much debate on the ethics of gene therapy [Kolata and Wade, 1980]. During the early 
1980s techniques were developed that enabled the genetic manipulation of retroviruses to 
incorporate therapeutically useful DNA. The high efficiency of this method of gene transfer to 
cells in culture generated increased interest and enthusiasm towards the possibility of human 
gene therapy, and towards the mid 1980s human gene therapy became accepted as a genuine 
possibility awaiting practical application. From 1989 onwards, increasing numbers of clinical 
trials of gene therapy and marker gene experiments were approved. In the late 1980s and early 
1990s, a variety of new methods of transfection were explored including electroporation, new 
viral vectors and lipid based excipients. There has been a remarkable growth in research effort 
directed towards gene therapy since the early 1990s. This is illustrated by the growth in the 
number of research papers published in this field. Figure 21 shows the number of articles 
published, that appear on the Science Citation Index database, containing the phrase “gene 










F igure  21 Articles containing “gene therapy” in their title 1981-1998, taken from the Science 
Citation Index database.
2.3 Germ-line Gene Therapy
Although all current gene therapy protocols are being performed on somatic cells, gene transfer 
could also be performed on germ cells. If the target cells are spermatozoa, ova or their 
precursors, the genetic modification will be passed on to the individual’s descendants. This is 
referred to as germ-line gene therapy. If the target cell is somatic the modification will not be 
hereditary. There is, of course, an extremely tiny risk of inadvertent germ-line gene transfer
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occurring via somatic gene therapy. Germ-line gene therapy is a controversial topic, largely due 
to the fact that it is not reversible. Ethical issues also surround its potential for misuse, such as 
for cosmetic purposes.
2.4 In Utero Gene Therapy
Advances in in utero diagnosis and gene delivery have led to the concept of prenatal gene 
therapy, an opportunity to treat disease before birth [Senut and Gage, 1999]. In utero gene 
therapy is also a controversial procedure, owing to many safety concerns and social and ethical 
issues [Billings, 1999; Senut and Gage, 1999]. Probably of greatest concern, in terms of safety, is 
the risk of inadvertent gene transfer to tissues other than the target tissue, particularly germ 
cells. The procedure does have potential advantages [Schneider and Coutelle, 1999; Senut and 
Gage, 1999]. Post-natal gene therapy may be too late to avoid irreversible disease 
manifestation, whereas gene delivery in utero may prevent the onset of disease. A developing 
foetus may be more amenable to uptake and permanent integration of foreign genes and organ 
stem-cell populations, inaccessible later in life, may be targetable. The immaturity of the foetal 
immune system may be more tolerant towards both vector and transgene and the size of the 
foetus means that fewer cells are targeted, thus less vector is required. The immaturity of the 
foetal blood-brain barrier may facilitate delivery to the brain.
2.5 Therapy with Antisense Oligonucleotides
Antisense oligonucleotides are sequences of around 15 to 20 nucleotides, complementary to 
specific sequences of DNA or RNA. They have been proposed as therapeutic entities because 
they are able to inhibit gene expression; thus there is the possibility to down-regulate the 
production of deleterious proteins. There is controversy over the mechanism of action of 
antisense oligonucleotides; a number of mechanisms have been put forward [Grooke, 1998; 
Israel and Domb, 1998]. These include activation of RNase H  (causing arrest of transcription 
by breakdown of RNA) by formation of a heteroduplex double-stranded sequence with target 
mRNA, inhibition of translation by binding to the initiation region, and formation of a triplex 
with a specific DNA sequence which can cause inhibition of transcription. Antisense 
oligonucleotide therapy suffers the same major problem as gene therapy using DNA, the lack of 
efficient vectors for intracytoplasmic delivery. Antisense oligonucleotides can be modified such 
that they are more resistant to nucleases, for example by producing phosphorothioate analogues 
[Crooke, 1998].
2.6 Ethical Issues
It seems almost certain that at some stage in the future gene therapy will become a widely 
practiced technique in medicine. However, when gene therapy eventually does emerge as a fully 
developed branch of medicine, it seems unlikely that it will avoid media and thus public scrutiny
58
Chapter 4: An Introduction to the Science of Gene Therapy
in terms of ethics and safety. It can be seen that germ-line and in utero gene therapy raise obvious 
ethical questions but consideration of ethical issues is important in gene therapy as a whole, 
more so than other emerging medical advances. Any new technology involving genetic 
manipulation tends to be greeted with apprehension and public perceptions of the relative risks 
and benefits of gene therapy will be important considerations in measuring its acceptability and 
consequent success.
3 What Diseases May be Treatable and With Which Genes?
3.1 Overview
In theory, one can envisage treating any disease with gene therapy. It is usually not too difficult 
to imagine a protein that may confer some benefit to a patient if it were expressed within a 
specific tissue or even systemically. In practice certain diseases are more suitable candidates for 
gene therapy, the obvious examples being genetic disorders where gene therapy is often the only 
treatment that may promise a complete cure. Diseases not treatable or curable by conventional 
therapies such as many cancers and AIDS, are other examples. Recent clinical trials statistics 
[http://www.wiley.com/wileychi/genmed/clinical/diseases.html; 1st June 1999] show that 
there are 380 gene therapy clinical trials protocols, involving 3173 patients, approved 







F igure 22 Gene therapy protocols per type of indication.
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3.2 Cancer
It can be seen from figure 22 that the majority of current gene therapy trials are aimed at 
treating cancer. Cancer represents an attractive target for gene therapy. The lack of recent 
significant advances in conventional therapies, that is surgery, radiotherapy and chemotherapy, 
has obviously led to a greater interest in alternative therapeutic approaches. The possibility of 
direct injection of the gene medicine into a tumour may also have influenced research effort 
towards treating cancer, since this negates the need for selective targeting via the systemic 
circulation, a problem yet to be overcome satisfactorily. Another consideration that potentially 
makes cancer a  less demanding target for gene therapy is that once the cancer has gone the 
genetic modification may no longer be required. This is in contrast to the situation with 
monogenic diseases where the formulation may have to be administered for the life of the 
patient if prolonged expression of the gene cannot be achieved.
Strategies fo r  the gene therapy o f  cancer
There are numerous strategies for the gene therapy of cancer [Dachs et al, 1997; Hersh and 
Stopeck, 1998; Culver et al, 1995; Blaese, 1997]. Perhaps the most obvious approach is the 
introduction of a gene encoding a protein toxic to tumour cells, so-called suicide genes. Another 
approach is gene-directed enzyme prodrug therapy (GDEPT). Here, a gene that encodes a prodrug- 
activating enzyme is introduced, for example herpes simplex virus thymidine kinase (HSV-TK). 
This enzyme phosphorylates non-toxic nucleoside analogues such as ganciclovir which then act 
as chain terminators, killing dividing cells [Dachs et al, 1997]. One could also introduce genes 
that render cancer cells more sensitive to conventional chemotherapy, or attempt to protect 
vulnerable non-cancerous tissues against the toxic effects of systemic chemotherapy. For 
example, insertion of multi-drug resistance genes into haematopoietic stem cells would allow 
bone marrow to tolerate higher chemotherapeutic doses [Culver et al, 1995]. This could be 
accomplished using an ex vivo approach ie. bone marrow transplantation with transduced stem 
cells.
Many approaches are aimed at stimulating the immune system against the tumour. This may 
involve genes expressing cytokines such as IL-12 [Mendiratta et al, 1999], or genes for tumour 
antigens, so-called DNA vaccines (Hersh and Stopeck, 1998]. Another approach is mutation 
correction or compensation. This may involve introduction of a tumour suppresser gene such as 
p53, activation of repair processes or blockage of oncogene activity.
Targeting
Some approaches require the gene to be expressed exclusively in tumour tissue, therefore
strategies for selective delivery or selective expression are required [Dachs et al, 1997]. Tum our
selective delivery via the systemic circulation may be possible by constructing a vector that
60
Chapter 4: An Introduction to the Science of Gene Therapy
includes a targeting ligand capable of binding predominantly to tumour cells, for example, by 
taking advantage of the over-expression of certain receptors such as epidermal growth factor 
receptors and folate receptors seen in many tumours. Targeted expression may be possible if 
tissue specific promoters are included within a gene construct to allow expression of the transfer 
gene only in the tissue of interest. The simplest method of selective tumour targeting is direct 
injection of the formulation into the tumour mass. However, this may be impractical if there is 
more than one tumour mass or if the tumour(s) are not easily accessible.
The bystander effect
It has been observed within in vivo tumour models that complete ablation of the tumour can 
occur without 100% of the cells receiving the transgene. This is termed the bystander effect and 
is thought to occur by the passage of the therapeutic protein through gap junctions [Blaese, 
1997]. This is an important observation since it is not possible to achieve anything near 100% 
gene transfer in vivo with current methods of delivery. A recent study using a GDEPT approach 
(using HSV-TK  and ganciclovir) for retinoblastoma [Hayashi et al, 1999] reported 90% cell 
killing when only 50% of cells expressed H SV-TK  in an in vitro model.
3.3 Monogenic Diseases
The paradigm here is cystic fibrosis. Cystic fibrosis is caused by a defect in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene and consequent defective production of the 
CFTR protein, a  cAMP-regulated Cl~ channel. The end result of this is impaired Cl~ transport 
at the apical surface of epithelial cells. This leads to abnormal secretions in the gut, liver, 
pancreas and reproductive tract, although the clinical picture is dominated by a chronic lung 
disease caused by abnormal mucus secretion and impaired mucociliary clearance leading to 
chronic bacterial infection. Gene therapy, at present, is aimed at delivering a normal copy of the 
CFTR gene to the lungs. This represents a  different challenge from the gene therapy of cancer. 
One could imagine that the delivery of a gene to the epithelial cells of the lungs was perhaps 
one of the easier tasks set the gene therapy scientist given its accessibility. However, the lungs 
present a number of barriers to successful gene delivery. These are applicable to lung delivery 
for any condition and are described in general later (see discussion on pulmonary delivery). In 
particular, the thick secretions produced by GF patients provide a major physical barrier to 
access of the epithelial cell surface [Davies etal, 1998].
The first approved gene therapy clinical trial actually aimed at curing a disease was for 
adenosine deaminase (ADA) deficiency [Blaese et al, 1995], a disease caused by a defect in the 
ADA gene which leads to severe combined immunodeficiency (SGID). In ADA deficiency 
patients, deoxyadenosine, usually catabolised by adenosine deaminase, is converted to the toxic 
compound deoxyadenosine triphosphate. T  cells have a high turnover of deoxyadenosine and
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are particularly prone to its toxic effects and those of its metabolites, thus the immune system is 
disabled [Blaese et al, 1995]. This first trial provides an illustration of the approach to gene 
therapy of ADA deficiency; T  cells were separated from the patients blood, proliferated in 
culture, transduced with the ADA gene and reinfused into the patients.
Other monogenic disease candidates for gene therapy include Duchenne-Boulogne muscular 
dystrophy, Gaucher’s disease (glucocerebrosidase deficiency), mucopolysaccharidosis ([3- 
glucuronidase deficiency), hyperammonemia (ornithine transcarbamylase deficiency) and 
familial hypercholesterolemia.
3.4 Infectious Diseases
Although gene therapy could be used to target a number of infectious diseases, to date, AIDS is 
the only one for which there have been clinical trials. In fact, this disease represents the next 
largest group of studies after cancer. The goal of gene therapy here is to stop HTV from 
replicating inside infected cells or prevent the virus from spreading to healthy cells [Blaese, 
1997]. The delivered gene may, for example, encode an inactive version of a protein that HTV 
uses in replication, the altered protein would then disrupt viral replication.
3.5 Other Diseases
Gene therapy has the potential to be used in many other disease states including Parkinson’s 
disease, Alzheimer’s disease, diabetes, rheumatoid arthritis, asthma and cardiovascular disease. 
In Parkinson’s disease, use of the tyrosine hydroxylase gene has been suggested [During and 
Ashenden, 1998]; tyrosine hydroxylase is the rate-limiting enzyme in dopamine biosynthesis. 
However, increased tyrosine hydroxylase activity would not prevent the ongoing disease 
process, so an alternative approach might be to use genes for neurotrophic factors with the aim 
of regenerating existing neurons [During and Ashenden, 1998]. Symptoms of Parkinson’s 
disease occur when 80% of striatal dopaminergic neurons have been lost, hence minimal 
increase in dopamine production could be sufficient to ameliorate symptoms. The brain is 
difficult to target; it is not accessible (due to the skull and blood brain barrier), neurons are 
largely terminally differentiated post-mitotic cells and there is a lack of well-characterised, cell 
specific promoters. There would usually be a need for global gene delivery in Alzheimer’s and 
most neurogenetic disorders [During and Ashenden, 1998]. Diabetes may be targeted by genes 
whose products stimulate pancreatic (3-cell neogenesis, as although (3-cells are largely 
eliminated, more so in type I, precursor cells still remain [Levine and Leibowitz, 1998]. Early 
intervention to locally ablate the autoimmune response in type I disease by expression of 
immunomodulatory molecules by islet cells is another approach [Levine and Leibowitz, 1998]. 
Gene therapy for cardiovascular disease has focused on the vascular response to injury following 
surgery such as bypass grafting and angioplasty which can limit the long term efficacy of these
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techniques [Svensson and Schwartz, 1998]. Gene therapy for rheumatoid arthritis may involve 
the delivery of genes whose products are anti-inflammatory, immunomodulatory or both. A 
current trial is using the interleukin-1 receptor antagonist gene IL-lra with some success 
[Reinecke et al, 1999].
3.6 Gene Marking
Note that about 10% of trials (figure 22) involve so called gene marking. This term is used when 
the gene being introduced is not expected to confer any beneficial therapeutic effect and the 
study is being conducted only to analyse the fate of the gene or its product.
4 Routes of Administration
4.1 Overview
With the exception of the oral route, virtually every conceivable route of drug delivery has been 
used in a trial of some sort. Figure 23 shows the most common routes of administration being 
used in current trials [http://www.wiley.com/wileychi/genmed/clinical/routes.html; 1st June 
1999]. The chosen route of administration will obviously depend on the target tissue and upon 
the method of delivery, although this may be limited by the technologies available.
Others






Figure  23 The routes of administration being used in current gene therapy trials expressed in 
terms of per cent of patients receiving the formulation by that route. Approximately half the 
current trials are using ex vivo techniques; in these cases the route of administration refers to the 
route by which the transgenic cells are administered.
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4.2 Systemic Delivery
Probably the ultimate goal of gene therapy research is the production of a gene medicine that is 
stable in the circulation and can therefore be intravenously injected, possesses some sort of 
targeting system allowing tissue specific expression, and is able to release the DNA efficiently at 
the desired location. At present, the first step, a long-circulating gene delivery system, is not 
available. Naked DNA injected intravenously is rapidly eliminated from the plasma due to 
extensive uptake by the liver and rapid degradation by serum and tissue nucleases [Takakura 
and Hashida,1998]. Hepatic uptake is highly efficient, clearance being nearly identical to 
plasma flow through the organ. The uptake is thought to be by non-parenchymal cells via 
scavenger receptors for polyanions. No significant gene expression is observed [Takakura and 
Hashida, 1998]. Liposome-DNA complexes are also rapidly cleared by the liver. Hydrophobic 
particles are typically coated by specific plasma proteins (opsonisation) and taken up by 
macrophages in the liver and spleen ie. activation of the complement system. The complement- 
activating properties of a range of polymers used for gene delivery and cationic lipids and their 
complexes with DNA has been examined [Plank et al, 1996]. Strong activation is seen with poly- 
L-lysine (PLL), polyethylenimine (PEI), a polyamidoamine (PAMAM) dendrimer and 
dioctadecylamidoglycylspermine (DOGS), other cationic liposomes are weaker activators. 
Short-chain oligolysines are comparable to cationic lipids. The degree of activation by 
complexes is lower, and for PLL, PEI, PAMAM dendrimer and DOGS, is strongly dependent 
upon charge ratio. Surface modification of preformed PLL complexes with PEG considerably 
reduces complement activation. Complexes of DNA with cationic polymers also show short 
plasma circulation times [Pouton and Seymour, 1999], Again, there is hepatic uptake but also 
evidence of accumulation in the skin and intestine, probably due to physical trapping of the 
complexes within the fine capillaries of these organs, possibly after binding to plasma proteins. 
Glycosylated cationic polymers have been widely studied as possible liver-selective carriers for 
DNA via the systemic circulation. Liver parenchymal cells possess asialoglycoprotein receptors, 
which have limited distribution in other tissues and which recognise galactose. A complex of 
radiolabelled DNA and galactosylated PLL rapidly accumulated in the liver of mice (80% of the 
injected dose within 5 minutes of injection) [Hashida et al, 1998]; of this, 70% was found in 
parenchymal cells. Uptake was selectively inhibited by pre-injection of excess Gal-bovine serum 
albumin, an asialoglycoprotein receptor ligand, indicating that the complex is being taken up by 
receptor-mediated endocytosis. Clearly systemic gene delivery is not an easy task; we have yet to 
jum p the first hurdle, to develop a delivery system that is not cleared rapidly from the 
circulation.
4.3 Intratumoural Injection
It can be seen from figure 23 that almost 40% of patients enrolled in gene therapy trials are
being given the formulation via the intratumoural route. This is largely a reflection of the fact
64
Chapter 4: An Introduction to the Science of Gene Therapy
that many trials are being conducted in the area of oncology, but may also be biased by the fact 
that direct injection of the formulation into the target tissue is considerably easier than targeting 
cancer tissue via the systemic circulation. In this context, naked DNA has been shown to be 
more active than lipidic formulations [Yang and Huang, 1996]. This is possibly due to the high 
hydrostatic pressure within solid tumours, caused by poor lymphatic drainage and poor 
vascularisation, preventing adequate dispersion of the formulation [Pouton and Seymour, 1998] 
which may limit release of DNA from the complex.
4.4 Intramuscular Injection
Gene transfer into muscle cells in vivo follows injection of naked DNA. This was first observed in 
the mouse in 1990 [Wolff et al, 1990]; reporter genes were injected directly into the mouse 
quadricep muscle and protein expression was detectable. Formulations of reporter genes with 
the hydrophilic polymers PVP and PVA show enhanced expression over naked DNA [Mumper 
et al, 1996], this may be due to enhanced dispersion and /o r osmotic effects. A more detailed 
discussion concerning PVP-DNA formulations for muscle delivery will be presented later in this 
chapter. After direct injection of lipoplexes, gene expression is often localised to regions close to 
the injection site; this suggests that dispersion of the formulation within the muscle tissue is 
critical [Pouton and Seymour, 1998].
The finding that primary myoblasts (easily identifiable and isolable muscle stem cells) can be 
grown in culture and be stably transduced with recombinant genes further stimulated interest in 
muscle delivery. The modified myoblasts fuse with endogenous myofibres to become stably 
incorporated into muscle tissue [Svensson et al, 1996], The modified cells can produce and 
secrete large amounts of recombinant protein and the rich vascular supply to skeletal muscle 
promotes the efficient access of secreted proteins into the systemic circulation. This approach, 
although successful in animal studies, was difficult to translate to human gene therapy [Svensson 
et al, 1996]. Hum an muscle appears to be significantly less receptive to translated myoblasts. 
The technique is also labour intensive and expensive. Despite this promising technique not yet 
fulfilling its potential, muscle remains an attractive tissue for gene delivery, not only for 
treatment of muscular disorders but for the treatment of other diseases where the muscle could 
act as a  factory for therapeutic proteins [Mumper and Rolland, 1998]. This approach may be 
particularly useful in the treatment of serum protein deficiencies, and muscle may provide a 
useful site for the delivery of DNA vaccines where DNA encoding a foreign protein is used to 
stimulate an immune response. Here, only transient production of the protein may be required 
and the technique may be successful even with low efficiency, localised gene expression.
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4.5 Pulmonary Delivery
Gene delivery to the lung is of interest for a number of reasons. The tissue is potentially more 
accessible than many other tissues; this may overcome problems with targeting. Further, cystic 
fibrosis is an attractive target for gene therapy; lung disease is the dominant manifestation of this 
condition and delivery of the CFTR gene to the lung may prove to be the best way to manage 
the condition. The lung may also be useful for the systemic delivery of genes. Furthermore, 
much is known about the fate of inhaled formulations in the lungs, largely through the 
development of asthma medicines. Delivery to the lung is, however, presented with significant 
barriers. Epithelial monolayers are polarised cells with characteristic tight junctions; the apical 
surfaces are tough, strengthened by actin filaments close to the plasma membrane and do not 
have extensive endocytic capacity [Pouton and Seymour, 1998]. The mucociliary clearance 
system of the respiratory tract is highly effective at excluding foreign material and, as such, is a 
major barrier to access of the lung epithelium by gene medicines. Mucus, secreted by goblet 
cells within the epithelium, provides a mechanical and diffusional barrier. In bronchiolar 
regions, cilia move the mucus and trapped particles up and out of the lung and alveolar 
macrophages clear particles deeper in the lung. Much work has been focused upon optimizing 
lipoplex formation for pulmonary delivery. In one study, a large series of lipo-polyamines were 
synthesized and their transfection efficiency was examined in vivo in mouse lung [Lee et al, 1996]. 
One cationic lipid in particular, GL-67, gave a 1000-fold increase in reporter gene expression 
over a naked DNA formulation.
GL-67 NH;
A formulation of GL-67 and the CFTR gene, administered via the nasal epithelium, was 
evaluated in CF patients. However, correction of the electrolyte transport defects was not 
appreciably greater than from a formulation of naked DNA [Zabner et al, 1997]. GL-67 was re­
evaluated in transgenic GF mice [Jiang  et al, 1998]. The study found that although GL-67 
mediated transduction of CFTR to airway epithelia, the process was relatively inefficient giving 
marginal correction of ion transport.
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5 Methods of Delivery
5.1 Naked D N A
The direct injection of DNA not formulated with any delivery vectors may have application in 
certain situations. The low level expression seen after the direct injection of naked DNA into 
muscle tissue may be enough to achieve an immunological response and hence have application 
in the development of DNA vaccines. Expression may also be seen after direct injection of 
naked DNA into solid tumours.
5.2 Viral Vectors
Viruses are the professionals of gene delivery; they have evolved specific mechanisms to enter 
cells and express their genes and do so highly efficiently. Technology to substitute genes 
involved in viral replication for potentially therapeutic genes is well established, thus they are 
attractive as vectors for gene therapy. Over 70% of current trials are using viral gene delivery 
[http://www.wiley.com/wileychi/genmed/clinical/vectors.html; 1st June 1999] and the 
majority of these involve the use of retrovirus. Although at present viral vectors are generally 
more efficient than non-viral systems, there are a number of problems associated with the use of 
viral vectors, including immunogenicity, transient duration of gene expression, small capacity 
for foreign genes and the generation of sufficiently high titres (the number of infectious viral 
particles per ml) [Robbins et al, 1998; French Anderson, 1998; Friedmann, 1997]. Four types of 
virus have found use in clinical trials - retroviruses, adenoviruses, herpes-simplex viruses (HSV) 
and adeno-associated viruses (AAV) [Robbins et al, 1998]. Viruses must bind to extracellular 
receptors before they are internalised and most cell types possess receptors to which viruses can 
bind. The engineering of viral envelope proteins to include new components or to replace 
existing ones may allow targeting to different cells from those that the virus would naturally 
infect [Friedmann, 1997]. The different properties of different types of virus dictate how they 
may be used for gene delivery. Retroviruses can splice copies of the genes they carry 
permanently into the chromosomes of the cells they invade [Friedmann, 1997] which may allow 
long term expression of the gene. However, they usually require the cells to be dividing to stably 
infect them, thus an ex vivo approach is primarily used. In addition, they do not have the 
capacity for large genes such as the dystrophin gene [Robbins et al, 1998]. Adenoviruses can 
accommodate large DNA inserts, up to 35Kb, they are able to transduce a wide variety of cell 
types including non-dividing cells and can be grown to high titres [Robbins et al, 1998; 
Friedmann, 1997] however, they may only produce transient expression of the gene. 
Adenoviruses have been the vector of choice for cystic fibrosis and a variety of trials in oncology 
[French Anderson, 1998]. AAV is a human virus for which the majority of the population is 
seropositive; it is not associated with pathologies. The degree of infection of muscle, brain and
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liver cells with recombinant AAV is reported to be high in vivo [Robbins et al, 1998]. AAV has a 
small capacity for foreign genes (about 4.8Kb of DNA) and production of viral particles is very 
labour intensive due to the lack of efficient packaging cells [French Anderson, 1998]. HSV is 
particularly able to transfect nerve cells and may have potential as a vector for delivery to the 
nervous system [Ho and Sapolsky, 1997]; is has a large capacity for DNA (up to 50Kb). Thus 
viral vectors have much potential as instruments for clinical gene delivery, however, they have 
disadvantages which may be difficult to overcome. In the future we may see more vectors 
incorporating components of viral and non-viral delivery systems, so-called “artificial viruses” 
that mimic the highly efficient processes of viral infection [Lehn et al, 1998]; there is much that 




Synthetic gene delivery systems have developed as two broad classes of compounds, the cationic 
lipids and the cationic polymers. DNA complexes with cationic lipids have been named lipoplexes 
and the process of DNA delivery mediated by cationic lipids termed lipofeciion [Feigner et al,
1997]. Similarly DNA complexes with cationic polymers have been named polyplexes and 
cationic polymer mediated DNA delivery termed polyfecdon [Feigner et al, 1997]. Further, the 
term “interpolyelectrolyte complex (IPEC)”, which in general refers to any complex of 
oppositely charged polyions, has been used to describe DNA-polycation complexes [Kabanov 
and Kabanov, 1995]. Synthetic vectors are most relevant to the work in this thesis and a 
detailed account of the most important synthetic vectors will be presented in the next section.
Physical m ethods
Microinjection
This is the direct injection of DNA into the nucleus of the target cell [Sih et al, 1994]. The 
technique is highly labour intensive and has little application in vivo as a large number of cells 
would need to be injected; this is not practicable.
Particle Bombardment
In this technique, DNA is coated onto the surface of 1-3 micron diameter gold or tungsten 
beads. The particles are accelerated by an electric discharge device or gas pulse and fired at the 
tissue [Schofield and Caskey, 1995]. The gene-coated particles penetrate the plasma membrane 
of cells and deliver the gene to the cytosol. The technique has been applied in vitro and in vivo 
with variable success depending on the tissue.
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Electroporation
In this technique an electric field is applied to the cell membrane causing the formation of 
hydrophilic pores {electropores) in the lipid matrix. The electropores are relatively stable, lasting 
from seconds to minutes [Sukharev etal, 1994] and may be further stabilised by the involvement 
of membrane proteins. Upon pulse termination electropores eventually reseal, although small 
residual leaks may remain indefinitely, unless there is repair by membrane turnover. These 
electric pulses lead to cellular uptake of DNA. The mechanism of this phenomenon is poorly 
understood, the apparent size of the electropores is considerably smaller than a typical piece of 
DNA. Electroporation appears to be biologically non-specific and has been applied in vitro and 
in vivo. Its major limiting factor may be hindrance for the access of DNA to the membrane. 
Recently an electroporation method has been shown to be highly efficient in transfer of reporter 
and therapeutic genes to muscle in a  variety of species in vivo [Mir et a/,1999]. Electroporation is 
a  promising technique; there are currently two protocols under way utilising electroporation as 
the gene transfer method [http://www.wiley.com/wileychi/genmed/clinical/vectors.html; 1st 
June 1999].
Calcium  phosphate precip ita tion
This is one of the earliest methods for the delivery of DNA to cells in vitro [Graham and Van der 
Eb, 1973]. DNA is precipitated with calcium phosphate and the precipitate is applied to cell 
monolayers. The technique has a  low transfection efficiency but proved to be a useful catalyst 
for the study of cellular DNA uptake and the development of gene delivery systems. The 
mechanism is thought to involve the uptake of particulate Ca2+-DNA complexes by non-specific 
endocytosis. Efficiency of uptake is dependent upon the quality of the precipitation reaction and 




These represent the best characterised gene delivery systems, largely due to their success in 
mediating transfection in vitro and the fact that they are easily produced by short, high yielding 
syntheses. The most successful systems are cationic, consisting of a lipid with a cationic or 
polycationic head group. These lipids self-assemble in aqueous solution forming microscopic 
structures such as bilayers, micelles and liposomes. They fall into two broad categories:
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1. Those with a  monovalent head group which typically form liposomes often with the aid of a 
neutral co-lipid such as dioleoyl-Lr-a-phosphatidylethanolamine (DOPE, figure 24), some 












Figure 25 Some monovalent cationic lipids, N-[l-(2,3-dioleyloxy)propyl]-N,N,N- 
trimethylammonium chloride (DOTMA), l,2-dioleoyloxy-3-(trimethylammonio)propane 
(DOTAP), 3J3-[N-(N’,N’-dimethylaminoethyl)carbamoyl]cholesterol (DC-Ghol) and N-(l,2- 
dimyristyloxypropyl)-N,N-dimethyl-N-(2-hydroxyethyl)ammonium bromide (DMRIE).
2. Those with a polycationic head group, the lipopolyamines, some examples of which are 
illustrated in figure 26. Lipospermines are reported to form tubular micelles in aqueous 
solution [Remy et al, 1998].
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Figure 26 Lipids with a polycationic head group, dioctadecylamidoglycylspermine 
tetrakistrifluoroacetic acid salt (DOGS), 2,3-dioleyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N- 
dimethyl-l-propanaminium trifluoroacetate (DOSPA) and N 15-cholesteryloxycarbonyl-3,7,12- 
tri-azapentadecane-1,15-diamine (CTAP).
Synthesis o f  cationic lip ids
D O TM A has been synthesised via a simple two step procedure [Feigner et al, 1987], illustrated 
in scheme 23. It can be seen that the DO TM A analogues DOTAP and DM RIE can also be 
synthesised using similar procedures.
?H  ^  OR  ^  OR 0
HOv x Av ^NMe2 R O ^ X ^ N M e 2 RO,s-XAsSv^ NMe3
Cl®
DOTMA
Scheme 23 Synthesis of D O T M A
Synthesis of the polycationic lipids is a little more demanding. For example the synthesis of 
DOGS via a multistep convergent synthesis is illustrated in scheme 24 [Behr et al, 1989]. Note 
that the cyanoethylation then reduction of lysine provides a simple method for the synthesis of 
branched spermine derivatives.
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Scheme 24 Synthesis of DOGS.
DC-Chol can be synthesised by simply coupling cholesterol chloroformate to N,N-dimethyl 
ethylenediamine [Gao and Huang, 1991], Efficient syntheses of a number of polyamine 
analogues of DG-Chol, including CTAP, using cholesterol chloroformate have recently been 
reported [Cooper et al, 1998].
Preparation o f  liposom es
Although some cationic lipids may self-assemble in aqueous solution to form microscopic 
structures, the formation of liposomes often requires some energy input into the system. 
Typically this involves vortexing, extrusion, sonication or homogenisation-microfluidisation of 
multilamellar vesicle suspensions prepared by the hydration of thin lipid films in aqueous 
solutions [Lasic and Templeton, 1996].
72
Chapter 4: An Introduction to the Science of Gene Therapy
Transfection using lip id ic system s
Since Feigner and co-workers [Feigner et al, 1987] showed that DNA complexes with lipidic 
vectors have high transfection efficiency in vitro, there have been hundreds of reports of the 
highly successful use of lipidic formulations for the transfer of DNA in vitro and there are many 
reviews covering this area [for example: Lasic and Templeton, 1996; Mahato et al, 1997; Remy 
et al, 1998; Miller, 1998]. The success of lipidic formulations has led to the widespread 
application of these systems as in vitro research tools and a number of systems are available 
commercially, some examples are given in table 4.
Trade nam e and manufacturer Formulation
Lipofectin, Gibco D O TM A /D O PE 1:1
DOTAP, Boehringer Mannheim DOTAP
Lipofectamine, Gibco D O SPA /D O PE 3:1
Transfectam, Promega DOGS
Table 4 Common commercial lipidic transfection agents.
Whilst these systems have been a great success for delivering DNA to cells in culture, their 
performance for the transfer of DNA in vivo has been somewhat disappointing and moreover, 
there is poor correlation between in vitro and in vivo activity. There are a number of possible 
reasons for this. Plasmid-lipid complexes often aggregate over time in the presence of salt or 
serum proteins [Mahato et al, 1997]. In particular, interaction of positively charged complexes 
with serum proteins and other extracellular matrix components may lead to aggregation or 
premature release of the DNA. As described earlier, the complexes are prone to opsonisation, 
activation of complement and subsequent reticuloendothelial clearance upon IV administration. 
There have, however, been a number of reports of successful gene transfer in vivo using cationic 
lipids via various administration sites [reviewed in Lasic and Templeton, 1996; Miller, 1998].
Transfection m echanism  fo r  lip id ic  system s
Liposome-DNA complexes are thought to enter cells via an endocytotic mechanism [Zabner et
al, 1995] and there have also been suggestions of the complex entering the cell via plasma
membrane fusion [Mahato et al, 1997]. Zabner et al have studied the mechanism and found that
the overall process of cationic lipid-mediated gene transfer is inefficient despite most cells taking
up the DNA. The study suggests that the limiting factors are release of the complex from the
endosome and translocation of the DNA from the cytoplasm to the nucleus. The majority of
delivered DNA accumulated in perinuclear endosomes. Release of the DNA from the complex
is important, as free plasmid injected directly into the nucleus is expressed whereas plasmid-lipid
complexes are not [Zabner et al, 1995]. The release of DNA from the complex has been studied
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[Xu and Szoka, 1996]. It was found that cytoplasmic-facing components of the plasma 
membrane such as phosphatidylserine cause rapid release of DNA from the complex. The 
authors suggest that, once the complex is internalised by endocytosis, destabilisation of the 
endosomal membrane occurs. This induces the formation of a  charge neutral ion pair between 
the cationic and anionic lipids of the endosomal membrane causing release of the DNA into the 
cytoplasm. Uptake of DNA into the nucleus is thought to involve an active transport process 
involving nuclear localisation signal proteins [Mahato et al, 1997].
6.2 Polymeric Vectors
A number of polymers, having various structures and properties, have been used in gene 
delivery experiments and the most important will be considered in turn. With the exception of 
PVP and PVA, which are neutral polymers, they are all polycationic.
Polyethylenim ine
Polyethylenimine (PEI) is a highly branched polyamine having two methylenes between each 
nitrogen, synthesised by the acid-catalysed polymerisation of aziridine. The general structure is 
depicted in figure 27.
NH2 h 2n
Figure 27 Polyethylenimine
PEI forms complexes with DNA via electrostatic interactions, it is around 20% protonated at 
physiological pH [Remy et al, 1998]. The transfection ability of PEI (800KDa and 50KDa) has 
been evaluated and compared with that of lipidic systems [Boussif et al, 1995]; it was found to 
be comparable to, or better than, lipopolyamines in mediating the transfer of a luciferase
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reporter gene in a number of cell lines. Luciferase gene transfer via intracerebral injection into 
newborn mice was also reported to be successful. The authors attribute the efficiency of PEI- 
plasmid complexes on an extensive lysosome buffering effect, so-called “proton sponge” 
behaviour. At pH  5, protonation of PEI increases from around 20% to 45% [Remy et al, 1998], 
this property allows the polymer to accumulate protons in the endosome. The protons are 
pumped in by the endosomal ATPase in a  process which is coupled to an influx of chloride ions. 
There is a net increase in the ionic concentration within the endosome and the polymer swells 
due to charge repulsion within its structure [Remy et al, 1998]. The authors postulate that this 
effect may cause endosomal disruption and inhibit the action of lysosomal nucleases. PEI has 
been shown to promote delivery of DNA to the nucleus (Pollard et al, 1998]. The study showed 
that PEI and, to a  lesser extent PLL, enhanced transgene expression when the complexes were 
injected into the cytoplasm of a number of mammalian cell lines, no enhancement was seen 
with cationic lipids. The study also showed that cationic lipids prevented expression when the 
complex was injected into the nucleus, this was not the case for PEI or PLL complexes. How 
significant these finding will be in terms of future novel vector design remains to be seen but the 
study does highlight the fact that the fate of the complex at the sub-cellular level is an important 
consideration.
A linear 22 kDa form of PEI, ExGen 500, has been shown to be more efficient than cationic 
lipids in mediating transfection of reporter genes to CF epithelial cell lines and normal trachea 
cells in vitro [Ferrari et al, 1997]. ExGen 500 was also more efficient than DOGS in mediating 
transfection of reporter genes to the lungs of newborn rabbits [Ferrari et al, 1997]. The authors 
suggest the high transfection efficiency may be a result of the “proton sponge” behaviour of the 
polymer.
Poly-L-lysine
NHCbz -o H -o H '
r N> ----- ►  "
. S. - n ■
NHCbz
86
Scheme 25 Synthesis of poly-L-lysine.
PLL 87 is synthesised by polymerisation of the N-carboxyanhydride (NCA) of Cbz-protected L- 
lysine 85 initiated with an amine nucleophile such as diethylamine to yield Cbz-protected PLL
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86  (scheme 25); the Cbz protection is removed from the polymer typically with HBr in glacial 
acetic acid. The primary amino groups are protonated at physiological pH  and the polymer is 
thus able to interact electrostatically with DNA. PLL-DNA complexes have been extensively 
studied and are well characterised [Shapiro et al, 1969; Wolfert and Seymour, 1996; Pouton et al,
1998]. PLL is able to mediate transfection in vitro, but typically requires an endosomolytic agent 
such as chloroquine [Pouton et al, 1998], There are many problems associated with the 
potendal use of PLL in vivo, not least, toxicity; it causes activation of complement and hepatic 
uptake. Further, aggregation of particles is a  significant problem; PLL-DNA complexes are only 
soluble up to about 20jig/ml DNA [Wagner, 1998]. The size of DNA-PLL complex particles 
was found to be dependent upon the molecular weight of the PLL, PLL 224500 produced 
particles with diameters ranging from 120-300nm (as determined by atomic force microscopy) 
[Wolfert and Seymour, 1996], whereas PLL 3970 produced particles in the 20-30nm range. 
Complexes formed using lower molecular weight PLLs showed significantly decreased 
cytotoxicity in vitro [Wolfert and Seymour, 1996]. In attempts to improve the properties of PLL 
for in vivo delivery, PLL has been modified with many functionalities including targeting ligands 
and hydrophilic polymers [Wagner, 1998; Zauner et al, 1998]. The discussion below gives 
examples of the modification of PLL with hydrophilic polymers; a very large number of 
targeting ligands have been conjugated to PLL, these are mainly aimed at receptor-mediated 
delivery and include galactose to target the asialoglycoprotein receptor of hepatocytes, folic acid 
for folate receptors on tumour cells and transferrin for the ubiquitous transferrin receptor 
[Wagner, 1998; Zauner, 1998].
H ydrophilic copolym ers
A number of block and graft copolymers of a polycation and a hydrophilic polymer have been 
prepared with a view to use in gene delivery. Hydrophilic polymers are used in an attempt to 
improve the biopharmaceutical properties of DNA-polycation complexes; the complexes with 
these copolymers have a greater water solubility and may have a reduced clearance and toxicity. 
Moreover, the use of hydrophilic constructs may allow the formulation of larger amounts of 
DNA than is possible with polymers such as PLL and PEI, whose complexes with DNA tend to 
aggregate at high DNA concentration. Many constructs have used PEG and given that the 
novel vectors described in this thesis are mPEG based, it will be useful here to summarise some 
properties of PEG.
Properties o f Poly (Ethylene Glycol)
PEG has some interesting properties that have led to its use in a number of biomedical 
applications. PEG has extremely low toxicity [Pang, 1993] and is non-immunogenic. It has 
been approved by the FDA for internal consumption and can be safely administered 
intravenously. Small PEGs of molecular weight less than 400Da may exhibit some toxicity. It
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has excellent solubility in aqueous solutions but also in many organic solvents including 
dichloromethane and toluene. It is not soluble in diethyl ether or in hexane, a property that can 
be useful in the isolation of PEG conjugates. Its presence in aqueous solutions has no deleterious 
effect on protein conformation or enzyme activity [Zalipsky, 1995]. A key property is the 
incompatibility of PEG with other polymers. PEG is effective at excluding other polymers from 
its presence in an aqueous environment; at high concentration a two phase system can be 
formed by solution of PEG and dextran for example [Harris, 1992]. Low toxicity and 
immunogenicity, and some properties of PEG-modified proteins are linked to this behaviour. 
These systems can also be useful in the purification of biological materials, as PEG can be used 
to precipitate proteins and nucleic acids. Further, partitioning of materials between two phase 
systems can be controlled by varying the phase components, for example in a PEG-dextran 
system, increasing PEG molecular weight acts to drive proteins into the dextran-rich phase.
PEG has been studied extensively in terms of modification of proteins and drugs by covalent 
attachment. Molecules to which PEG is attached usually remain pharmacologically active 
[Harris, 1992] but PEGylation affects certain properties of the molecule; these effects are often 
desirable ones. PEG solubilises other molecules, improves the water solubility of lipophilic 
organic compounds and the solubility of proteins in organic solvents. It renders proteins non- 
immunogenic, alters the pharmacokinetics of molecules and may aid the movement of 
molecules across cell membranes [Harris, 1992]. The most commonly used PEG molecular 
weights for biotechnical and biomedical applications are 2000-20000Da. The monomethyl 
ethers are commonly used to avoid cross-linking.
PEG-PLL block copolymers
An A-B type block copolymer of PEG and PLL (figure 28) has been synthesised by 
polymerisation of the NGA of Cbz-protected L-lysine initiated with a-m ethoxy-oam ino PEG 
10000 [Wolfert etal, 1996]. The copolymer formed self-assembling 
complexes with DNA. The complexes showed less surface charge 
than corresponding PLL-DNA complexes reaching a zero value of 
zeta potential at a higher charge ratio. Atomic force microscopic 
analysis showed that the complexes have an extended form with 
relatively thick linear and toroidal strands in contrast to the 
discrete, roughly spherical particles of PLL-DNA complexes. The 
authors suggest the unusual conformation of the complexes is possibly due to interaction of the 
polycationic block with DNA giving a structure with the PEG orientated outwards; with the 
inability of PEG to form intramolecular hydrogen bonds, possibly requiring hydrogen bonding 
to water for stability, the whole structure may be prevented from collapsing by the hydration 




Figure 28 PEG-PLL block 
copolymer.
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PLL complexes showed a significantly increased ability to transfect 293 cells (a human 
transformed foetal kidney cell line) with the P-Gal reporter gene compared to PLL. Optimal 
activity was at a charge ratio of around 1.5. It is suggested that this enhancement of gene 
transfer may be due to membrane activity or dehydrating fusogenic properties of PEG [Wolfert 
etal, 1996].
Another study using an A-B type block copolymer of mPEG 4300 and PLL 2500 [Katayose and 
Kataoka, 1997] examined the thermal melting curve of DNA complexed with PEG-PLL and 
with PLL alone, and the nuclease resistance of the complexes. The PEG-PLL copolymer 
produced a higher stabilisation of DNA structure compared to PLL, which the authors attribute 
to the compartmentalization of DNA into the microenvironment of PEG with low permittivity. 
Moreover, the copolymer-DNA complex, found to be ca. 50nm in diameter (by dynamic light 
scattering), showed high resistance to DNase I attack.
mPEG grafted poly-L-lysine
mPEG bearing a terminal carboxyl group was prepared from mPEG-NH2 by reaction with 
succinic anhydride [Toncheva et al, 1998]. The carboxyl groups were coupled to amino groups 
of PLL 20000 using 1-ethyl-3-[(dimethylamino)propyl]carbodiimide hydrochloride (EDC) and 
the resulting copolymer purified by dialysis. Copolymers were prepared with 5 and 10 mole% 
mPEG 5000 and 12000. In contrast to the PEG-PLL block copolymer [Wolfert et al, 1996], 
these graft copolymers produced discrete and well-defined particles as judged by atomic force 
microscopy. Copolymers with the longer mPEG chains showed particularly effective shielding 
of surface charge of the complex as indicated by zeta potential measurements. The complexes 
were considerably more water soluble than PLL-DNA complexes. Transfection efficiency (293 
cells) was greater for copolymers with longer mPEG chains or higher percentage mPEG grafting 
suggesting that possible membrane activity of PEG was promoting DNA entry into the 
cytoplasm [Toncheva et al, 1998]. In this study, PLL grafted with dextran (lOOODa) and with 
polyHPMA (4400Da) were also prepared.
mPEG grafted PLL has been prepared by conjugating mPEG 500 carboxylic acid to the amino 
residues of PLL by generating the acid chloride with thionyl chloride and allowing this to react 
with PLL in DM SO [Choi et al, 1998]. Copolymers with 5, 10 and 25 mole% mPEG were 
prepared and purified by dialysis. The amount of mPEG grafting was determined from the *14 
NM R spectra by using the ratio of the mPEG C H 2 signal to the PLL C H 2 signals. The 
molecular weight of the PLL used was 25000Da. The mPEG grafted PLL showed a 5-30 fold 
increase in transfection efficiency in Hep G2 cells compared to unmodified PLL. Chloroquine 
increased transfection efficiency suggesting cellular uptake of the complexes is through 
endocytosis. Although the study showed that lipofectin produced a slightly higher transfection
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efficiency, the mPEG PLL copolymers were less cytotoxic and showed earlier gene expression. 
The 10 mole% copolymer showed the best transfection efficiency and the 25 mole% copolymer 
was considerably lower. The authors offer the explanation that this degree of mPEG grafting 
(25%) hinders contact of the complex with the cell membrane thus hindering penetration into 
the cell.
Recendy, a PLL dendrimer has been synthesised and conjugated to mPEG-amine 6000 [Choi et 
al, 1999]. The PLL dendrimer, synthesised from L-lysine using Fmoc chemistry, has a  globular 
structure with 16 surface amine groups. The study showed that this copolymer formed a water- 
soluble complex with DNA that increased the stability of the DNA to DNase I.
PEG-polyspermine block copolymer
A block copolymer of PEG 1500 and a polyamine with around 12 nitrogen atoms 91 (which the 
authors named polyspermine) has been prepared [Kabanov et a/,1995]. The polyspermine was 
prepared by the reaction of 1,4-dibromobutane 89 with bis(3-aminopropyl)amine 88 followed 
by the reaction of this intermediate 90 with further 1,4-dibromobutane 89 (scheme 26).
Scheme 26 Synthesis of polyspermine [Kabanov et al, 1995].
The product of the reaction in scheme 26 was a mixture of polyspermines and unreacted 
monomers. These were separated by gel filtration chromatography and the molecular weights 
determined by end group analysis; three fractions were obtained with molecular weights of 980, 
720 and 490 g/m ol. The 720Da polymer was conjugated to PEG 1500 using 1,1'- 
carbonydiimidazole as a coupling agent. This produced a mixture of triblock polymers PEG- 
polyspermine-PEG and polyspermine-PEG-polyspermine and the desired diblock PEG- 
polyspermine (figure 29). To separate these, the authors conjugated the free amino groups to 2 -
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deoxyadenosine, as a chromophore, and then carried out gel filtration followed by reverse- 
phase HPLC.
Figure 29 PEG-polyspermine block copolymer.
The formation of micellar complexes with an oligonucleotide was demonstrated by reverse- 
phase HPLC. The copolymer was shown to prolong the toxic effects of an antisense 
oligonucleotide against HSV-1 virus in Vero cells; the authors suggest that this is due to an 
enhanced uptake of the oligonucleotide and protection against nuclease degradation. A later 
study examined the properties of the complex formed between the PEG-polyspermine 
copolymer and phosphorothioate oligonucleotides [Vinogradov et al, 1998]. This study 
described the polyamine segment of the PEG-polyspermine copolymer as being randomly 
branched, this is not surprising given the method of synthesis. PEGylated PEI was also prepared 
using a similar coupling procedure. Both PEG-PEI and PEG-polyamine complexes with a 
phosphorothioate oligonucleotide were found to be stable at physiological pH  and could be 
stored for several months after lyophilising. The complexes with PEG-polyamine were found to 
be ca. 12nm in diameter and the PEG-PEI, ca. 32nm, by light scattering and transmission 
electron microscopy techniques. The complexes were water soluble. Delivery of a 
phosphorothioate antisense oligonucleotide, targeted to fibronectin transcripts, to retinal 
vascular cells has been demonstrated using PEG-polyspermine as a carrier [Roy et al, 1999]. 
The oligonucleotide-polymer complex was injected intravitreally into rats; fibronectin mRNA 
levels were consistendy decreased compared to a  control. Fibronectin, a  basement membrane 
protein, is over-expressed in diabetic retinopathy causing basement membrane thickening, a 
histological marker for this disease. This approach therefore has potential in diabetic 
retinopathy and may be useful in other retinal diseases.
Polyvinylpyrrolidone and p o ly v in y l alcohol
The neutral polymers polyvinylpyrrolidine (PVP) and 
polyvinyl alcohol (PVA), shown in figure 30, were examined tH
OH
tHas carriers for gene delivery to skeletal muscle [Mumper et
a/,1996]. PVP is a strong hydrogen-bond acceptor, PVA PVP PVA
functions as a hydrogen-bond donor. Formulations of pCMV- Figure 30 Polyvinylpyrrolidone
(3-gal with PVP and with PVA were injected into rat tibialis and polyvinyl alcohol.
muscle in vivo and resulted in an increase in the number and distribution of cells expressing (3-gal 
compared to injections of the DNA formulated in saline. Up to a ten-fold enhancement in gene
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expression was observed over naked DNA using PVP of 50 kDa formulated at 5%, similar 
results were obtained with PVA 18 kDa formulated at 2%. Further studies were conducted to 
determine possible mechanisms of interaction of these polymers with DNA and the mechanism 
of enhancement of gene expression in muscle [Mumper et al, 1998]. Molecular modeling of 
PVP-DNA interaction showed that PVP forms hydrogen bonds with the base pairs of DNA 
within its major groove with the vinyl backbone of PVP providing a hydrophobic surface on the 
DNA. The addition of increasing amounts of PVP to DNA at pH  4 results in an increase in zeta 
potential corresponding to a decrease in the overall net negative charge. It was found that PVP 
carries a small positive charge in water below pH 5.5, but there is no evidence that PVP 
condenses DNA into particles as shown by laser light scattering of electron microscopy 
[Mumper et al, 1998]. Quenching of ethidium bromide-DNA complex fluorescence is observed 
with PVP in water at pH 4, a decrease in fluorescence of about 40% is seen at a  mass ratio 
(PVP:DNA) of around 100. PVP and PVA delivery systems have been termed Protective, 
Interactive, Non-Condensing (PINC) systems [Mumper et al, 1998].
Considering the findings of the various in vivo delivery studies and the experiments to determine 
the mechanisms of interaction of PVP with DNA, formation of PVP-DNA complexes is thought 
to enhance expression of reporter genes in rat muscle in vivo by the following mechanisms 
[Mumper etal, 1996,1998; M umper and Rolland, 1998]:
♦ Protection of plasmids from rapid nuclease degradation; this has been demonstrated in vitro 
using a DNase I degradation assay [Mumper et al, 1996]. This may be due to formation of a 
hydrophobic coating on the DNA.
♦ Dispersion of DNA throughout the muscle; this is likely to be due to osmotic effects.
♦ Retention of the intact DNA in muscle.
♦ Facilitation of the uptake of DNA by muscle cells, possibly due to increased hydrophobicity 
and decreased surface negative charge.
Recently, PVP has been used successfully to deliver the IL-12 gene to murine tumours in vivo 
[Mendiratta et al, 1999]. Intratumoural injection of the formulation led to IL-12 expression and 
subsequent induction of a potent antitumour immune response.
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Chapter 5: 
Synthesis of mPEG-Thermine Conjugates
1 Introduction
Recall that to date, gene therapy is severely limited by the lack of efficient gene delivery systems; 
all vectors that have been developed have significant drawbacks. It is becoming clear that agents 
that condense DNA, forming relatively insoluble particulate systems, have not lived up to early 
expectations since, though they can efficiently deliver DNA in cell cultures, they often have low 
transfection efficiency in vivo. There is therefore a need for new vectors. There has been 
increasing interest in water soluble complexes as opposed to lipidic systems [Kabanov et al, 
1995; Toncheva el al, 1998; Wolfert el al, 1996; Choi el al, 1998; M umper el al, 1996]. Broadly, 
the aim here was to synthesise a family of PEGylated polyamines that would be expected to 
form hydrophilic complexes with DNA capable of gene transfer in vivo. At the outset of the 
study, it was not certain how these conjugates would interact with DNA, whether they would 
condense DNA, forming a particulate system, or if the interaction would be somewhat weaker. 
This Chapter describes the synthesis of the first generation of these conjugates, those based on 
the linear tetramine, therminet 92. It will first be useful to 
consider, in general terms, how PEG may be conjugated 
to amines and how polyamincs may be synthesised and 
protected.
H2N
1.1 Activation of PEG as an Electrophile
In order to react with amines, PEG must be activated in some way such that it is electrophilic. 
PEG electrophiles have been used extensively in the preparation of PEG-protein conjugates due 
to their reactivity towards lysine residues, which often provide convenient, unhindered sites for 
PEG attachment. Many PEG electrophiles have been developed [Zalipsky, 1995; Zalipsky and 
Lee, 1992] some examples are shown in figure 31.
t The polyamine 92, N,N'-bis(3-aminopropyl)propane-1,3-diamine/1,11 -diamino-4,8-diazaundecane is a 
natural product isolated from the extreme thermophilic bacterium Thermus thenmphilus and has been given 
the trivial name thermine [Oshima, 1975]; it is referred to as thermine throughout this thesis.
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Figure 31 Electrophilically activated mPEGs.
The carbonate compounds are the most reactive towards amines and generate a  carbamate 
linkage upon reaction. The tresylate is less reactive and is now thought to yield a  sulfonate- 
amide upon reaction with amines [Gais and Ruppert, 1995]. The aldehyde is used under 
reductive conditions to yield a secondary amine, it has the advantage, in protein PEGylation, 
that its mild reactivity avoids potential side reactions with other nucleophilic functionalities. The 
acid chloride of mPEG 500 has been used to conjugate the mPEG to poly-
is to use a PEG glycidyl ether (oxiranylmethyl ether) 93.
Why choose the g lyc id y l ether as the PEG electrophile?
• Reaction with a secondary amine forms a tertiary amine; reaction with a primary amine 
may form a secondary amine or a tertiary amine depending on the compound and 
conditions employed. Therefore the basicity is not quenched, as is the case for derivatives 
that form amides or carbamates, and thus the amine is able to be protonated.
•  The pKa of the resulting secondary or tertiary amine may be such that it is only protonated 
within the endosomal compartment; this is potentially a desirable effect that is seen with 
polymers such as PEI and supposedly causes endosomal disruption aiding escape from the 
endosome.
•  There is no leaving group, therefore there are less potential problems with purification of 
the polymer conjugate.
•  Preparation of the PEG glycidyl ether is straightforward and it is relatively stable upon 
storage.
L-lysine [Choi et al, 1998J. The initial approach to be used here however, O
93
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1.2 Synthesis o f Polyamincs
Cyanoethylation fo llo w ed  by reduction
The Michael-type addition of certain compounds to acrylonitrilc which results in the formation
of a molecule containing a cyanoethyl group is generally referred to as cyanoethylation. Many 
classes of compound undergo this type of reaction (including amines, certain amides, alcohols, 
thiols, oximes), most require catalysis, however amines add more readily than any other class of 
compound and do not generally require catalysis [Bruson, 1949]. A widely used procedure for 
the introduction of aminopropyl units is cyanoethylation followed by reduction of the nitrile. 
Primary amines may react with one or two moles of acrylonitrile; low temperatures favour the 
addition of one equivalent, high temperatures and excess acrylonitrile favour the addition of 
two equivalents [Bruson, 1949] and stcric factors arc also involved; the rate of addition to 
secondary amines decreases progressively with the size of the alkyl groups. Very harsh 
conditions are often required to force a primary amine to add twice to acrylonitrile. For 
example, the reaction of benzylamine 94 with acrylonitrile (scheme 27) to yield the 
dicyanoethyl derivative 95 required heating to 110°C in a  sealed tube for 7 days [Bergeron et al,
Scheme 27 Dicyanoethylation of benzylamine, used during the synthesis of bis(3- 
aminopropyl)amine.
Nitrile groups can be reduced to the corresponding amine with a  variety of reagents, most 
commonly lithium aluminium hydride (LAH) or catalytic hydrogenation, typically over Raney 
nickel. Hydrogenation should be performed under basic conditions to suppress secondary amine 
formation by attack by the nascent amine on the imine intermediate; sodium hydroxide in 
E tO H  [Bergeron and Garlich, 1984] or methanolic ammonia [Schlogl and Schlogl, 1964] are 
commonly used. Nitrile groups have been reduced, in the synthesis of a polyamine, using 
sodium borohydride in the presence of cobalt (11) chloride hexahydrate [Buhleier et al, 1978J; 
this procedure is essentially a catalytic hydrogenation as colloidal cobalt, catalytically analogous 
to Raney nickel, is formed in situ and hydrogen is evolved.




Amines undergo alkylation by7 alkyl halides. O f particular use in 
polyamine synthesis is alkylation using bromoalkyl phthalimides such 
as N-(3-bromopropyl)phthalimide 96. Bromoalkylphthalimides are
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stable, readily available, cheap crystalline solids. The phthalimido protection on the amine can 
be removed efficiently using hydrazine. A typical example of the use of amine alkylation using 





Scheme 28 An example of the use of N-(3-bromopropyl)phlhalimide in polyamine synthesis.
Compound 97 was treated with N-(3-bromopropyl)phthalimide 96 in the presence of KF on 
Celite in acetonitrile to yield 98. The secondary amine was protected with Boc and the 
phthalimido group was removed with hydrazine. This sequence was repeated twice to yield 
tetra-protected pentamine 99. KF on Celite is typically used in these reactions; it enhances the 
nucleophilicity of the alkylating species by hydrogen-bond formation with the fluoride anion 
[Ando and Yamawaki, 1979]. Formation of tertiary or quaternary amines presumably docs not 
readily occur due to steric constraints. Alkylation can also be achieved by generating the anion 
of a sulfonamide (such as 100) and allowing this to reacl with a halo compound, for example 














Scheme 29 Synthesis of homospermine 102.
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Reduction o f  am ides
Given the wealth of literature available concerned with peptide synthesis, i.e. making amides, it 
is perhaps surprising that the synthesis of polyamines via the reduction of amides has not been 
widely reported. This may be due to the harsh conditions that are often required to reduce 
amides, limiting functionality elsewhere in the molecule, and difficulties in isolating the highly 
polar polyamine products from borane or LAH reaction mixtures. A simple example of the use 
of this approach for the synthesis of diBoc spermidine 104, by reduction of amide 103 using 




Scheme 30 Reduction of an amide in the synthesis of a  spermidine derivative.
R eductive am ination
Aldehydes react with primary and secondary amines to form imines; reduction of the imine in 
situ, typically with sodium cyanoborohydride, under mildly acidic conditions, gives the 
corresponding secondary or tertiary amine. This procedure is referred to as reductive amination 
or, alternatively, as reductive alkylation. Polyamines can be built with N-protected amino 
aldehydes using this procedure; amino aldehydes arc easily synthesised from the corresponding 
amino alcohol by Swern oxidation. An example is illustrated in scheme 31 where a wasp toxin, 
philanthotoxin-4.3.3 (107 after deprotection) was constructed using a reductive alkylation 










N. ^  .NHCbz
Scheme 31 Reductive amination in the synthesis of a polyamine derivative [Moya and 
Blagbrough, 1995].
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1.3 Which Polyamincs ?
M any studies using polyamines in the synthesis of gene delivery vectors or other applications
have used the widely occurring polyamines such as spermine and spermidine. However, in this
study it was decided to use thermine 92 as a rational ,, ,
H2N N N NH2
starting point, where the methylene spacing between the ^ 92 ^
nitrogens is 3-3-3 as opposed to 3-4-3 as in spermine.
Furthermore, in a study on the compaction of DNA by diaminoalkanes, it was found that 
diaminoalkanes that possessed 3 or 5 methylenes between the nitrogens were considerably more 
efficient in inducing compaction than the other compounds (diaminoalkanes with between 1 
and 6 methylenes were examined in the study) [Yoshikawa and Yoshikawa, 1995J.
1.4 Protection of the Amino Group
Polyamines possess many reactive nitrogens, thus an effective protection strategy is fundamental 
to the synthesis of polyamines and polyamine conjugates/analogues. Many amino protecting 
groups have been developed [Kocienski, 1994; Greene and Wuts, 1999] and much of the 
chemistry has come from the synthesis of protected amino acids for peptide synthesis. A brief 
account of the most commonly used amino protecting groups will follow.
t-Butoxy carbonyl (Boc)
OThe Boc group has been extensively applied in amine and amino acid JF \ /
protection chemistry. It is easily introduced with di-£-butyl dicarbonate J H 
(B0 C2O) [Tarbell et al, 1972] in a fast and high yielding reaction, the by-products being carbon 
dioxide and ^-butanol. It is stable to many reaction conditions including catalytic 
hydrogenolysis, bases and nucleophilic reagents. It is easily and rapidly removed with acid, 
commonly HC1 or trifluoroacelic acid. 2-(£-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
(BOC-ON) can also be used to introduce Boc protection; it is less reactive than Boc-iO and has 
been applied to the selective protection of primary amines in the presence of secondary amines 
(Hu and Hesse, 1996].
Benzyloxycarbonyl (Cbz)
The discovery of benzyloxycarbonyl protection in 1932 [Bergmann and 
Zervas, 1932] paved the way for significant advances in peptide synthesis * h 
and it remains a widely used, versatile protecting group. It is efficiently 
introduced to amino acids and other amino compounds under Schotten-Baumann conditions 
using benzyl chloroformate, although this reagent can be used to equal effect in organic solvent 
systems. Tt is highly stable in strongly basic conditions and acidic conditions up to pH  1. Tt is 
easily removed by catalytic hydrogenation typically with palladium on charcoal, often at
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atmospheric pressure. HBr in glacial acetic acid or Na in liquid ammonia may also be used. 
Benzyl chloroformate has the disadvantage that it decomposes on storage, even at low 
temperature, and contents of up to 20% benzyl chloride can be observed [Wiinsch, 1986] 
leading to possible side reactions. This can be avoided by the use of dibenzyl diearbonate 
[Wiinsch, 1986], although this reagent is expensive and requires storage at <0°G.
9-Fluorenylm ethyloxycarbonyl (Fmoc)
This is introduced with 9-fluorcnylmcthyl chloroformate and can be 
removed selectively with a  secondary amine such as piperidine. It is 
highly resistant towards acid, but may be sensitive to hydrogenolysis 
albeit at a much lower rate than Cbz. This group has been 
extensively applied to solution and solid phase peptide synthesis.
Boc, Cbz and Fmoc represent the most useful amino protecting groups and many protection 
strategies can be solved using these groups alone; all are fully orthogonal to each other. There 
are many other carbamate protecting groups including 2,2,2-trichloroethoxycarbonyl (Troc) 
and 2-(trimethylsilyl)ethoxycarbonyl (Teoc). The Troc group is useful as it is stable to acid and 
base (thus Boc and Fmoc can be removed in its presence) but is easily removed under mildly 
reductive conditions such as Zn/am m onium  acetate which does not affect groups such as Boc or 
TFAc.. Teoc can be removed using the highly selective reagents typically used to remove 
organosilicon protecting groups such as tetrabutylammonium fluoride.
Trifluoroacetyl (TFAc)
Amides are not generally useful as protecting groups due to the harsh conditions required to 
cleave them, the exception being trifluoroacetamide which is readily base hydrolysed and thus 
can be removed in the presence of Boc and Cbz. TFAc is a very useful amino protecting group 
as it can be introduced selectively to primary amines over secondary amines using ethyl 
trifluoroacetate [Xu et al, 1995]. Secondary amines can be protected with TFAc by reaction 
with trifluoroacetic anhydride.
Phthalim ido (Phth)
The phthalimido group is useful as amines can be extended with aminoalkyl units using N- 
bromoalkyl phthalimides (see the discussion on polyamine synthesis above). Phth protection can 
be removed in high yield with hydrazine, conditions that do not affect Boc or Cbz.
Sulfonam ides
Sulfonamido protection is introduced using the corresponding sulfonyl chloride and can be 
removed using N a/liquid ammonia or HBr/glacial acetic acid/phenol. Examples of the use of 
sulfonamido protection in polyamine synthesis are provided in scheme 29 [Bergeron etal, 1996]
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(page 86) and scheme 37 [Bergeron etal, 1988] (page 95). Sulfonamides are very stable and often 
highly crystalline.
Although the benzyl group is not a particularly useful or often used protecting group for 
amines, as it is not very easily introduced or removed, it is worth a mention here because the 
di-functionalisation of benzylamine with cyano-alkyl chlorides or acrylonitrile (see scheme 27) 
followed by reduction of the nitrilcs is a useful way into spermidine derivatives bcnzyl-protcctcd 
on their central nitrogen [Bergeron et al, 1981]. Bergeron and co-workers were able to reduce 
nitrile groups without affecting the benzyl group using LAH [Bergeron et al, 1981]. N-Benzyl 
groups can be cleaved by catalytic hydrogenolysis, but the reaction is often slow and requires a 
higher catalyst loading an d /o r higher pressure of H 2 and /o r a higher temperature then O- 
benzyl protection. N a in liquid ammonia provides an alternative, efficient removal of N-benzyl 
groups.
Recently Hesse and co-workers have described the construction of linear pentamines bearing 
five independently removable N-protccting groups [Pak et al, 1998; Pak and Hcssc, 1998a,b] 
Scheme 32 shows some of their work [Pak et al, 1998] and serves to illustrate a good example of 
the synthesis/protection and deprotecLion of a linear pentamine.
B enzyl























Scheme 32 Synthesis of a  penta-N-protected pentamine 108 with five independently 
removable protecting groups.
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This represents an elegant five-step convergent synthesis of a penta-N-protected pentamine 108. 
Each protecting group was removed independently thus allowing elaboration of any number of 
the five amines. The Boc group was removed with trifluoroacetic acid in dichloromethane. The 
triethylsilylethanesulfonyl (SES) group, which is stable to acid and base, was removed with GsF 
in DMF. The allyl group could be cleaved with N,N'-dimethylbarbituric acid and 
tetrakis(triphenylphosphine)palladium and the Phth with hydrazine. The authors found it was 
not possible to remove the 2-pyridinesulfonyl group (with S1T1I2) without reduction of the Phth. 
They could however exchange the Phth group for TFAc (treatment with hydrazine followed by 
acylation with trifluoroacetic anhydride), this allowed the 2-pyridinesulfonyl group to be 
removed selectively and quantitatively by electrolysis. Finally the trifluoroacetyl group could be 
hydrolysed with potassium carbonate in M eO H /FkO .
1.5 Aims and objectives o f this work
♦ To explore established methods an d /o r to develop new methods for the synthesis of a range 
of suitably protected polyamines, for coupling to electrophilically activated mPEGs.
♦ To synthesise mPEG derivatives, suitably activated to allow coupling to primary and or 
secondary amino groups. Specifically, it was intended to utilise mPEG glycidyl ethers.
♦ To investigate the reaction of PEG glycidyl ethers with suitably protected polyamines. This 
should determine whether or not it is desirable to N-methylate the amine (scheme 33, line 
A); or, whether or not the reaction can be controlled such that the PEG glycidyl ether adds 
only once to a primary amine (scheme 33, line B); or, whether or not it is possible to 
separate mono from diPEGylated material (scheme 33, line C) using the methods available 
on a large scale ie. column chromatography on silica. It was intended to synthesise 
symmetrical diPEGylated and unsymmetrical monoPEGylated conjugates of thermine, and 
PEG conjugates of branched polyamines.
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'N 'CH3 ---------------- ►  i V - ^ N ' ^ Y ^ 0 (CH2CH20)„C H 3 ^
H CH3 OH
'NH' N^V^O (CH2CH20)nCH3 B  
H OH
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N ^ t /V "0(CH2CH20)nCH3 
H OH +
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"Y ^O (C H 2CH20)nCH3 
OH
Scheme 33 Possible reactions of mPEG glycidyl ethers with amines.
♦ To measure the ability of the synthesised conjugates to form complexes with DNA, using a 
spectrofluorimetric assay, in order to establish their potential as excipients for the 
formulation of gene medicines.
2 Synthesis of Thermine Derivatives for Coupling to mPEG
At the outset of this study it was felt that separation of mixtures of different PEGylated 
polyamines by chromatography may not be practicable and that coupling using secondary 
amines would be desirable; thus initially N-methylated thermine derivatives were prepared. In 
practice it was possible to explore coupling to both primary and secondary amines with success 
and both methods have advantages and disadvantages.
2.1 N^N^N^N^-Tetramethylthermine
Route a ttem pted  via  N 1, N3, N9, N 1S tetraform yItherm ine
The simplest thermine derivative that could be coupled to an electrophilically activated mPEG, 
such as the glycidyl ether, to form a symmetrical a,co-diPEGylated conjugate, is the tetramethyl 
compound 110 (scheme 34). This would require no modification, such as protecting group 
removal, after conjugation. This was the first target polyamine. It was thought that the methyl 
group would not interfere with the electrostatic interaction of the protonated amine with DNA.
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H3CHN nhch3
Scheme 34 Proposed synthesis of 110.
The proposed synthesis was to make the tetraformyl derivative 109 of thermine 92 and then to 
reduce the amides to give the tetramethyl compound 110. Krakowiak et al [Krakowiak et al, 
1989] described the synthesis of the tetra-N-ethyl homologue of 111 (scheme 35) by reducing 
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Scheme 35 Synthesis of a tetraethyl polyamine 113 by reduction of the tetraacetamide 112 
[Krakowiak et al, 1989].
Further, formylation followed by reduction using BH3.Me2S has been described as a general 
procedure for the production of N-methyl (N-aikyl) amines [Krishnamurthy, 1982] and, in 
general, the reduction of primary, secondary and tertiary amides to yield their corresponding 
amines is a well-documented procedure [Brown and Heim, 1973; Brown et al, 1981a,b]. 
Treatment of thermine with excess ethyl formate gave tetraformamide 109 in 85% yield after 
chromatography. Although thermine is commercially available, the commercial material is 
expensive and of variable quality. Thermine 92 was easily prepared by the symmetrical 
dicyanoethylation of propane-1,3-diamine 114, in quantitative yield by treatment with two 
equivalents of acrylonitrile at 0°C then room temperature, followed by reduction of dinitrile 
compound 115 by catalytic hydrogenation over Raney nickel in methanolic ammonia (scheme 
36).
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Scheme 36 Preparation of thermine 92.
After filtering off the catalyst, washing it, and evaporating the methanolic ammonia, the sample 
appears as a blue oil. This is thought to be due to a complex forming between trace amounts of 
Ni2+ ions and the polyamine or ammonia or involving both. This did not pose a purification 
problem in this case, the thermine was obtained as a colourless liquid in 67% yield by 
Kugelrohr distillation of the crude, blue material.
The tetraformamide was found to have very low solubility in a range of organic solvents. It was 
insoluble in the aprotic solvents commonly used for LAH or borane reductions, such as diethyl 
ether, TH F, dioxane or 1,2-dimethoxyethane. It was soluble in bis(2-methoxyethyl)ether 
(diglyme) at temperatures near its boiling point (162°C) and was slightly soluble in C H 2CI2. 
Reduction was attempted using LAH in boiling diglyme; however, numerous new products 
were observed by TLC. The reduction was attempted using BH3.Me2S in C H 2CI2. Although 
the tetraamide was only slightly soluble in C H 2CI2, it was thought that the product would have 
a higher solubility. Hence, as product forms, more tetraamide may go into solution and 
eventually the reaction may go to completion. Thus the reduction was attempted using the 
method of Brown [Brown et al, 1981a,b]. The amide was treated with BH3.Me2S in C H 2CI2 in 
the presence of BF3.Et20. No products could be isolated from the reaction mixture. In 
conclusion, reduction of tetraformamide 109 is not a viable method for the synthesis of 
tetramethyl amine 110, thus an alternative method was sought.
Route a ttem pted  via  N 1, NI3-bis {triJluoroacetyl)-N5} N9-dim ethyltherm ine
The terminal primary amines of spermine have been N-methylated (scheme 37) by preparation 
of tetratosyl spermine 116 followed by treatment with sodium hydride and methyl iodide, then 
removal of the tosyl protection with N a/liquid ammonia [Bergeron et al, 1988].
93
Chapter5: Synthesis of mPEG-Thermine Conjugates
I s  116
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Scheme 37 Preparation of dimethylated spermine from spermine 3 [Bergeron etal, 1988]
Trifluoroacetamide derivatives have also been used in this way for N-methylation; an example 
is illustrated in scheme 38 [Broka and Gerlits, 1988].
K ^ ^ N h 2 (F3C C 0 )2 0 /p y r id in e  | v
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Scheme 38 Methylation of a primary amine via its trifluoroacetamide [Broka and Gerlits, 
1988].
Obviously, this type of method could not yield the required tetramethyl compound 107, as 
secondary amines cannot be methylated in this way. However, the diamine, N,N '- 
dimethylpropane-1,3-diamine, 119 (scheme 39), is commercially available and could thus be 
used as a starting material. Following the successful cyanoethylation and reduction sequence 
used in the synthesis of thermine, an analogous procedure utilising the dimethylated diamine 
119 would yield 121. This could be N-methylated using a similar procedure to that used for the 
synthesis of dimethylated spermine 118. The reduction of 120 by hydrogenation over Raney 
nickel had previously been reported [Schlogl and Schlogl, 1964].
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Scheme 39 Proposed synthesis of tetramethyl amine 110; R  would be tosyl or trifluoroacetyl.
Thus 119 was treated with acrylonitrile to yield the dinitrile 120, quantitatively. Compound 
120 was reduced with PG/Raney nickel in saturated ethanolic N aO H  at 35°C. N aO H  was used 
as the base to investigate if this would suppress the formation of the nickel complex seen when 
methanolic ammonia is used. After the catalyst was removed, the mixture was concentrated to 
low volume and the amine was caused to come out of solution by the addition of 70-80% 
aqueous NaOH. Extraction of the highly polar amine with chloroform proved to be difficult 
due to formation of emulsions. However, the crude amine was indeed colourless prior to 
Kugelrohr distillation and not a blue nickel complex. The tetramine 121 was obtained in 36% 
yield. It is likely that the low yield is largely due to poor recovery of the polyamine from the 
N aO H  mixture. In a further attempt to improve the yield, the reaction was carried out in 
methanolic ammonia as described for the synthesis of thermine. This again gave a blue product. 
This time however, the Ni2+ contaminant was removed by precipitation as NiS, by bubbling 
H 2S through a solution of the amine. This gave the crude amine as a pale brown oil. Attempts 
to purify this by making the hydrochloride salt and then recrystallising it were unsuccessful. 
However, the !H  NM R spectrum illustrated that the material was of sufficient purity to be 
useful synthetically and is shown in figure 32.
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3.2 3.0 2 .6 2.42 .6 2,2
F igure  32 'H  NMR spectrum of the hydrochloride salt of compound 121 (270MHz, D2O).
Following the successful synthesis of the tetramine with methyl groups on the middle secondary 
nitrogens, attempts could be made to methylate the terminal primary amino groups. It was 
decided to use the bis(trifluoroacetamido) derivative (scheme 40) as the intermediate for the 
methylated tetramine as this group is easier to introduce, and also to remove, than tosyl groups, 
cleavage of which requires harsh procedures using Na/liquid ammonia or HBr/glacial acetic 
acid. Hence, the bis(trifluoroacetamide) 124 was prepared in quantitative yield by treatment of 
121 with ethyl trifluoroacetate in MeOH at room temperature. The use of ethyl trifluoroacetate 
provides a mild and efficient introduction of the TFAc group to primary amines; the reaction 
by-product following acyl transfer, EtOH, is simply evaporated from the reaction mixture along 
with any excess reagent [Xu etal, 1995; Curphey, 1979].
H o C H N ^ ^ N ^ ^ N ^ ^ N H C H o
CH3 ch3 
110
Schem e 40 Proposed use of bis(trifluoroacetamide) 124 as an intermediate in the synthesis of 
N^N^N^N^-tetramethyl thermine.
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Attempts to methylate compound 124 failed. The bis(trifluoroacetamide) was treated with 
potassium fert-butoxide in dry TH F under nitrogen, followed by methyl iodide. Although there 
was some evidence of further methyl groups in the 'H  NM R spectrum of the crude product, 
recovery of organic products, after aqueous work up to remove the inorganic by-products, was 
low. There are were other problems associated with this reaction. Firsdy, the trifluoroacetamide 
is a  hygroscopic oil and it is difficult to remove all traces of water from it, this may react with the 
potassium tert-butoxide an d /o r the formed anion. Secondly, there is a chance some of the 
methyl iodide may react with the middle tertiary amines forming quaternary ammonium salts. 
In addition, the di-anion is not very soluble in THF. A third synthesis was proposed, this proved 
to be successful and is described below.
Route f ro m  trButyl N -m ethy l-N-(3-jmethylaminopropy I) carbam ate
In this approach, no methyl groups are introduced as electrophiles, rather the molecule is 
constructed by joining two N,N'-dimethylpropane-1,3-diamine molecules together to form the 
tetramine. The approach is illustrated in scheme 41.
CH3 CH3 Boc CH3 CH3 Boc
110 127
Scheme 41 Synthesis of tetramethylthermine 110 from N,N'-dimethylpropane-1,3-diamine 
119.
NjN'-Dimethylpropane- 1,3-diamine 119 was treated with V 3 equivalents of di-fert-butyl 
dicarbonate in T H F to give the mono-Boc derivative 126 in 71% yield after chromatography. 
Treatment of 126 with V2 equivalents of 1,3-dibromopropane in DM F at 80°G gave the 
desired tetramethyl compound as the diBoc derivative 127 in 52% yield after chromatography. 
The Boc protection was removed by treatment with 5M hydrochloric acid to yield the 
tetramethyl compound 110 as its tetrahydrochloride salt.
2 .2  N^N^-diBoc-N1 ,N 2 3-dimethylthermine
Recall that the methylation of 124 was unsuccessful, possibly due to poor extraction of the 
product during aqueous work up or to low solubility of the di-anion in THF.
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An approach to overcome these problems was to replace the middle methyl groups with a 
protecting group that would increase the solubility of the compound in organic solvents to make 
extraction from inorganic by-products easier and increase the solubility of the di-anion in THF. 
It is important that the protecting group should be easy to remove, once coupling to PEG had 
been achieved. The Boc protecting group is easy to introduce, should be stable under the PEG 
coupling reaction conditions and is easy to remove with acid, generating only gaseous by­
products. This group should improve the solubility of the tetramine in organic solvents and the 
solubility of the di-anion in TH F and was the protecting group of choice. Compound 128 was 
thus the target polyamine for coupling to mPEG and the proposed synthesis is shown in scheme 
42. Synthesis of this protected polyamine was also desirable because its mPEG conjugates may 
have potential advantages; the less polar nature of this protected polyamine may make 
purification and characterisation easier and the absence of methyl groups on the middle 
nitrogens makes hindrance of DNA interaction less likely.
The preparation of diBoc protected tetramine 130 by symmetrical dicyanoethylation of 
propane-1,3-diamine (as in scheme 34) had been described by McCormick et al [McCormick et 
al, 1993]. Treatment of 115 with B0 C2O gave 129, reduction with IA H  gave the diamine 130.
'N N ^  ^  N N'
115
H H Boc J 2 9  Boc
Boc Boc 
130











h 3c h n . ,NHCFh
128
Scheme 42 Synthesis of compound 128.
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The procedure was carried out according to the literature procedure [McCormick et al, 1993]. 
The dinitrile 115, used in the preparation of thermine (scheme 34), was treated with B0 C2O in 
CH 2CI2 to give the diBoc protected derivative 129 in quantitative yield. Reduction of the nitrile 
groups was carried out using LAH in dry ether/TH F at 0°C.
Boc
The reduction step, however, gave only 22% yield of the
133
desired diamine, the reaction yielding a significant quantity of a
by-product 133. This presumably formed via a reverse Michael addition type mechanism.
Indeed, McCormick et al [McCormick et al, 1993] did report the reaction to be of disappointing 
yield:
 The one disadvantage of this route is the disappointing yield (40 to 50%) in the nitrile reduction. The
reduction was also carried out via catalytic hydrogenation (Adams’ catalyst, Raney Nickel and Pearlman’s 
catalyst), but none of these reactions represented an improvement.
In contrast to the findings of McCormick et al, reduction of 129 by catalytic hydrogenation 
improved the yield to 69%. Compound 129 was treated with Raney nickel in methanolic 
ammonia under 50psi of hydrogen for 72 hours. This yielded a blue oil which was purified by 
column chromatography. The terminal free amino groups were converted to their 
trifluoroacetamide derivatives by treatment with ethyl trifluoroacetate in MeOH at room 
temperature. Treatment of 131 with potassium /-butoxide, 
followed by methyl iodide in dry THF gave the methylated 
amide 132 which could be isolated by a conventional work up; 
evaporation of the THF left a residue which was dissolved in 
CH 2CH 2 and was washed with water to remove the inorganic 
by-products. The yield of the reaction was disappointingly low, 
until freshly distilled THF was employed when highly pure 132 
could be isolated in 98% yield without the need for 
chromatography. Initially it was not obvious from the H  NMR 
spectrum that methylation had occurred. However, careful 
analysis suggested the new methyl signal appeared as two peaks 
due to rotational isomerism. Re-running the spectrum at 100°C 
overcomes the barrier to rotation and the methyl signal appears 
as one peak. Interestingly, the 19F spectrum (figure 33) shows 
two peaks in a 2:1 ratio suggesting the ratio of the Z  to the E  rotational isomers is 2:1. The 
trifluoroacetamides were effectively cleaved by treatment with concentrated aqueous ammonia 
in methanol (1:4) in a sealed vessel at 55-60°C. This gave the dimethylated diBoc-protected 
tetramine 128 in 79% yield after chromaography.
-68 -69
Figure 33 19F spectrum 
of compound 131.
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C o m pou n d  131 can be syn th e s ise d  by an a lte rn a tive  m e th o d
Note that the method used to introduce the trifluoroacetamido group, an acyl transfer using 
ethyl trifluoroacetate, was that described by Xu et al [Xu et al, 1995]. In this communication, the 
authors describe how this reagent can be used to differentiate primary from secondary amino 
functions. Using this methodology it was possible to selectively trifluoroacetylate the terminal 
primary’ amino groups of thermine. Thermine was treated with 2 equivalents of ethyl 
trifluoroacetate in MeOH at 0°C then room temperature. Simply evaporating the solvents gave 
highly pure bis(trifluoroacetamido) compound 134 in quantitative yield (scheme 43). The 13C 
NMR of this product shows a good example of fluorine-carbon coupling and this is illustrated in 
figure 34.
1 F3CCO
J  = 37Hz c f 3
..1 J J  = 288Hz.J______
150 100
Figure 34 section of the 13C spectrum of compound 134 illustrating fluorine-carbon coupling.
Treatment of 134 with di-/-butyl dicarbonate in THF at 0°C, then room temperature gave the 
bis(trifluoroacetamido)-diBoc compound 131 in quantitative yield.
Scheme 43 Synthesis of compound 131 from thermine.
This therefore represents an alternative route to the fully protected intermediate 131 in two 
steps (quandtative yield) from thermine 92 as opposed to four steps (69% yield) from 
propane 1,3-diamine (scheme 42).
100
Chapter 5:Synthesis of mPEG-Thermine Conjugates
3 Coupling of mPEG to the polyamines
3.1 Overview
When deciding which mPEG molecular weight would be desirable for conjugation to the 
polyamine it was considered that using a PEG of molecular weight greater than about 4000Da 
may hinder binding of the polyamine to the DNA and would also make chemical 
characterisation of the conjugate more difficult. The molecular weight would however need to 
be higher than about 400Da to avoid potential future problems with toxicity. A sample of 
mPEG 2000 glycidyl ether was available*, so it was decided to use this as a starting point.
The reaction between epoxides and amines has been widely studied, largely because of its use in 
the curing of epoxy resins. The reaction occurs most readily in hydroxylic solvents [Shechter et 
al, 1956] and there is no great difference in the reaction of primary amines compared to that of 
secondary amines; sterically hindered amines react more slowly. The study by Shechter et al 
[Shechter et al, 1956] suggests that the possible competing reaction, that between hydroxyl 
group, either from the solvent or the ring opened epoxide, and epoxide does not occur to a 
noticeable extent. The choice of hydroxylic solvent here was uopropanol, being less nucleophilic 
than lower alcohols and allowing a higher reaction temperature if required.
3.2 Preliminary Reaction with Phenyl Glycidyl Ether
Before using the mPEG glycidyl ether, the reaction was tried using phenyl glycidyl ether 135 as 
a model. It was thought that this would give a product that was easy to purify and characterise 
and thus demonstrate the feasibility of the coupling reaction. The diBoc-protcctcd polyaminc 




Scheme 44 Model glycidyl ether coupling reaction.
t1 am grateful to Dr S.E. Matthews, Institute of Macromolecular Chemistry, Prague, Czech Republic for 
the kind gift of a sample of mPEG 2000 glycidyl ether.
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Thus compound 128 was treated with 2 equivalents of phenyl glycidyl 135 ether in wopropanol 
(scheme 44) at reflux for 10 hours. The product 136 was isolated by preparative TLC in 26% 
yield. The low yield may have been due to poor recovery of product from the crude mixture by 
the preparative TLC method; the reaction may also require longer than 10 hours to proceed 
fully.
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137
S ch em e 45 Synthesis of mPEG 2000 conjugate of 128.
Again the diBoc-protected polyamine 128 was used, this time it was felt the Boc methyl signals 
may provide a useful *H NM R reference. A solution of the polyamine 128 and two equivalents 
of mPEG 2000 glycidyl ether 138 in ijopropanol was heated to reflux for 27 hours. A minor 
difficulty was monitoring the progress of the reaction; it was difficult to visualise the conjugate 
on TLC. Reaction progress could be followed by observation of a fall in intensity of the spot 
corresponding to the starting amine. Although the evidence from TLC indicated that a 
conjugate had formed, confirmation that the mPEG epoxide had indeed reacted with each 
amine was required. It was not possible to obtain a mass spectrum with the instrument available 
and it could not be decided with certainty from the *H NM R spectrum that conjugation had 
occurred. The peaks corresponding to the protons of the polyamine chain, and the atoms 
linking the PEG to the polyamine, were very small in comparison to the peak for the methylenes 
of the mPEG chain. NM R decoupling experiments, involving signals that potentially 
corresponded to the protons of 2-hydroxypropyl unit linking the PEG and amine, provided 
some evidence, albeit weak, that the coupling had been successful. A matrix-assisted laser 
desorption ionisation time of flight (MALDI-TOF) mass spectrum was required to confirm that 
the diPEGylated conjugate 137 had been synthesised, the spectrum is shown in figure 35.
102





32*00" ' 34*00 ' ' 36*00' ’ 38*00' ' 40*00' ‘ 42*00 ‘ ‘ 44*00' '^ O o ' ’ 48*00' ' 50*00' '52*00* ' 54*00' ' 56*00
F igure  35 MALDI-TOF spectrum of conjugate 137.
3.4 Coupling with mPEG 550 Glycidyl Ether
Following the difficulties in characterising the mPEG 2000 conjugate, it was decided to use a 
lower molecular weight mPEG (550Da), so that NMR spectra may be clearer and it may be 
possible to gain useful mass spectra, as the molecular weight of the conjugates should be within 
the capabilities of the available instrument using FAB or electrospray ionisation.
S yn th esis o f  m PEG  550g ly c id y l e ther
The method used here was adapted from the method of Gu et al [Gu et al, 1985; Matthews, 
1995J for the synthesis of diglycidyl ethers of oligo(ethylene glycol)s using epichlorohydrin and 
sodium hydroxide under phase-transfer catalysis. The work of Gu et al describes the effect of 
phase transfer catalysis and molecular weight of the glycol upon the efficiency of the reaction. 
The reaction proceeded more efficiently, even in the absence of catalysis, with increasing 
molecular weight and the authors suggest this is due to increased solubility of the alkoxide anion 
in epichlorohydrin. Thus, it was reasonable to assume that using mPEG 550 may require no 
catalysis. mPEG 550 was dried by azeotropic removal of water in toluene and then treated with 
epichlorohydrin, NaOH and water at 60°C for 3 hours. A small amount of water was added to 
allow a greater amount of NaOH into solution. The reaction solvent is effectively 
epichlorohydrin as a large excess is used (12eq). After the reaction the mixture is dissolved in
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C H 2CI2 and the N aO H  filtered off. The mixture requires evaporation under high vacuum for 
several hours to remove all the excess epichlorohydrin. Complete conversion of the hydroxyl to 
glycidyl ether could be conveniently determined by NM R in [2H]6-DMSO. The mPEG O H  
resonates as a clear triplet at 84.56 [Dust et al, 1990], disappearance of this signal indicates 
complete conversion to the glycidyl ether.
Coupling
Compound 128 was treated with mPEG 550 glycidyl ether in wopropanol at reflux for 29 
hours. This lime, however, it was possible to obtain a FAB mass spectrum of the product which 
confirmed that the diPEGylated conjugate had been synthesised. The mass spectrum shows the 
typical distribution of peaks, 44 mass units apart, expected for the mPEG 550. The reaction was 
repeated with the tetramethyl compound 110 and mPEG 550 glycidyl ether in wopropanol. The 
free amines were generated by the addition of a slight excess of 5M aqueous N aO H  prior to the 
addition of the glycidyl ether. One question that did arise at this stage was of the purity of these 
conjugates. By TLC (the mPEG 550 conjugates were easier to see on TLC than the mPEG 
2000 conjugate) it appears that the reaction had formed one product but that a very small 
amount of amine and mPEG glycidyl ether remains. This cannot be noticed with certainty in 
*H NM R spectra of the conjugates. Further, the mPEG conjugate of tetramethyl compound 
110 was contaminated with inorganic salts after generation of the amines from their 
hydrochlorides using NaO H. Purification of this conjugate was attempted by column 
chromatography on silica. This also served to investigate the feasibility of chromatography of 
the conjugates; this proved to be successful and the pure diPEGylated conjugate was obtained in 
32% yield.
3.5 Coupling to Primary Amines
Following the successful chromatography, it seemed logical to attempt the coupling of the
mPEG glycidyl ethers to thermine, protected on the middle secondary amines but bearing
primary terminal amines such that, if the glycidyl ether reacts twice with one amine to any
extent, this could be separated from material bearing just one mPEG chain (see scheme 33 on
page 92). Whilst compounds PEGylated twice on a primary amine group may be interesting, it
was thought that this would not be desirable, as DNA
& Boc Boc
binding may be sterically inhibited to some extent. The
130DiBoc diamino compound 130 had already been
prepared (scheme 42, page 99) during the synthesis of compound 128. This could therefore be 
used in the coupling reaction to see whether the mPEG glycidyl ether reacts with the primary 
amine once or twice. Obviously, secondary amines do react with glycidyl ethers as illustrated by 
the reaction with the dimethyl compound. The study of Shechter et al [Shechter et al, 1956]
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suggests that primary and secondary amines have a similar reactivity towards epoxides, but 
sterically hindered amines have a significantly lower reactivity. Once the mPEG epoxide has 
reacted once with the primary amine, the formed secondary amine may be sufficiently hindered 
such that it has lower reactivity towards a further addition of mPEG. In addition, the hydroxyl 
P to the amine may have a deactivating effect due to the electron-withdrawing effect of the 
oxygen.
Note that compound 130 could be synthesised via the alternative route shown in scheme 46 by 
removing the TFAc groups of compound 131, synthesised from thermine (scheme 43).
Boc H 




Scheme 46 Alternative synthesis of compound 130.
Both routes to 130 are three steps, the route from thermine has the advantage that it is quicker 
and near quantitative in terms of yield. However, purification posed a problem, in that it was 
difficult to remove all of the reaction by-product after TFAc deprotection, which is presumably 
trifluoroacetamide; this is discussed in more detail in chapter 7.
The coupling was therefore attempted using 130 and 2 equivalents of mPEG 550 glycidyl ether 
as before. A small-scale preliminary experiment was conducted and TLC of the reaction 
mixture suggested that the amines had largely reacted only once. The !H  NM R spectrum was 
not useful in determining the extent of PEGylation, but showed the presence of a small amount 
of unreacted glycidyl ether suggesting that a reaction time of around 24h may not be long 
enough. The best evidence for the epoxide only adding once to each amine was from the FAB 
mass spectrum which showed the presence of an appropriate range of peaks corresponding to 
the correct masses for the symmetrical diPEGylated conjugate 139, albeit at low abundance.
CH3(OCH2CH2)nO'XN ^ N ' ^ ^ ^ N ' ^ ^ ^ N x^ S^ ^ N ' ^ ,V^O(CH2CH20)nCH3 
OH H B0C B0C H OH
139 mPEG = 550
The reaction was repeated on a larger scale to allow easier chromatography and to establish 
whether or not the procedure was amenable to larger scale synthesis. This time two products 
were obtained and these were separated by column chromatography. The FAB mass spectra of 
both did not correspond to that obtained for the small scale preliminary experiment. One 
contained peaks approximately at the correct mass, but this could not be correlated to any
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possible species and the abundance of the ions was very low (less than 1%). Further, the 'H  
N M R spectra suggested that further PEGylation had occurred, based on the integral of the 
PEG C H 2 signal against the Boc C H 3 signal. Thus the two products must have been di and 
triPEGylatcd material or tri and tctraPEGylatcd material. Although the JH  NM R spectra 
suggested tri and tetraPEGylated, mass spectra would be required to confirm this. The FAB 
mass spectra obtained were not useful. This is possibly because the analysis of molecules of this 
type and size is beyond the capabilities of the available spectrometer or because FAB is not a 
particularly suitable ionisation method for these compounds once the conjugate has more than 
two mPEG 550 chains. The samples were analysed by electrospray mass spectrometry and at 
first glance the spectra seemed no more conclusive than the FAB ones. However, on closer 
examination the peak clusters corresponding to each mass were at intervals of 22 mass units. 
This suggested that they corresponded to doubly charged ions, and indeed they were at the 
correct masses for doubly charged ions \ie. V2 the apparent mass of the expected (M+H)+] 
corresponding to tri and tetraPEGylated material, compounds 140 and 141. It is well 
documented that multiply charged species often form during the electrospray ionisation process 
[Saf et al, 1997], TetraPEGylated conjugate 141 was isolated in 15% yield and the 
triPEGylated conjugate 140 in 24% yield. A M ALDI-TOF spectrum of 141 confirmed that it 
was tetraPEGylated.
HO,
CH3(OCH2CH2)nO/ 'vY XSv N 
OH H
' J ^ '0 ( C H 2CH20)„CH;
0(C H 2CH20 ) nCH3
CH3(0C H 2CH2)n0 ‘
CH3(OCH2CH2)nO
0(C H 2CH20 ) nCH3
0(C H 2CH20 ) nCH3
mPEG = 550
It is possible that higher PEGylation products formed in the preliminary reaction but not 
enough formed to be noticed by TLC; the tri and in particular the tetraPEG products stain less 
clearly on TLC.
4 Synthesis of Unsymmetrically Protected Thermine
A conjugate bearing a mPEG at only one end of the polyamine, an unsymmetrical conjugate,
may show a stronger interaction with DNA because the polyamine may be less sterically
hindered in its electrostatic interaction. Further, if the conjugation to mPEG lowers the pKa of
the amine (by a deactivating effect of the hydroxy group p to the amine) such that it is less likely
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to be protonated at physiological pH, then a conjugate having just one of these amines such as 
an unsymmetrical conjugate may carry more positive charge at pH 7.4. Thus the synthesis of 
unsymmetrical conjugates is desirable.
An unsymmetrical mPEG conjugate may be synthesised using methods analogous to those used 
for the symmetrical diPEGylated conjugates except that an additional amine would need to be 
protected. Alternatively one could attempt to treat 110, 128 or 130 with one equivalent of 






0 - 7^ v '0(CH2CH20)nCH3
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Scheme 47 Possible synthesis of a monoPEGylated conjugate.
It is possible that by using this method a significant quantity of symmetrical diPEGylated 
material would be produced and that the yield of the desired compound would be poor. 
Moreover, during the course of this study a relatively simple method of producing tri-Boc 
spermine (scheme 48) in one pot from spermine (50% yield) on a fairly large scale, appeared in 






Scheme 48 Preparation of tri-Boc protected sperm inel44 [Blagbrough and Geall, 1998].
The method is based on the selectivity of ethyl trifluoroacetate for primary amines over 
secondary amines [Xu et al, 1995] as the key first step in this procedure is the mono-
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trifluoroacetylation of free spermine 3 by treating it with one equivalent of ethyl trifluoroacetate 
at -78°C  then 0°C in M eOH. This affords a mixture of diTFAc and, predominantly, 
monoTFAc compounds. This mixture is immediately treated with four equivalents of B0 C2O 
which reacts with all the remaining amino groups; at this stage the mixture presumably contains 
a mixture of tetraBoc spermine, diBoc diTFAc spermine and triBoc monoTFAc spermine. The 
TFAc groups are immediately cleaved using aqueous ammonia to yield a mixture of tetra, tri 
and diBoc spermine. Chromatography gives the triBoc material 144 in 50% yield.
Thus triBoc thermine 145 was synthesised by an NHBoc
1 1 r™ , • , Boc Bocanalogous procedure. Thermine was treated with one 145
equivalent of ethyl trifluoroacetate in E tO H  at -78°C  (dropwise over 40min) then 0°C (30min). 
E tO H  was used here as opposed to M eOH as in the literature procedure [Blagbrough and 
Geall, 1998] as it was thought there was a chance it may improve the selectivity; when ethyl 
trifluoroacetate is used in M eOH, it presumably becomes methyl trifluoroacetate by 
transcstcrification, methyl trifluoroacetate is presumably more reactive. The mixture was then 
treated with B0 C2O  (0°C then room temperature, overnight), then with concentrated aqueous 
ammonia and ammonia gas (0°C then room temperature, sealed bottle, overnight). 
Chromatography gave triBoc thermine in 51% yield. Consideration was given to the isolation 
of triBoc monotrifluoroacetyl material before the trifluoroacetamides were cleaved with 
aqueous ammonia as this would provide the option of methylating the amine before removing 
the TFAc groups. However, examination of the TLC in a number of systems at this stage 
showed just one spot suggesting the triBoc monoTFAc material and the tetraBoc material had 
the same R f value and that separation would be difficult. Modifications to this method 
produced a more rapid, simpler procedure; however this did result in a moderate reduction in 
yield. Thermine was treated with ethyl trifluoroacetate at 0°C in TH F for 15 minutes (as 
opposed to one hour at -78°C  then one hour at 0°C, in M eOH, as in the method of 
Blagbrough and Geall). Then with B0 C2O (0°C then room temperature, two hours), at this stage 
the TH F was evaporated and then the TFAc groups were removed by heating the residue in 
propylamine at reflux overnight. It was decided to utilise the compound for coupling to PEG at 
this stage ie. not to methylate the primary amine as it was thought that enough monoPEG 
material would result from the reaction with the primary' amine to be able to isolate it by 
chromatography and that this would provide sufficient material for this study.
5 Coupling of TriBoc Thermine to mPEG
The triBoc thermine was treated with one equivalent of mPEG 550 glycidyl ether under the 
same conditions employed for the synthesis of the symmetrical conjugates. The monoPEGylated
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m aterial 146 (figure 36) was isolated by chrom atography in 21%  yield and the diPEGylated 
m aterial 148 in 9%  yield.
BocHN"
BocHN'
N v  N 
Boc Boc
146 mPEG = 550
147 mPEG = 2000
‘NT v  'N' 
Boc Boc
148 mPEG = 550
149 mPEG = 2000







Figure 36 Unsym m etrical m PEG  550 conjugates of therm ine.
FAB mass and *H N M R  spectra confirm ed the structure of these com pounds. Interestingly, a  
higher yield was obtained when the reaction was repeated using m PEG  2000 glycidyl ether; 
35%  for diPEG  and 28%  for m onoPEG . A M A L D I-T O F spectrum  o f the diPEG ylated 
conjugate 149 (figure 36) confirm ed its identity, this is illustrated in figure 37. It was possible to 
gain a  FAB spectrum  of the m onoPEG ylated conjugate 147.
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Figure 37 M A L D I-T O F spectrum  o f conjugate 149.
6 Deprotections
T he Boc protection was easily rem oved from the conjugates by treatm ent with acid. T he 
com pounds were dissolved in dichlorom ethane and HC1 was bubbled through for 20-30
109
Chapter 5:Synthesis of mPEG-Thermine Conjugates
minutes. Evaporation of the solvents gave the conjugates as their hydrochloride salts in 
quantitative yield. The samples were dried by lyophilisation and were semi-solids or waxes. It 
was immediately obvious from the NM R of the products whether or not the deprotection 
had gone to completion by the disappearance of the Boc methyl signals at 51.45. In all cases, 
complete deprotection occurred within 20-30 minutes. There was no evidence from NM R 
or mass spectrometry that treatment with HG1 in this way had any other effect on the molecule. 
All the conjugates that were deprotected are shown in figure 38.
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Figure 38 Deprotected mPEG-polyamine conjugates, all compounds were hydrochloride salts.
The ability of each conjugate to form complexes with DNA was examined. A 
spectrofluorometric assay based on the quenching of the fluorescence of an ethidium bromide- 
DNA complex was used. The assay principles and procedures, and the results for the conjugates 
described in this chapter are the subject of the next chapter.
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C hapter 6: 
Ethidium Bromide Assays
1 Introduction
The performance of a non-viral vector for gene delivery in vivo is dependant upon how the 
complex formed with DNA interacts with the biological milieu. Various physical and biological 
properties of the complex can be studied in order to gain information useful for predicting the 
possible fate of the complex in vivo. These include particle size analysis, zeta potential 
measurements, in vitro cell cytotoxicity studies, in vitro transfection experiments, gel 
electrophoretic studies and ethidium bromide exclusion/displacement assays. However, one 
must be careful in the interpretation of these data. Whilst physical characteristics of the complex 
can be correlated, to a certain extent, with transfection efficiencies in vitro, predictions of 
performance in vivo are considerably harder to make. Some surprising results have emerged 
from experiments in vivo, such as the activity of naked DNA in muscle [Wolff et al, 1990] and the 
high activity of complexes with the neutral polymer PVP in muscle [Mumper et al, 1996]. 
Further, there is poor correlation between in vitro and in vivo gene transfer ability. Ethidium 
bromide assays provide a useful, rapid measure of how strongly the vector interacts with DNA. 
They give us an idea of whether or not a compound is condensing the DNA; condensing agents 
are very efficient at excluding ethidium bromide from DNA. Thus, ethidium bromide assays 
were used here to study the ability of the conjugates to form complexes with DNA. This chapter 
describes the principles of the assay and present the results for the conjugates whose synthesis 
was described in chapter 5.
2 Principles o f  the Procedure
Ethidium bromide, figure 39, is an intercalator.
Compounds that bind to DNA, both those that are 
intercalators, and non-intercalating agents such as 
polycationic species which bind as a result of 
electrostatic interactions with the polyanionic DNA, 
can displace ethidium bromide from ethidium 
bromide-DNA complexes. There is correlation 
between the affinity of a given binding agent for DNA 
and the agent’s efficiency at displacing ethidium 
bromide [Cain et al, 1978]. When ethidium bromide binds to DNA, there is a large increase in
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Figure 39 Ethidium bromide
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the fluorescence of the ethidium bromide molecule; this fluorescence is quenched when the 
ethidium bromide is displaced by higher affinity compounds. Simple spectrofluorimetric 
methods can therefore be used to study the interaction of a range of compounds with DNA and 
the technique has been widely described [Cain el al, 1978; Gershon el al, 1993; Tang and 
Szoka,1997; Delcros et al, 1993; Stewart and Gray, 1992]. The mechanism by which ethidium 
bromide is displaced by agents which do not intercalate, such as polyamines, may be non­
competitive and involve changes in DNA conformation [Delcros et al, 1993]. Displacement 
could result from polyamine binding in the major groove, minor groove or along the phosphate 
backbone [Stewart and Gray, 1992]; the exact mechanism is not known. The binding affinity of 
polycations to DNA decreases with an increase in ionic strength of the test medium as one 
would expect with what is primarily an electrostatic interaction.
3 DNA Condensation
In solution DNA exists as a worm-like coil. The dramatic decrease in the volume occupied by a
DNA molecule provoked in vitro by chemical agents, particularly polyvalent cations, is referred
to as DNA condensation [Bloomfield, 1996]. The condensed particles often assume a toroidal
shape but may also form rod-like structures or globular structures. In this highly compact state
the helices may be separated by just one or two layers of water. Condensation of single DNA
molecules has been observed for large DNA molecules. With plasmid-size, or smaller DNA,
incorporation of several molecules into the condensed structure is common and it may be
difficult to distinguish condensation from aggregation or precipitation; the term condensation is
usually reserved for situations where the aggregate is of finite size and orderly morphology
[Bloomfield, 1996]. There are a number of agents that can cause DNA to condense, these
include multivalent cations, ethanol, basic proteins (histones), cationic lipids and certain neutral
polymers such as PEG and PVP. Condensation has been observed by many techniques
including electron microscopy, laser light scattering, viscomctry, circular dichroism and more
recently by fluorescence microscopy. Agents may cause DNA condensation by a num ber of
mechanisms; by modifying electrostatic interactions between DNA segments; by altering DNA-
solvent interactions; by excluding volume to the worm-like coil; by causing localised distortion
of the helix; or a combination of these effects [Bloomfield, 1996]. Polycations cause DNA
condensation when 89-90% of the negative charge on the DNA is neutralised [Bloomfield,
1996]. PEG is known to induce DNA collapse [Vasilevskaya et al, 1995; Minagawa et al, 1994],
It is suggested that the contacts between DNA and PEG are considered to be
thermodynamically unfavourable. Thus the solvent quality for DNA becomes poorer and there
is an increase in attraction between DNA segments; at a critical concentration of PEG the
abrupt contraction of the DNA occurs known as a coil to globule transition [Vasilevskaya et al,
1995]. In one study it was found that transition of DNA to the globule state occurred at a  PEG
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concentration of 250m g/m l for PEG 8000; for PEG 20000 DNA collapse was observed at ca. 
3m g/m l and a return to the expanded coil state at ca. lOOrng/ml [Vasilevskaya et al, 1995].
4 Assay Procedure
Thus an assay was used which was based on the quenching of the fluorescence of the ethidium 
bromide-DNA complex by the conjugates. Initially, the assay was adapted from that described 
by Gershon et al [Gershon et al, 1993]. In this assay, the polymer-DNA complex is formed 
before adding the ethidium bromide and thus measures the ability of the polymer to exclude 
ethidium bromide from intercalating DNA. This is generally described as an ethidium bromide 
exclusion assay. Briefly, complexes of calf thymus DNA and polymer are formed in buffer at 
pH7.4, at increasing polymer concentration and left at room temperature for 30-40 minutes. 
The complexes are diluted with saline (150mM) and then ethidium bromide solution is added. 
The fluorescence is measured immediately after vortexing the mixture. The results are 
expressed as fluorescence of the complex relative to a standard where no polymer is added. The 
results from this assay proved to be a little inconsistent within a set of data for a single 
conjugate. Even very small inaccuracies in the amount of DNA solution pipetted into each 
sample vial gave enough variation in fluorescence (with more DNA giving more fluorescence as 
an excess of ethidium bromide was used) to give poor data. In addition, the assay was not easily 
reproducible and was time-consuming. This assay may be more suited to compounds having a 
stronger interaction with DNA than the PEG-polyamine conjugates, such as cationic lipids. 
Thus an alternative method was adopted based on that described by Tang and Szoka [Tang 
and Szoka, 1997]. Here the compound being analysed is added to the preformed ethidium 
bromide-DNA complex; it is thus described as a displacement assay. Briefly, the ethidium 
bromide-DNA complex is formed in buffer in the fluorimeter cuvette equipped with a stirrer 
bar. The conjugate is added in small aliquots to the constantly stirring solution. A new 
fluorescence reading is taken 45 seconds to 1 minute after adding the polymer. The total 
volume of polymer solution added was no more than 2.6% of the final total volume of solution. 
The results are expressed as fluorescence relative to the fluorescence of the ethidium bromide- 
DNA complex before any polymer is added. More consistent data were produced using this 
method.
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5 R esults
5.1 Controls
Assays were run using PLL (30000-70000Da) and PVP (50000Da); these provide standards for 
comparison with the mPEG-polyamine conjugates. All the assays were performed in HEPES 
buffered saline at pH 7.4 except the assay for PVP which was performed in acetate buffer at pH 
4 (the ethidium bromide assay for PVP that has been reported [Mumper et al, 1998] was 
performed at pH 4; PVP carries a small positive charge below pH 5.5). Figure 40 shows the 
result for PLL and figure 41 for PVP. Some of the earlier assays conducted used calf thymus 
DNA, however, most illustrated here were conducted using the plasmid pCMVcat (this was one 
of the plasmids used for the in vivo delivery studies). The assay for PT T  was conducted using both 










M a ss R atio  (PLL:DNA)
Figure 40 Changes in the fluorescence intensity of an ethidium bromide-DNA complex in the 
presence of increasing amounts of poly-L-lysine for calf thymus DNA and the plasmid 
pCMVcat (n = 1).
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M ass R atio  (PVP: DNA)
300 400
Figure 41 Changes in the fluorescence intensity of an ethidium bromide-DNA complex in the 
presence of increasing amounts of PVP 50000 (n = 1).
It can be seen that PLL and PVP differ greatly in their interaction with DNA; PLL condenses 
DNA efficiently and displaces much ethidium bromide at a mass ratio of ca. 0.2. PVP has a 
considerably weaker interaction and displaces little ethidium bromide at mass ratios up to 400.
5.2  Symmetrical Conjugates
Compound 152 was found to cause no change in fluorescence when assayed.
CH3(OCH2CH2)nO' ‘ N ^ p Y ^ ° ( CH2CH20)nCH3
152 mPEG = 2000
OH
In order to establish that this lack of interaction was not due to the mPEG, other than steric 
effects, a sample of 128 was deprotected with HC1 (scheme 49) to yield 159 and assayed in the 
presence of two molar equivalents of free mPEG 2000. Figure 42 shows the exclusion of 
ethidium bromide from calf thymus DNA by polyamine 159 and by 159 in the presence of free 
PEG.




Schem e 49 Deprotection of 128.
159 4HCI
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C om pou nd 159
159 plus free m PEG  2 0 0 0
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M ass R atio  (Polym er:D N A )
F igure  42 Changes in the fluorescence intensity of an ethidium bromide-DNA complex in the 
presence of increasing amounts of compound 159 and compound 159 plus free mPEG 2000 (n 
= 1).
Next, the mPEG 550 conjugates were assayed. Again there was little or no interaction observed; 
the results for conjugates 150 and 153 are illustrated in figure 43.
CH3(OCH2CH2)nO^Y^N"^ V^ ^ N/NV^ /V 'N/X^ ^ N^ VT ^ 0(CH2CH2° )nCH3OH ^ 3  CH3 CH3 q |_j
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M a ss R atio  (P o ly m er: DNA)
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Figure 43 Changes in the fluorescence intensity of an ethidium bromide-DNA complex in the
presence of increasing amounts of conjugates 150 (n = 1) and 153 (n = 2).
It is likely that any DNA interaction seen with these conjugates is very weak because they do not 
carry' enough charge to induce significant conformational change in the DNA by charge 
neutralisation to displace ethidium bromide. In addition, it is likely that the PEG sterically
hinders interaction when conjugated to both ends of a tctraminc.
5.3  Unsymmelrical Conjugates
The unsymmetrically mPEGylated conjugates 155, 156, 157 and 158 showed a significantly 
greater interaction. In general the interaction became weaker with an increase in mPEG 
molecular weight and a higher degree of mPEGylation. Figure 44 shows the results for 155, 
156 and 157, and figure 45 shows the results for 158, which only showed significant interaction 
at high mass ratio.
H 2 N ' ^ ^ N ^ ^ N ^ ^ N ^ Y ^ 0 (CH2CH2°)nCH3
155 mPEG = 550
156 mPEG = 2000
157 mPEG = 550
158 mPEG = 2000
‘0 (C H 2C H 20 ) nCH3
"0(C H 2C H 20 ) nC H 3
OH
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M ass R atio  (p o ly m e r : DNA)
F igure  44 Changes in the fluorescence intensity of an ethidium bromide-DNA complex in the 
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Figure 45 Changes in the fluorescence intensity of an ethidium bromide-DNA complex in the 
presence of increasing amounts of conjugate 158 (n = 2).
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The pKa of each nitrogen in these conjugates is not known, thus the number of charges that 
each carry at pH 7.4 is not known. If the pKa value for one or more nitrogens is below 7.4 then 
they will not be protonated in the assay buffer solution. It was reasoned that if the assay was 
conducted at a lower pH and the conjugate thus carried more charge, then the DNA interaction 
would be stronger and more ethidium would be displaced. This proved to be the case; the assay 
was conducted at pH 5.5 in MES buffered saline for compound 155 and the results are 












pH  7.4  
p H 5.5
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M ass r a t io  (com p ou n d  155:DNA)
F igure  46 Changes in the fluorescence intensity of an ethidium bromide-DNA complex in the 
presence of increasing amounts of conjugate 155 at pH 7.4 and at pH 5.5 (n = 3).
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C hapter 7: 
Synthesis of m PEG conjugates of a Hexamine and 
Branched Polyarnines
1 Introduction
D uring  the course o f this study, a  hypothesis was put forward by M um per and R olland 
[M um per and R olland, 1998] which suggested that an increased binding affinity in non ­
condensing (PINC) systems would increase gene expression following in tram uscular injection, 
until a  point is reached, in term s o f D N A  interaction, when condensation of the D N A  occurs 
leading to decreased bioavailability in muscle. T hey described this as an “interactive w indow of 
opportun ity” .
 we propose an “interactive window of opportunity” whereby enhanced binding affinity of the future
PINC systems will result in a further enhancement of gene expression after intramuscular injection due to 
more extensive protection of plasmids from nuclease degradation. We predict that there will be an 
optimal interaction beyond which either condensation of plasmids or “triplex”-type formation will occur, 
resulting in decreased bioavailability in muscle and, consequently, gene expression.
This is illustrated graphically in figure 47.
W indow o f  
Opportunity'
PVA, PVP, NMZP 
PVP-VA copolymen, propylene glycol 
Saline, CMC, Deilrao,PEG
“Interactive Strong interaction becomes 
prohibitive to gene expression 
(L#., “triplex formation') 
or to plasmid mobility In muscle 
(Le., condensation into rigid 
particles).
Cumulative Interaction 
(i.e., H-bonding, Hydrophobic, Van der W aals, Ionic, etc.)
Figure 47 Future developm ent o f P IN C  systems: “interactive imndow of opportunity” [M um per and 
R olland, 1998]
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If one examines the unsymmetrical conjugates described in chapter 5 in terms of this hypothesis, 
it can be seen that their interaction with DNA is indeed somewhat stronger than the interaction 
of PVP with DNA based on the ethidium bromide assays. However, it is still considerably 
weaker than the cationic lipids or PLL for example. Thus it may be desirable to produce 
conjugate® having a stronger interaction with DNA than those described in chapter 5 but not 
as strong as the condensing, particle-forming vectors such as cationic lipids. This would provide 
a range of polymers having a range of affinities for DNA interaction. These polymers may have 
use as PINC systems for delivery of DNA to muscle, in addition they may find use in delivery to 
solid tumours via direct injection and those having a stronger interaction with DNA may be 
useful for delivery to other sites such as the lung, where particulate systems have shown some 
promise [for example: Lee et al, 1996].
One way to increase the interaction with DNA would be to increase the amount of positive 
charge carried by the conjugate. This may be achieved by increasing the number of amino 
groups. The interaction with DNA may be inhibited to some extent by the steric bulk of the 
mPEG chain, the introduction of some sort of inert spacer between the polyamine and the 
mPEG may circumvent this problem. Further, the use of a branched polyamine, such that the 
spacer and mPEG are not attached to one end of the polyamine, may also lessen steric 
constraints. In addition, the use of a more reactive mPEG electrophile could be used, the 
glycidyl ether having relatively mild reactivity.
Four conjugates were synthesised in an attempt to produce compounds with a greater affinity 
for DNA, two based on a linear hexamine and two branched conjugates. This chapter describes 
the synthesis of these compounds and their interaction with DNA.
2 Synthesis of Hexamine Conjugates
Two compounds based on the linear hexamine 160 were synthesised and coupled to mPEG in 
a similar m anner to the tetramine conjugates described in chapter 5.
H H H H
160
Obviously the coupling step would require the secondary amines to be protected. The Boc 
group had proved a good choice of protecting group in the tetramine routes, so again was the 
choice here.
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2.1 Synthesis o f a protected hexamine
The protected hexamine intermediate 163 was synthesised by the route shown in scheme 50 
from the diBoc protected compound 128 used in the synthesis of the tetramine conjugates 
(chapter5).
H Boc Boc H
t
Boc Boc Boc Boc 
162
t
Boc Boc Boc Boc 
163
S chem e 50 Synthesis of protected hexamine 163.
Recall that 130 could be synthesised by two routes; from propane-1,3-diamine as in scheme 42 
(page 99) and from thermine as in scheme 46 (page 106). Although the route from thermine 
may be higher yielding, the purifieation of 130 produeed by that route is somewhat more 
difficult. Removal of the TFAc groups with ammonia, presumably yields trifluoroacetamide as a 
by-product. It was difficult to separate this from 130 for two reasons; it has an R f value very 
close to that of 130 and tended to co-elute from the silica column and it is difficult to visualise 
on TLG. Consequently, meticulous chromatography was required to separate 130 from 
trifluoroacetamide in high yield. However, it was thought that a small amount of 
trifluoroacetamide contamination would not interfere with the cyanoethylation reaction and 
that it could be more easily removed later in the reaction sequence. This proved not to be the 
case. Cyanoethylation in the presence of trifluoroacetamide occurred only to a small extent as 
judged by TLC. Therefore the nitrile reduction method (scheme 42) was used to produce 130 
for this route. This cyanoethylation reaction does not work in the presence of 
trifluoroacetamide, probably because trifluoroacetamide is sufficiently acidic to protonate the
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am ine (scheme 51). If protonation does occur, the protonated  am ine will not add to acrylonitrile 
and  the trifluoroacetam ide anion m ay itself react with the acrylonitrile.
0  0+ X  w i <±> I©




N v  F3C N
H H
S c h e m e  51 T rifluoroacetam ide m ay protonate prim ary am ines which m ay not then undergo 
cyanoethylation.
C om pound 130 was treated with acrylonitrile to give the dicyanoethylated interm ediate 161, 
quantitatively. T h e  dicyano com pound 161 was treated with B0 C2O  in C H 2CI2 to give the 
tetraBoe protected com pound 162 in quantitative yield. This was not purified a t this stage bu t 
im m ediately reduced to the tetra-protected hexam ine 163. D icyano com pound 162 was treated 
with R aney nickel in m ethanolic am m onia a t GOpsi o f hydrogen for 65 hours. This gave the 
am ine 163 in 88%  yield after chrom atography.
2.2 Coupling to mPEG 550
M ono and symmetrical diPEG ylated conjugates o f hexam ine 163 were synthesised. It was 
decided not to m ethylate the prim ary amines but ra ther to separate any mixtures of conjugates 
by chrom atography after this had proved feasible with the tetram ine conjugates.




For the synthesis o f the m ono-PEG ylated com pound 164 it was decided to treat 163 with ju st 
one equivalent o f m PEG  550 glycidyl ether and isolate the m onoPEG ylated product from  the 
potential m ixture and thus not to attem pt the selective protection of one of the prim ary am ines 
with Boc, followed by a m PEG  coupling step. T hus the reaction was carried out in ?^opropanol 
at rellux for 48 hours and the m onoPEG ylated conjugate was isolated by colum n
123
Chapter 7: Synthesis of mPEG conjugates of a Hexamine and Branched Polyamines
chromatography in 32% yield? . The structure was confirmed by 'H  NM R and FAB mass 
spectrometry. Although some further PEGylated products formed, as judged by TLC, these 
were not recovered.
S ym m etrica l diPEGylated conjugate
CH3(OCH2CH2)rO ^NV ^ S'N 
OH H
‘N N ^  N N
Boc Boc Boc Boc
165
N/Nv^ ^ 0 (C H 2CH20)nCH3















The tetraBoc hexamine 163 was treated with two equivalents of mPEG 550 glycidyl ether. 
Recall that, in the equivalent reaction on tetramine, no diPEGylated material could be isolated, 
only tri and tetraPEGylated material. In an attempt to control the reaction, to produce some 
diPEGylated material, the temperature was lowered to 65°C (as opposed to 80°C in the 
tetramine reaction) and the reaction mixture was made more dilute. This proved to be 
successful as diPEGylated conjugate 165 was isolated, albeit in a modest 12% yield, together 
with some triPEGylated material 166. Confirmation that the first product to elute was 
iriPEGylated and lhat ihe second product was diPEGylated was from their mass spectra. 
Although it was possible to gain a useful FAB spectrum for the diPEGylated conjugate, it was 
not possible for 166. However, a MALDI-TOF spectrum confirmed that it was triPEGylated. 
This is shown in figure 48.
11 am grateful to Owen R. Davies, who carried out this reaction as part of a B.Pharm final year project.
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F igure  48 MALDI-TOF spectrum of conjugate 166.
2.3 Deprotection
The conjugates were deprotected with HC1 using the method described in chapter 5. A sample 
of hexamine 163 was also deprotected to provide a standard for use in the ethidium bromide 
assays. Figure 49 illustrates the deprotected compounds.
J L  H H H H HOH 167
CH3(OCH2CH2)nO/ ^ y ^ V N N n N ' ^ V ^ 0 ( C H 2CH20 ) nCH3 
o h  H H H 168 H H H ° H
H2N N N N N NHo
H H H H
169
F igure  49 Deprotected hexamines, all compounds are hydrochloride salts.
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3 Synthesis of Branched Conjugates
3.1 Overview
The overall strategy for the branched conjugates was to produce a pentamine bearing a spacer, 
to reduce the possibility of steric constraints affecting DNA interaction, to a mPEG chain on the 
central secondary amine (scheme 52).
S chem e 52 Branched PEG-polyamine conjugate.
The rationale is that this could be constructed by attachment of the spacer to the secondary 
amine of the commercially available triamine bis(3-aminopropyl)amine 88 after selective 
protection of the primary amines. Following this, further aminopropyl units could be added via 
a strategy such as cyanoethylation followed by reduction or alkylation using N-(3- 
bromopropyl)phthalimide. Also, the branched triamine itself may have interesting properties 
with respect to DNA interaction, if PEGylated. An alternative strategy would be to construct the 
pentamine first and then attach the spacer and mPEG. Constructing the conjugates in this 
m anner also allows for more versatility in the future design of novel vectors as the spacer may 
incorporate a biodegradable linker or functionality for the attachment of targeting ligands.
3.2 Synthesis o f a Branched Triamine
Initial work on branched conjugates produced a PEGylated triamine with a short spacer, via the 
rapid route shown in scheme 53.
a,co-DiBoc bis(3-aminopropyl)amine 170 was prepared according to the method of Hu and 
Hesse [Hu and Hesse, 1996]. Treatment of bis(3-aminopropyl)amine 88 with 2 equivalents of 
2-(/-butoxycarbonyloxyimino)-2-phenylacetonitrile (BOC-ON) in TH F at 0°C then room 
temperature, gave the diBoc triamine in 54% yield after chromatography. The authors claim 
that the product was purified by recrystallisation. Repeated attempts to recrystallise this 
material failed, in that the product always contained traces of impurities. Compound 170 was 
cyanoethylated with acrylonitrile in THF. The reaction mixture needed to be heated to reflux, 
and excess acrylonitrile used, in order to obtain the cyano compound 171 in good yield (80%).
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Scheme 53 Synthesis of a branched triamine.
The nitrile group was reduced under 60psi of hydrogen with Raney nickel, in methanolic 
ammonia for 72 hours to give 172 as a  blue-green oil. This was not purified, but treated with 
mPEG 550 chloroformate 173 to yield the PEGylated conjugate 174 in 28% yield after 
chromatography. The Boc protection was removed quantitatively, by dissolving the conjugate 
in C H 2CI2 and bubbling HC1 through the solution to give the conjugate 175 as its 
hydrochloride salt.
Synthesis o f  mPEG 550 chloroform ate
Note that the synthesis in scheme 53 used mPEG chloroformate as opposed to the glycidyl ether 
as in this case it was desirable that the basicity of the amine of the branch was quenched by 
formation of a  carbamate, so that it could not take part in electrostatic interaction with DNA; 
also it is more reactive. Although a number of mPEG electrophiles are commercially available 
they are often expensive and not readily available in lower molecular weights such as 550Da. 
Thus the chloroformate was synthesised by treating mPEG 550 in dichloromethane with a 
solution of phosgene in toluene. The mPEG had been previously dried by azeotropic removal of 
water using toluene in a Dean and Stark trap. A large excess of phosgene was used and the 
product was stored in the reaction vessel; an aliquot was removed when required and the 
solvents and excess phosgene were evaporated immediately prior to use.
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3.3  Attempted Construction of a Pentamine from Intermediate 172
Whilst 175 is an interesting conjugate, the major target was a pentamine which would carry' 
more charge at physiological pH. A route to a pentamine from intermediate 172 was attempted
and is illustrated in scheme 54.
H2N.




B ocH N . .N H B oc
HoN
176




0 ^ 0 (C H 2CH20)nCH3
Schem e 54 Proposed synthesis of a branched pentamine from intermediate 172.
Compound 172 was treated with benzyl chloroformate to give the Cbz protected derivative 
176 in 29% yield. The low yield in the chloroformate reactions on this compound could be due 
to the presence of nickel contamination. Furthermore, if the nickel complex involves ammonia, 
then the ammonia in the reaction mixture may react with the chloroformate. Synthesis of the 
Cbz derivative 176 allowed removal of the Boc groups, so that building the polyamine to a 
pentamine could be explored; it also allowed easier purification and thus full characterisation of 
the intermediate. The Boc protection was removed in the usual manner with HC1 to yield the 
triamine 177 as its hydrochloride salt. This was treated with triethylamine to generate the free 
base before the addition of acrylonitrile. This reaction was unsuccessful, only the 
tetracyanoethylated compound 179 was isolated by chromatography, 'l ’his route was not
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pursued further as a more efficient and versatile synthesis of a branched pentamine was 
progressing. Further, there is a potential problem in the route shown in scheme 54 in that the 
Cbz protection may not survive the reduction step of 178 to compound 180 and it is probably 
desirable to have a longer spacer than the aminopropyl unit.
3 .4  Synthesis of a Branched Pentamine
A more versatile synthesis of the desired pentamine was devised involving a strategy where the 
branch is attached by alkylation with a bromo compound. The first attempted route using this 






P h t h H N ^ ^ N  ^ ^ N  
F3C ^ O  





,N O - P E G  
190 I
Schem e 55 Proposed synthesis of a branched pentamine.
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The key steps are the alkylation of the branched bis(trifluoroacetamide) 185 with N-(3- 
bromopropyl)phthalimide 96, removal of all protecting groups with hydrazine and subsequent 
selective protection of the unmasked amines over the hydrazide in compound 187. The 
hydrazidc could then be converted to the azidc (for example with /-butyl nitritc/HCl); a Curtius 
rearrangement followed by trapping with a mPEG would give the PEGylated conjugate 190. 
This synthesis was unsuccessful as it was not possible to alkylate the bis(trifluoroacelamido) 
compound 185 using N-(3-bromopropyl)phthalimide 96.
Bis(3-aminopropyl)amine 88 was treated with ethyl trifluoroacetate in EtO H  to give the 
bis(trifluoroacetamide) 182 in quantitative yield. The ethyl ester of 6-bromohexanoic acid 184 
was prepared by boiling a solution of the bromo-acid 183 in EtO H  with sulfuric acid catalysis. 
Kugelrohr distillation gave the ester in 87% yield. The secondary amine of 182 was alkylated 
using this bromo-ester 184 in DM F at 80°C to yield branched compound 185. This was an 
adaptation of the procedure of Muramatsu et al [Muramatsu et al, 1993] who had used ethyl 6- 
bromohexanoate to alkylate an N-methylamine derivative. The next step was to alkylate the 
trifluoroacetamide nitrogens of 185 with N-(3-bromopropyl)phthalimide as a means of building 
the polyamine to a pentamine. It was thought that a procedure analogous to that used to 
methylate compound 131 (scheme 42, page 99) would yield the protected pentamine 186. Thus 
185 was treated with potassium /-butoxide in dry TH F followed by N-(3- 
bromopropyl)phthalimide 96, no new products could be detected in the reaction mixture. N-(3- 
Iodopropyl)phthalimidc 191 was synthesised from the bromo compound using a Finklcstcin 
procedure (scheme 56). It was thought that this may react more readily but again no new 
products formed. The fact that these halo compounds do not react with the trifluoroacetamide 





S chem e 56 Synthesis of N-(3-iodopropyl)phthalimide.
A new synthesis was needed and it was decided to employ the cyanoethylation and reduction 
sequence that had proved successful in the synthesis of linear polyamincs. In addition, the use of 
an amine as the functional group at the end of the spacer would allow the attachment of mPEG 
via the chloroformate, the successful use of which had been demonstrated during the synthesis of 
the previous branched conjugate. This would require a bifunctional molecule bearing an amine 
at one end and an electrophilic functional group at the other. An obvious example is an amino 
acid such as 6-aminohexanoic acid. This could be coupled, for example, to the di-protected
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triamine 182 via chemistry such as a carbodiimide coupling or via an active ester. However, this 
would yield an amide and thus quench the basicity of the middle secondary amine, not allowing 
it the potential to be protonated and therefore take part in interacting with DNA. The amide 
could be reduced with boranc or lithium aluminium hydride for example, but this may cause 
problems with protecting group selection and isolation of the products. Following the successful 
alkylalion of 182 with the bromo-esler 184, it was decided to use this procedure again to form 
the branch. The simplest way for the bromo compound to bear an amine function would be to 





















S chem e 57 Proposed synthesis of a branched pentamine.
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/-Butyl N-(2-aminoethyl)carbamate 193 was initially prepared according to a  literature 
procedure [Saari et al, 1990]. Ethane-1,2-diamine 192 was treated with Vs equivalents of 
B0 C2O in T H F over 30min at 0°C. Use of this procedure resulted in a significant quantity of 
diBoc protected material. Although it was found that this could be crystallised from the mixture, 
a  more satisfactory procedure was to utilise a ca. 20-fold excess of ethane-1,2-diamine 192 in the 
reaction. This ensured that no diBoc material formed; the excess diamine was easily removed by 
extraction into water. Some of the desired monoBoc. material is probably lost during water 
extraction but, given the simplicity of the synthesis and the low cost of the starting materials, this 
is acceptable. The next step was to couple this to 6-bromohexanoic acid 183 forming the amide 
195. There is much literature on amide bond formation owing to the vast amount of work that 
has been done in the area of peptide synthesis. One of the simplest ways to form an amide bond 
is by using the acid chloride. This is little used in peptide ehemistry, largely owing to the 
potential for racemisation and side reactions such as N-carboxy anhydride formation. This 
should not be a problem here, thus the acid chloride 194 was the active species of choice. The 
acid chloride was generated using oxalyl chloride with DM F catalysis. Tt was not isolated but 
was allowed to react with the monoBoc ethane-1,2-diamine in situ. The amide was conveniendy 
recrystallised from the reaction mixture, after aqueous work up, in 68% yield. The bromo- 
amide 195 was used to alkylate the diTFAc protected triamine 182. The triamine was treated 
with 195 in DM F at 80°C for 18 hours, this gave the branched polyamine 196 in 68% yield 
after chromatography. The next two steps were to be removal of the TFAc groups then 
cyanoethylation of the free amines. However, in a  preliminary experiment to remove the TFAc 
groups with am m onia/M eO H , it was not possible to move the deprotected product on TLC 
with any solvent useful for column chromatography and therefore it was not possible to purify it 
conveniently (although *H NM R of the crude material suggested that the deprotection was 
successful, as did the FAB mass spectrum). Given that the next step was to be cyanoethylation 
and given that such a reaction had previously proved to be difficult in the presence of 
trifluoroacetamide, it was considered at this stage that this route would not provide an adequate 
synthesis of the desired compound. Moreover, it is possible that the other amide in the molecule 
may suffer hydrolysis to some extent in the TFAc deprotection step, an d /o r this amide may also 
be affected in the reduction step which uses methanolic ammonia.
Given these difficulties it was decided to use an approach where the pentamine is constructed 
first and then the branch is alkylated on before coupling to mPEG. The next proposed route to 
the fully protected pentamine is illustrated in scheme 58.
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Schem e 58 Synthesis of fully protected branched pentamine 206.
Bis(trifluoroacetamido) triamine 182 was treated with B0 C2O in dichloromethane to yield 200 
quantitatively. The TFAc groups were removed with aqueous ammonia in M eOH and the 
resulting diamine was cyanoethylated. As predicted, the cyanoethylation did not proceed to 
completion as it was not possible to remove all the trifluoroacetamide by chromatography. In 
order to overcome this problem, it would have been possible to use alternative protecting 
groups such as Cbz but this would involve more demanding syntheses. The materials required 
for this synthesis arc cheap and readily available and it considered easier to proceed with the 
planned synthesis on a larger scale and accept the low yield and need to chromatograph the
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cyanoethylated intermediate 202. Furthermore, it was found that it was possible to proceed 
from 182 to 202 in essentially a one-pot procedure, without isolation of the intermediates in 
30% yield and moreover, that the problem of cyanoethylation in the presence of 
trifluoroacetamide could be ameliorated by the addition of potassium earbonate to the reaction 
mixture. The dicyano compound 202 was reduced with Raney nickel in methanolic ammonia. 
The resulting pentamine 203 was not isolated but immediately converted to compound 204 by 
treatment with dibenzyl dicarbonate in 60% yield after chromatography. The Boc protection 
was removed in 91% yield using HC1. The unmasked secondary amine was then alkylated with 
the protected bromo amide 195 in DM F at 80°C, as before, to give the fully protected 
branched polyamine 206 in 67% yield. The Boc protection was removed in 87% yield using 
HC1 to give amine 207 (scheme 59). The free amine was allowed to react with excess mPEG 
550 chloroformate, synthesised as described before, giving the PEGylated conjugate 208 in 
42% yield after chromatography. The Cbz protection was removed quantitatively by treatment 
with hydrogen at 60psi over Pearlman’s catalyst to yield 209 and the conjugate was converted 




















N 0(C H 2CH20 ) nCH3 
H
Schem e 59 Conjugation and deprotection of branched pentamine 206.
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4 Ethidium Bromide Assays
T h e  conjugates described in this chapter were assayed for their D N A  binding using the 
ethidium  brom ide displacem ent assay described in chapter 6.
4.1 Hexamine Conjugates
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Figure 50 illustrates the result for the m onoPEG ylated conjugate 167, figure 51 for 
diPEG ylated conjugate 168 and figure 52 for the free hexam ine 169; these results clearly show 








M ass R atio  (com p ou n d  167: DNA)
30
Figure 50 C hanges in the fluorescence intensity of an ethidium  brom ide-D N A  com plex in the 
presence of increasing am ounts o f com pound 167 (n =  3).
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Figure 51 C hanges in the fluorescence intensity of an  ethidium  brom ide-D N A  com plex in the 
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M a ss R atio  (com p ou n d  169: DNA)
Figure 52 Changes in the fluorescence intensity o f an ethidium  brom ide-D N A  complex in the 
presence o f increasing am ounts of com pound 169 (n = 1).
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4.2  Branched Conjugates
CH3(OCH2CH2)nOv^ O
N ^0(C H 2CH20)nCH3
Figure 53 shows the ethidium bromide exclusion results for the branched conjugates. 
DiPEGylated hexamine 168 is included for comparison. As would be expected, the branched 
triamine 175 has a much weaker interaction with DNA than the branched pentamine 209 as it 
carries less positive charge. The slightly weaker interaction of the hexamine conjugate 168 
compared to the branched pentamine 209 is explained by steric effects and the fact that it 












M a ss R atio  (P o ly m e r : DNA)
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Figure 53 Changes in the fluorescence intensity of an ethidium bromidc-DNA complex in the 
presence of increasing amounts of compounds 168 (n = 3), 175 (n = 2) and 209 (n = 3).
Chapter 8 gives further discussion on the significance of the results of these assays and those 
shown in chapter 6.
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Chapter 8: 
Gene Delivery Studies in vivo and General Conclusions
1 Introduction
This chapter gives a brief description of the in vivo gene delivery studies that were carried out using 
the conjugates whose synthesis and DNA interaction has been described. The results of these studies 
are presented along with conclusions drawn from the synthesis, the ethidium bromide assays and 
the in vivo work.
Some of the conjugates were tested for their ability to facilitate the introduction of P-galactosidase 
and chloramphenicol acetyl transferase reporter genes into the hind leg muscle, and into RIF-1 
tumours of mice. The conjugates were compared to PVP and naked DNA.
2 Method for In Vivo Studies
T am grateful to M r David A. Milroy and Dr PaulineJ. Wood for performing these experiments. 
Im plantation o f  RIF-1 tum our cells
Female C3H mice were obtained from Charles River at 6-7 weeks of age and allowed to acclimatise 
for one week prior to the experiments. Murine fibrosarcoma RIF-1 cells were cultured in RPMI 
1640 medium supplemented with 15% foetal calf serum, penicillin and streptomycin. The cells 
were not passaged more than 7 times prior to trypsinisadon for implantation. Prior to implantation, 
the mice were lightly anaesthetised using intraperitoneal Hypnorm. A suspension of RIF-1 cells 
(containing approximately 2x l05 RIF-1 cells in 0.05ml of phosphate buffered saline) was injected 
intradermally midway along the shaved back of the mouse, approximately 2cm from the base of the 
tail. To obtain an acceptable tumour implant, the cell suspension should leave a spherical bump 
devoid of any tracks caused by leakage upon needle removal. The tumours are visible after 
approximately seven days, with experimental size being reached 12-14 days post-implantation. One 
day before tumour injection, the mice were weighed and the dimensions of the tumour recorded. 
The average tumour was approximately 6-7mm in diameter and 250mg in weight at this stage. The 
mice were then randomly assigned to the different treatment cages.
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Injection o f  the DNA form u la tion s
Injections were made using a sterile Hamilton syringe fitted with a 3 1G1/2 needle and a calibrated 
dosing clamp which ensured that each injection was 20jal. Each 20pl injection contained 50pg of 
DNA (pCMV(3-gal or pGMVcat) alone or in combination with a polymer adjuvant adjusted to be 
isotonic. Five days before the tumours were dosed, an injection of the formulation was made into 
the right hind leg muscle of each mouse. To facilitate muscle injection the mice were anaesthetised 
using a combination of Hypnovcl and Hypnorm intrapcritoneally and the right hind thigh was 
shaved. The needle was left in place for a short period to prevent formulation being expelled by the 
tissue. The tumours were injected five days after the muscle, using the same procedure, but without 
anaesthetising the mice. Tissue harvesting following culling (by cervical dislocation) of the mice was 
performed two days after the tumours were injected and thus seven days after the muscle was 
injected. Eight mice were used for each formulation. The negative control represents the injection 
of the expression construct from which the reporter gene has been removed. The positive control is 
the injection of DNA with no polymer adjuvant.
Tissue processin g  fo r  gene expression
Tum our and muscle tissue was processed for gene expression using one of two methods depending 
on whether the tissue was dosed with a plasmid encoding for the cat reporter gene or the f-Gal 
reporter gene. Both reporter gene assays share a common tissue preparation protocol. Following 
weighing, the tissue is homogenised in lysis buffer (0. lM potassium phosphate buffer pH 7.8, 0.2% 
Triton X-100). The tissue suspension is then centrifuged at 4°C to remove the cellular debris. The 
protein in this supernatant is analysed using the Bio-Rad Dc Protein Assay kit. The supernatant is 
then assayed for either (3-Gal or CAT depending on the plasmid injected. The (3-Gal assay was 
carried out using the Tropix (Bedford, MA) Galacto-Light Plus chemiluminescent assay which 
yields Relative Light Units (RLU). While CAT activity was assayed for using a CAT ELISA 
colorimetric enzyme immunoassay from Bochringcr-Mannhcim (Mannheim, Germany). For both 
reporter genes, expression was normalised to either total muscle protein, tissue weight or tissue 
volume.
3 Results of In Vwo Studies
Constraints on time and resources allowed the in vivo testing of only three of the conjugates. These 
were compounds 155, 167 and 168. The data for these studies arc presented as box plots; on the 
lines that connect the data for each formulation, one star (*) indicates a 95% probability of 
significance and two stars (* *) indicate a 99% probability of significance.
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Figure 54 shows the result for com pound 155 in muscle for transfer o f pC M V p-G al. In this 
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Control-ve Control+ve DNA+PVP DNA+SG166
Figure 54 |3-galactosidase expression in mouse muscle after direct injection of various form ulations 
of pC M V p-G al. In this graph com pound 155 is denoted SG166.
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Figure 55 shows the result for pC M V p-G al transfer into tum our using com pound 155 com pared to 
PV P and positive and negative controls. C om pound 155 produced a  significant enhancem ent of 
gene expression over naked DNA. Although enhancem ent of expression com pared to PV P is also 








Control-ve Control+ve DNA+PVP DNA+SG166
Figure 55 P-galactosidase expression in RTF-1 tum ours after direct injection of various 
formulations of pC M V P-G al. In this graph com pound 155 is denoted S G I66.
Figures 56 and 57  show experim ents where com pounds 155 and 167 are com pared to naked DN A  
and PVT in tum our (figure 56) and  in muscle (figure 57), this lime using the pC M V cal reporter 
plasmid. C om pounds 155 and 167 both significantly enhance expression in tum our, whereas no 
activity is seen in muscle.
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DNA DNA+PVP DNA+SG166 DNA+OD22
Figure 56 Chloramphenicol acetyl transferase expression in RIF-1 tumours after direct injection of 
various formulations of pCMVcat. In this graph compound 155 is denoted SG166 and compound 
167 is denoted OD22.
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DNA DNA+PVP DNA+SG166 DNA+OD22
Figure 57 Chloramphenicol acetyl transferase expression in mouse muscle after direct injection of 
various formulations of pCMVcat. In this graph compound 155 is denoted SG166 and compound 
167 is denoted OD22.
Another set of experiments examined compounds 167 and 168 compared to PVP and naked DNA 
using the pCMV|3-Gal reporter plasmid (figures 58 and 59). No enhancement of gene expression 
was seen with 167, 168 or with PVP in either muscle or tumour.
143























 1 1 1 1 1
Blank DNA DNA+PVP DNA+OD22 DNA+SG240
F igure  58 3 -Galactosidase expression in mouse muscle after direct injection of various 
formulations of pCMVJ3-Gal. In this graph compound 167 is denoted OD22 and compound 168 is 
denoted SG240.
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Blank DNA DNA+PVP DNA+OD22 DNA+SG240
F ig u r e  59  {3-Galactosidase expression in tum our after direct injection o f various form ulations of 
pC M V P-G al. In this graph com pound 167 is denoted O D 22 and com pound 168 is denoted 
SG 240.
4 C onclusions
V ersatile, efficient syntheses o f protected linear tetram ines, suitable for coupling to mPEGs, have 
been dem onstrated and N -m ethylation was achieved in high yield by alkylating trifluoroacetam ide 
derivatives, A high yielding synthesis o f a  linear hexamine was devised. Acceptable m ethods for the 
coupling o f m PEG  glycidyl ethers to prim ary and secondary nitrogens o f polyamines have been 
established. T h e  coupling m ay have room  for im provem ent in terms o f yield; relatively low 
reactivity of the glycidyl e ther and difficult chrom atography to isolate the conjugates are possibly 
responsible for this. In one respect the use of N -m ethylated derivatives was vindicated since 
diPEG ylation of prim ary am ines readily occurred, however, it has been dem onstrated that colum n 
chrom atography can be carried ou t to separate m ono from diPEG ylated conjugates, so in this 
respect the use o f N-melhyl derivatives is redundant. Exploration of alternative isolation and
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purification techniques would have been desirable. The use of higher molecular weight mPEGs 
may have allowed purification using techniques such as dialysis, gel permeation chromatography 
and centrifugation but would have caused problems with characterisation of the conjugates; the 
more extensive use of mPEG 2000 may have been desirable since lower molecular weight PEGs 
such as 550 may be associated with some toxicity.
The synthesis of two novel branched polyamines was achieved and these were coupled to mPEG 
550 using the mPEG 550 chloroformate. The use of the chloroformate has the advantage over the 
glycidyl ether in that it is considerably more reactive, however, a  suitable spacer must be used if the 
basicity of the conjugating amine is to be retained and it is less stable upon storage.
The conjugates show a range of interactions with DNA and this work essentially suggests that the 
higher the degree of PEGylation or the higher the PEG molecular weight, the weaker the 
interaclion with DNA. This may be because of steric effects; the PEG section of one conjugate 
molecule, when complexed, may prevent other conjugates from accessing the DNA. Further, given 
the highly hydrophilic nature of PEG, it may be more favourable for the conjugate to remain in free 
solution rather than forming strong complexes with DNA. Increasing the number of nitrogens 
enhances DNA interaction, this predictable effect was shown by the synthesis of the hexamine and 
branched pentamine conjugates (chapter 7).
Although the interaction of these conjugates with DNA is relatively weak, it may be enough to 
protect plasmids from nucleases and aid dispersion with tissues such as muscle and tumour i.e. these 
conjugates may find use as PING systems. As judged by the ethidium bromide assays it is unlikely 
that any of these conjugates cause DNA to condense with the possible exception of the 
monoPEGylated hexamine 167 which caused a reduction in ethidium bromide-DNA complex 
fluorescence of ca. 65% suggesting a large conformational change in the DNA. Further studies using 
different techniques are required to determine the nature of the complex between DNA and these 
novel copolymers.
The in vivo experiments show that the conjugates tested show a similar enhancement of gene 
expression to PVP. Compounds 155 and 167 show a significant enhancement of pGMVcat 
expression in R IF-1 tumours compared to a formulation of DNA in isotonic saline alone. There 
appears to be no advantage gained over PVP or 155 by using 167, the monoPEGylated hexamine 
which showed the strongest DNA binding of all the conjugates synthesised. Although these results 
provide useful information for the future development of PING systems the levels of expression
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gained in muscle were somewhat disappointing. However the level of gene expression obtained in 
muscle can be highly variable and be strongly influenced by injection technique [Mumper and 
Rolland, 1998].
In summary, the second part of the thesis described the synthesis a  number of mPEG-polyamine 
conjugates demonstrating a range of affinities for DNA by ethidium bromide assays; two of the 
conjugates enhanced the tumoural expression of reporter genes in mice bearing RTF-1 tumours 





1. Materials and General Procedures
Chemicals were purchased from the Aldrich, Fluka, Acros, Lancaster or Sigma chemical 
companies. Anhydrous solvents were purchased in anhydrous form, except T H F which was used 
freshly distilled from Na/benzophenone. iH, 13C and 19F NM R spectra were recorded on either 
JE O L  GX270 or EX400 spectrometers. 31P NM R spectra were recorded on JE O L  FX -90Q or EX- 
400 spectrometers. Chemical shifts are reported in ppm relative to standards. The standards were 
TM S for samples in CDCI3 and pHJyD M F, TM S or DM SO for samples in [2H]6-DMSO, TSP or 
H D O  for samples in D 2O, external 85 % aqueous phosphoric acid for 31P spectra and CCI3F for 
19F spectra. Multiplicities are indicated as follows: s (singlet), d (doublet), t (triplet), dd (doublet of 
doublets), q (quartet), m (multiplet), td (triplet of doublets), qn (quintet), tt (triplet of triplets) and br 
(broad signal). Thin layer chromatography (TLC) was performed on precoated plates (Merck TLC 
aluminium sheets silica 60 F254, Art no. 5554). The spots were visualised using phosphomolybdic 
acid, potassium permanganate, ninhydrin, iodine or UV light. Melting points were determined 
using a Reichert-Jung Thermo Galen Kofler block and are uncorrected. Elemental analysis was 
carried out by the University of Bath microanalysis service. Optical rotations were observed on an 
Optical Activity Ltd AA-10 polarimeter. Mass spectra were obtained by chemical ionisation (Cl), by 
electrospray (ES) or by fast atom bombardment (FAB) in a VG707E spectrometer and were 
recorded by the University of Bath mass spectrometry service. MALDI-TOF mass spectra were 
recorded at The School of Pharmacy, University of London. All evaporations were carried out 
under reduced pressure. Chromatography refers to the procedure developed by Clark Still [Clark 
Still etal, 1978] and was carried out using silica gel (Merck Kieselgel 60, mesh size 0.040-0.063mm). 
Ion-exchange chromatography was carried out on an LKB-Pharmacia medium pressure ion- 
exchange chromatograph on Q, sepharose fast flow resin. The brine was saturated. HC1 was 
generated by addition of concentrated sulfuric acid to NaCl. The boiling points quoted refer to the 
oven temperature of the kugelrohr apparatus.
2 Modification of Briggs5 Phosphate Assay
Q ualitative test
250jJ,l aliquots of each ion-exchange column fraction were transferred to test tubes and 4 drops of 
concentrated H 2SO4 were added. The samples were heated at 150-200°C for one hour. The
148
Chapter 9: Experimental
samples were then cooled and 250fJ,l water was added to each, followed by: 500pl aqueous 
ammonium molybdate solution (prepared using 2.5g in 20ml water and 8ml concentrated H 2SO 4); 
250jal aqueous hydroquinone solution (lOOmg in 20ml water and 1 drop concentrated H 2SO 4); 
250jil aqueous sodium sulfite solution (4g in 20ml water). Each sample was boiled for 8-10 seconds 
using a heat gun and then allowed to cool. The phosphate containing fractions could be identified 
by their blue colour.
Q uantitative test
The qualitative assay was repeated but this time known concentrations of potassium dihydrogen 
phosphate were co-assayed in order to construct a standard curve. Eight different concentrations of 
standard were used in triplicate. Three different sample sizes of the inositol phosphate to be 
analysed were taken, again in triplicate. The sample volumes taken were of an appropriate size such 
that they would lie within the limits of the standard curve, based on an assumed yield of around 70- 
80% at the phosphate deblocking step.
O n completion of the procedure as described for the qualitative assay, the test-tube fractions were 
transferred to 10ml volumetric flasks, water was added to 10ml and the U.V. absorbance at 340nm 
was measured in a 3ml quartz cell. This allowed the construction of a standard curve, an example 
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Figure 60 Standard curve for Brigg’s phosphate assay.
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3 Ethidium Bromide Assay
Calf thymus DNA “highly polymerised” sodium salt and poly-L-lysine hydrobromide (30000- 
70000Da) were purchased from Sigma. Plasmid DNA (pCMVcat) and PVP molecular weight 
50000Da were generous gifts from GeneMedicine, The Woodlands, Texas, USA. The experiments 
were performed in HEPES buffered saline (HBS), containing 20mM HEPES and 150mM NaCl; 
the pH  was adjusted to 7.4 with lM aqueous NaO H. The PVP experiment was performed in O.lM 
acetate buffer pH  4 (41ml 0.2M acetic acid + 9ml 0.2M potassium acetate, water to 100ml). The 
experiment at pH  5.5 was performed in MES buffered saline, containing 20mM MES and 150mM 
NaCl; the pH was adjusted to 5.5 with lM hydrochloric acid. Fluorescence was monitored on a 
Perkin Elmer Luminescence Spectrometer (LS-50B) with an excitation wavelength of 260nm and 
an emission wavelength of 600nm.
A ssay procedure
To 6jog of DNA in HBS (3ml) is added 3jil of ethidium bromide solution 0.5m g/m l and the 
mixture is stirred in the fluorimeter cuvette until no change in fluorescence occurred (usually ca. 2-3 
minutes). An aliquot of compound to be tested (dissolved in HBS), typically 4jxl, is added with 
continuous stirring. The new fluorescence reading is taken 45-60 seconds later then a another 
aliquot of compound is added. This is repeated until no further change in fluorescence is observed 
or when the volume of polymer added is 2.5% of the total volume of the system.
The percent relative fluorescence intensity was determined using the following equation:
Fr =  (FobS- F e ) / ( F o - F e )
Where Fr is the relative fluorescence, Fobs is the measured fluorescence, Fe is the fluorescence of EB 





m y o -ln o s ito l o r th o a c e ta te  (62)
To myo-inositol (20.0 g, 0.11 mol) and PTSA (5.3g, 0.03 mol) in DM F (200 ml) was added 
triethyl orthoacetate (38 ml, 0.21 mol) slowly at 140°C under N2. The mixture was stirred for 
2h and allowed to cool. The DM F was evaporated and saturated aqueous N a H C 0 3 (40 ml) was 
added. The mixture was stirred for 10 min, filtered, then diluted with water (200 ml). The 
solution was washed with CHCI3 (3x 100 ml) and the water was evaporated. The residue, in 
M eOH (800 ml), was heated to 50°C and filtered. Evaporation, chromatography (acetonitrile) 
and recrystallisation (MeOH) gave myo-inositol orthoacetate (12.95g, 57%) as colourless crystals: 
mp 185-187°C (with softening at 165°C); Found: C, 47.0; H, 6.0. calc, for C 8H 12O6: C, 47.06; 
H, 5.92%; 5h  (400 MHz; pKQe-DMSO) 1.28 (3H, s, C H 3), 3.94-4.0 (4H, m, Ins H), 4.21-4.27 
(2H, m, Ins H), 5.19 (1 H , s, OH-2), 5.38 (2H, d, J  5.2 Hz, OH-4 and OH-6); 5c (100 MHz, 
[2H]6-DMSO) 24.30 (CHs), 57.70, 67.24, 69.24, 74.98 (Ins C), 107.66 (CCH3); m /z  (FAB+) 205 
[(M+H)+, 100%].
D icam phanate esters o f  m y o in o s ito l orthoacetate
In dichloromethane
To myo-inositol orthoacetate (l.OOg, 4.90mmol), triethylamine (2ml) and DMAP (lOOmg) in dry 
CH 2CI2 (40ml) was added (-)-camphanoyl chloride (2.25g, 10.4 mmol), in dry C H 2CI2 (10ml) 
slowly at 0°C under N 2. After 15 min, the mixture was allowed to reach room temperature and 
stirring was continued for a  further 2h. Evaporation and chromatography (C ^ C b /E tO A c  3:1) 
gave the 2,6-dicamphanate 5 9  (940mg, 34%) as a white solid and the 2,4-dicamphanate 63  
(677mg, 24%) as a white solid. Samples for analysis were recrystallised from EtOAc/hexane.
In pyridine
To a solution of myo-inositol orthoacetate (970mg, 4.75 mmol) in dry pyridine (10ml) was added 
DMAP (50mg) and (—)-camphanoyl chloride (2.60g, 12.0mM) at 0°C. The mixture was allowed 
to reach room temperature and was stirred for lh. The solvents were evaporated. The residue, 
in C H 2CI2, was washed with lM hydrochloric acid (50ml) and brine (70ml), then dried with 
MgSO-t. Evaporation and chromatography gave the 2,6-dicamphanate 59  (542mg, 20%) as a 
white solid and the 2,4-dicamphanate 63 (996mg, 37%) as a white solid.
lD -2 ,6 -D i-0 - (—)-ca m p h a n o y l m y o -in o s ito l o r th o a c e ta te  (59)
mp 228-231°C; [<x]d 2* + 17° (c  1.0, GH2C12); Found: C, 59.6; H, 6.45. calc, for C28H 36O i2: G, 
59.59; H, 6.43%; 8H (400 MHz; CDC13) 0.98, 0.99, 1.08, 1.09, 1.10, 1.11 (18H, 6x s, Gamph
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C H 3), 1.44 (3H, s, O 3C C H 3), 1.67-1.76 (2H, m, Camph CH 2), 1.91-2.10 (4H, m, Camph C H 2), 
2.39-2.53 (2H, m, Camph C H 2), 3.23 (1H, d, J  6.4 Hz, OH-2), 4.33-4.36 (1H, m, H-3), 4.39- 
4.43 (1H, m, H -l), 4.45-4.50 (1H, m, H-5), 4.57-4.62 (1H, m, H-4), 5.21-5.25 (1H, m, H-2), 
5.52-5.57 (1H, m, H-6); 8c (100 MHz; CDCI3) 9.59, 9.66, 16.47, 16.54, 16.65 (Camph C H 3), 
23.94 (O3CCH3), 28.76, 28.90, 30.44, 30.86 (Camph C H 2), 54.41, 54.51, 54.80, 54.89, 90.86, 
91.03 (Camph C), 63.72, 66.78, 68.15, 69.14, 69.30, 71.86 (Ins C), 108.8 (O3C), 166.15, 
166.81, 177.73, 178.02 (Camph CO); m /z  (FAB+) 565 [(M+H)+, 100%].
lD -2 ,4 -D i-0 -(—)-cam phanoyl m jyo-inositol orth oacetate  (63)
mp 201-204°C; [a]D24 -4 °  (c 1.0, C H 2C12); Found: C, 59.5; H , 6.5. calc, for C28H36O i2: C, 
59.59; H , 6.43%; 8H (400MHz, CDCI3) 0.96, 0.97, 1.09, 1.10, 1.12, 1.14 (18H, 6x s, Camph 
C H S), 1.43 (3H, s, O 3C C H 3), 1.63-1.74 (2H, m, Camph C H 2), 1.90-2.11 (4H, m, Camph C H 2), 
2.43-2.53 (2H, m, Camph C H 2), 3.37 (1H, d, J  6.1Hz, OH-6), 4.30-4.36 (1H, m, H -l), 4.40- 
4.45 (1H, m, H-5), 4.49-4.55 (1H, m, H-3 or H-6), 4.51-4.62 (1H, m, H-3 or H-6), 5.23-5.25 
(1H, m, H-2), 5.53-5.55 (1H, m, H-4); 8c (100MHz, CDCI3) 9.58, 9.63, 16.50, 16.58, 16.63, 
16.81 (Camph C H 3), 24.0 (O3CCH3), 28.83, 29.03, 30.57, 30.70 (Camph C H 2), 54.31, 54.51, 
54.78, 54.89, 91.01, 91.12 (Camph C), 63.74, 66.67, 68.08, 68.96, 71.93 (Ins C), 108.79 
(O3CCH3), 165.94, 166.94, 177.86, 177.90 (CO).
lD -2 ,4 ,6 -T ri-0 -(—)-cam phanoyl m y o ~inositol orth oacetate  (64)
mp 210-211°C; Found: C, 61.2; H, 6.43. calc, for CssH^Ois: C, 61.28; H , 6.50%; 8H 
(400MHz, CDCI3), 0.98, 1.02, 1.11, 1.13, 1.14, 1.17 (27H, 6x s, Camph C H 3), 1.53 (3H, s, 
O 3C C H 3), 1.73-1.80 (4H, m, Camph C H 2), 1.98-2.08 (3H, m, Camph C H 2), 2.12-2.19 (1H, m, 
Camph C H 2), 2.30-2.38 (2H, m, Camph C H 2), 2.48-2.60 (2H, m, Camph C H 2), 4.36-4.39 (1H, 
m, Ins H), 4.53-4.58 (2H, m, Ins H), 5.05-5.09 (1H, m, H-2), 5.70-5.72 (1H, m, H -4 or H-6), 
5.77-5.79 (1H, m, H-4 or H-6).
lD -2 ,6 -D i-0 -(—)-cam phanoyl m y o ~inositol (51)
A solution of the alcohol 59 (455mg, 0.81 mmol) in M eOH (45ml) and 5M Hydrochloric acid 
(2ml) was heated to reflux. After 5h, further 5M Hydrochloric acid (2ml) was added and heating 
to reflux continued for 9h. Evaporation then chromatography (CHCl3/M eO H  5:1) gave tetrol 
51 (40mg, 9%) as a white solid: m p212-215°C (lit. [Riley, 1996] mp 211-213°C); [cc]D25 -8 °  (c 
0.01, DMF) (lit. [Riley, 1996] [cc]D25 -8 °  (c 0.01, DMF)}; 8H (400 MHz; [2FF]6-DMSO) 0.86-
1.07 (18H, m, Camph C H 3), 1.52-1.61 (2H, m, Camph C H 2), 1.87-2.05 (4H, m, Camph C H 2), 
2.35-2.50 (2H, m, Camph C H 2), 3.22-3.28 (1H, m, D 20  ex. gives t, J  9.2Hz, H-4), 3.44-3.46 
(1H, m, D 20  ex. gives t, J  9.5Hz, H-5), 3.50-3.54 (1H, m, D 20  ex. gives dd, J  2.8, 9.8Hz, H-
3), 3.74-3.79 (1H, m, D 20  ex. gives dd, J  2.8, 10.1Hz, H -l), 4.98-5.03( 1H, t, J  10.3FFz, H-6),
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5.09 (1H, d, J  4.4Hz, OH-5), 5.16 (2H, d, J  5.4Hz, OH-3 and OH-4), 5.32 (1H, d, J  4.9Hz, 
OH-1), 5.37 (1H, t, J2 .4 H z , H-2); 6c (100MHz; pHJe-DMSO) 9.51, 9.54, 16.06, 16.29, 16.33, 
16.49 (Camph CHs), 28.33, 28.38, 30.26, 30.19 (Camph C H 2), 53.89, 53.95, 54.28, 54.35,
91.09, 91,29 (Camph C), 66.89, 68.82, 71.96, 73.37, 75.75, 76.19 (Ins C), 166.16, 178.01 
(Camph CO).
A cetate e s ters  o f  lD -2 ,6 -d i-0 -(—)- cam phanoyl m y o -inosito l
The alcohol 59 (870mg, 1.54mmol) in 80% aqueous trifluoroacetic acid (60ml) was stirred at 
room temperature for 7 days. Evaporation then chromatography (EtOAc) gave the 3-acetate 49 
(172mg, 20%) as a white solid, the 1-acetate 60 (227mg, 25%) as a  white solid, and the tetrol 51 
(113mg, 14%).
lD -3-A cety l-2 ,6-d i-0-(—)-cam phanoyl m yo-inosito l (49)
mp 226-229°C; [a]D25 +5.2° (c 1.9, DMF); 6H (400 MHz; [2H]7-DMF) 0.96, 1.02, 1.05, 1.10,
1.12, 1.17 (18H, 6x s, Camph CHs), 1.55-1.67 (2H, m, Camph C H 2), 1.94-2.14 (4H, m, 
Cam ph C H 2), 2.02 (3H, s, C O C H 3), 2.49-2.61 (2H, m, Camph CH 2), 3.61 (1H, dt, J  5.9, 
9.3Hz, D 20  ex. gives t, J  9.8Hz, H-5), 3.86 (1H, dt, J  4.9, 9.8Hz, D sO ex. gives t, J  9.8Hz, H- 
4), 4.15-4.17 (1H, m, D sO ex. gives dd, J 2 .8 ,  10.4Hz, H-l), 4.96 (1H, dd, J  2.8, 10.1Hz, H-3), 
5.29 (1H, t, J  10.1Hz, H-6) 5.58 (1H, d, J 5 .4 H z , OH-5), 5.60 (1H, m, OH-4), 5.62-5.63 (1H, 
m, D20  ex. gives t, J  2.8FFz, H-2), 5.75 (1H, d, J  5.9Hz, OH-1); m /z  (FAB+) 583.2394. 
(M+H)+ (C28H 390i3 requires 583.2391).
lD -l-A cety l-2 ,6 -d i-0 -(-)-cam p h an oy l m y o -inosito l (60)
mp 146-150°C (with softening at ca. 112°C); 5h  (400MHz, CDC13), 0.90, 1.05, 1.07 (9H, 3x s, 
Cam phCH 3), 1.09 (6H, s, Camph C H 3), 1.13 (3H, s, Cam phCH3), 1.65-1.76 (2H, m, Camph- 
C H 2), 1.92-2.10 (3H, m, Camph C H 2), 1.96 (3H, s, C O C H 3), 2.11-2.18 (1H, m, Camph CH 2), 
2.38-2.53 (2H, m, Camph C H 2), 3.67 (1H, t, J  9.3Hz, H-5), 3.90-3.95 (2H, m, H-3 and H-4), 
4.35 (3H, br s, OH), 5.09 (1H, dd, J  2.4, 10.7Hz, H -l), 5.36 (1H, t, J  10.3Hz H-6), 5.62-5.65 
(1H, m, H-2); m /Z (FAB+) 583.2418 (M+H)+ (C28H 39O i3 requires 583.2391); 584.2444 (M+H)+ 
(13C iC 27H 39O i3 requires 584.2424).
lD -3-A cetyI-2,6-d i-0-(—)-cam p h an oyl-m yo-in osito l-l,4 ,5 -tr is(d ib en zy l phosphate)  
(66)
To bis(benzyloxy)diisopropylaminophosphine (174mg, 5.03mmol) in dry C H 2C12 (3ml) was 
added l//-tetrazole (70mg, l.Ommol). The mixture was stirred at room temperature for 30 min 
then added to the triol 49 (65mg, 0 .112mmol) with further dry C H 2C12 (1ml). The mixture was 
stirred at room temperature for 30 min [31P NM R (90 MHz) showed phosphite triester signals
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at 142.1, d, J  7.3Hz; 141.5, d, J  7.3Hz; and 140.7, s]. The mixture was cooled to -78°C and 
MCPBA (57-86%, 115mg) was added. The mixture was allowed to reach room temperature 
and was stirred for 20min. C H 2CI2 (50ml) was added and this solution was washed with 10% 
aqueous Na2SC>3 (50ml), saturated aqueous NaHCC>3 (50ml) and brine (50ml). The organic 
layer was dried with M gS 04. Evaporation and chromatography (EtOAc/hexane 3:2) gave the 
title compound (1 lOmg, 72%) as a colourless oil: 8p  (162 MHz CDCI3 ) -2 .05, -2.18, -2.33; 8 h  
(400 M Hz C D C ls;) 0.92, 0.95, 1.00, 1.04, 1.09, 1.11 (18H, 6x s, camph C H 3), 1.47-1.54 (1H, 
m, camph C H 2), 1.62-1.69 (1H, m, camph C H 2), 1.71-1.75 (1H, m, camph C H 2), 1.78 (3H, s, 
C O C H 3), 1.88-1.96 (2H, m, camph C H 2), 2.04-2.11 (1H, m, camph C H 2), 2.24-2.31 (1H, m, 
camph C H 2), 2.37-2.44 (1H, m, camph C H 2), 4.22 (1H, m, H -l), 4.40 (1H q, J  9.8Hz, H-4 or 
H-5), 4.83-5.08 (14H, m, 6x PhCH 2 and H-3 and H-4 or H-5), 5.61 (1H, t, J  9.8Hz, H-6), 5.93 
(1H, t, J  2.7Hz, H-2), 7.20-7.37 (30H, m, Ph); m /Z (FAB+) 1365.4273 (M+H)+ 
(13C2C68H78C>22P3 requires 1365.4265); 1364.4221 (M+H)+ (13CiC69H7s022P3 requires 
1364.4231); 1363.4216 (M+H)+ (C70H 78O 22P3 requires 1363.4198).
D-myo-Inositol-1,4,5-trisphosphate (19)
To the tris(dibenzylphosphate) 66 (110mg, 0.081 mmol) in M eOH (20ml) was added 10% Pd on 
activated charcoal (lOOmg) as a slurry in water (1ml). The mixture was stirred vigorously for 
12h at room temperature under H 2. The catalyst was filtered off and washed with M eOH 
(15ml). Evaporation of the solvent from the filtrate and washings gave a glassy white solid. This 
was dissolved in concentrated aqueous ammonia (10ml) and transferred to a  sealed bottle and 
heated at 60°C for 4h. The solvents were evaporated and the residue was purified by ion 
exchange chromatography on Sepharose fast flow resin using a gradient of 
triethylammonium hydrogencarbonate buffer (0-100% lM ) . Evaporation gave D-myo-inositol-
1,4,5-trisphosphate 19, triethylammonium salt (56pmol, 70%) as a colourless glass: [cx]d23 -17 .0  
(c 0.024, triethylammonium hydrogencarbonate buffer, pH 7.6) {lit. (ammonium salt)[Ozaki et 
al, 1992] [<x]d23 -10.3° (c 1.80, water, pH6.73)}; 8P (162 MHz, D 20 )  -0.40, 0.34, 0.92; 8H (400 
MHz, D 2O) 3.59 (1H, dd, J  2.8, 9.8Hz, H-3), 3.77 (1H, t, J  9.5, H-6), 3.86-3.94 (2H, m, H-5 







To myo-inositol (20.0g, O.llmol) and PTSA (4.7g, 0.025mol) in DM F (200ml) was added 
triethyl orthoformate (35ml, 0.210mol) slowly at 140°C. The mixture was stirred for 3h, 
allowed to cool and the DM F was evaporated. 10% Aqueous Na2CC>3 solution (50ml) was 
added. The mixture was stirred for 15 minutes, filtered then diluted with water (200ml), the 
solution was washed with C H C b (3x 100ml) and the water was evaporated. The residue, in 
M eOH (600ml), was heated to 50°C and the remaining solid was filtered off. Evaporation, 
chromatography (acetonitrile) and recrystallisation (MeOH) gave 1,3,5-O-methylidine-myo- 
inositol 74 (12.lg, 57%) as colourless crystals: mp >275°C (decomposes) (lit. [Billington et al, 
1989] mp 300-302°C); Found: C, 44.3; H , 5.3. calc, for C 7H i0O 6: C, 44.22; H , 5.30%; 5H 
(270MHz; pHJe-DMSO) 3.94-3.96 (2H, m, H -l and H-3), 3.99 (1H, br s, H-2), 4.06 (1H, m, 
H-5), 4.26-4.29 (2H, m, H-4 and H-6), 5.33 (1H, br s, OH-2), 5.45 (1H, s, OsCH) 5.47 (2H, br 
s, OH-4 and OH-6).
2,6-Di-0-(4>methoxybenzyl)-l,3,5-O-methylidene-myo-inositol (75)
To wyo-inositol orthoformate 74 (11.68g, 61.5mmol) in dry DM F (250ml) was added NaH 
(60% dispersion in mineral oil, 5.4g, 141 mmol) slowly at room temperature. The mixture was 
stirred for lh  then 4-methoxybenzyl chloride (17.5ml, 129mmol) was added. After 3h water 
(50ml) was added slowly, then the solvents were evaporated. W ater (300ml) was added to the 
residue and the products were extracted with C H 2CI2 (3x 200ml). The pooled organic phases 
were washed with brine and then dried with MgSO*. Evaporation, chromatography 
(CH2Cl2/EtO Ac 5:1) and recrystallisation (EtOAc/hexane) gave the title compound (10.26g, 
38%) as colourless crystals: mp 120-121°C (lit. [Riley et al, 1998] mp 120-121°C); Found: C, 
64.1; H, 6.1. calc, for C23H 26O 8: C, 64.18; H, 6.09%; 8H (270MHz; CDC13; ) 3.25 (1H, d, J
I I.4Hz, OH-2), 3.78 (6H, s, O C H 3), 4.13-4.15 (1H, m, H-2), 4.17-4.21 (2H, m, H -l and H-3), 
4.33 (2H, t, J  3.5Hz, H-4 and H-6), 4.39-4.41 (1H, m, H-5), 4.48 (2H, d, J  11.0Hz, C H 2), 4.56 
(2H, d, J  11.0Hz, C H 2), 5.46 (1H, s, OsCH), 6.69-6.83 (4H, m, Ph), 7.15-7.19 (4H, m, Ph); 5C 
(68 MHz; CDC13) 55.14 (OCH3), 61.35 (Ins C), 67.77 (Ins C), 71.26 (CH2), 72.95 (Ins C), 73.40 





To oxalyl chloride (12.8ml of a 2.0M solution in C H 2CI2, 25.6mmol) in dry C H 2CI2 (40ml) was 
added dry DM SO (3.6ml, 51 mmol) in dry C H 2CI2 (5ml) dropwise at -60°C  under N 2. The 
mixture was stirred for lOmin at -60°C . The alcohol 75 (lO.OOg, 23.2mmol) in dry C H 2CI2 
(30ml) was added dropwise. The mixture was stirred for 30min at -60°C , then triethylamine 
(15ml) was added. The mixture was allowed to warm to room temperature, then water (100ml) 
was added and the product extracted with C H 2CI2 (2x 150ml). The organic layer was washed 
with brine (200ml), 1% hydrochloric acid (150ml), water (150ml), 10% aqueous NaHCOs 
solution (200ml), and water (200ml), then dried with MgSCH. Evaporation gave a white solid 
which was dissolved in toluene (300ml) and heated to reflux with azeotropic removal of water 
using a Dean and Stark trap for 3h. Evaporation then recrystallisation (EtOAc/hexane) under 
N 2 gave the ketone 76 (8.13g, 82%) as colourless crystals: mp 126-127°C (lit. [Riley et al, 1998] 
mp 125-126°C); IR  1760cm"1 CO; 8H (400MHz; CDCI3) 3.78 (6H, s, O C H 3), 4.39 (2H, dd, J  
2.5Hz, 1.5Hz, H-3 and H-5), 4.48-4.50 (1H, m, H-4), 4.51-4.54 (6H, m, C H 2, H-2 and H-6), 
5.63 (1H s OsCH), 6.80-6.84 (4H m, Ph), 7.14-7.18 (4H, m, Ph); 6c (100MHz; CDCI3) 55.23 
(CHs), 68.87 (Ins C), 71.17 (CH2) 76.35 and 77.98 (Ins C), 102.63 (O3CH), 113.82 and 129.51 
(Ph C), 128.96 (CCH2), 159.45 (PhCOCHs), 199.28 (CO).
2,4-Di-0-(4-methoxybenzyl)-6-methyIidine-l,3,5-0-methylidine-cyclohexane 
1,3,5/2,4-pentol (77)
To methyltriphenylphosphonium bromide (12.4g, 34.7mmol) in dry T H F (40ml) was added 
potassium fert-butoxide (33ml of a 1M solution in THF, 33mmol) at 0°C under N 2, with stirring. 
The yellow suspension was allowed to reach room temperature. After lOmin, the ketone 76 
(7.0lg, 16.4 mmol) in dry T H F (60ml) was added. The mixture was heated to reflux for 3h. The 
TH F was evaporated and the residue was dissolved in diethyl ether (200ml), washed with brine 
(200ml) then dried with MgSCU. Evaporation, then chromatography (EtOAc/hexane 1:2) gave 
the alkene 77 (5.89g, 84%) as a white solid: mp 90-91°C (from EtOH) (lit. [Riley etal, 1998] mp 
95-97°C); Found: C, 67.5; H, 6.2 calc, for C 24H 26O 7: C, 67.59; H, 6.15%; 8H (270MHz; 
CDCls) 3.80 (6H, s, CHs), 4.23 (2H, dd, J  3.5, 3.6Hz, H-2 and H-4), 4.30-4.35 (1H, m, H-3), 
4.40-4.42 (2H, m, H -l and H-5), 4.53 (2H, d, J  11.9Hz, C H 2), 4.58 (2H, d, J  11.9Hz, C H 2), 
5.25 (2H, s, = C H 2), 5.56 (H, s, O C 3H), 6.82-6.85 (4H, m, Ph), 7.22-7.25 (4H, m, Ph); 6c 
(68.8MHz; CDCI3) 55.17 (OCHs), 68.97 (Ins C), 71.09 (CH2), 74.29 and 73.58(Ins C), 103.69 




(1,3,5 /  2,4,6) -6-Hy droxymethyl-1,3,5-0-methylidene-2,4-di-0-(4-methoxybenzyl)- 
cyclohexane 1,2,3,4,5-pentol (78)
To the alkene 77 (5.00g, 11.72mmol) was added 9-borabicyclononane (50ml of a 0.5M solution 
in TH F, 25mmol) at room temperature under N 2. The mixture was stirred for 2h at 50°C 
under N 2. The mixture was then cooled to 0°C, then ethanol (17ml), 6M aqueous N aO H  
(4.2ml) and 30% H 2O 2 were added dropwise. The mixture was then stirred at 50°C for a 
further 30 minutes. The mixture was cooled and water (20ml) was added. The aqueous layer 
was saturated with K 2C O 3 and the organic layer was removed, dried with MgSCb then 
evaporated. Chromatography (EtOAc/hexane 1:1) gave the title compound (3.88g, 74%) as a 
white solid: mp 79-81°C (from EtOH) (lit. [Riley et al, 1998] mp 81-82°C); 8 h  (400MHz; 
CDCI3) 1.72-1.76 (1H, m, C H 2Ofl), 2.95-2.99 (1H, m, H-6), 3.79 (6H, s, CH 3), 4.06-4.08 (2H, 
m, C H 2OH), 4.26-4.28 (2H, m, H -l and H-5), 4.34-4.36 (2H, m, H-2 and H-4), 4.48 (1H, d, J  
10.7Hz, C H 2), 4.49 (1H, d, J  11.3Hz, C H 2), 4.51-4.53 (1H, m, H-3), 4.57 (1H, d, J  11.3Hz, 




The alcohol 78 (3.88g, 8.73mmol) in M eOH (150ml)/lM hydrochloric acid (15ml) was heated 
to 50°C. After 40 min, concentrated aqueous ammonia solution (20ml) was added and the 
mixture stirred at room temperature for lh. Evaporation then chromatography (C H C b/M eO H  
5:1 then 1:1) gave the title compound (2.8 lg, 74%) as a white solid: mp 135-136.5 °C (lit. [Riley 
etal, 1998] mP 136-137°C); 8H (270 MHz; pHJe-DMSO) 1.25 (1H, tt, J  10.7, 2.0Hz, H-6) 3.09 
(2H, dd, J 9 .5 ,  9.2Hz, H-2 and H-4), 3.21 (1H, dt, J 5 .5 ,  9.2Hz, D 20  ex. gives t, J9 .5 H z , H-3), 
3.29-3.33 (2H, m, D 20  ex. gives dd, J  10.4, 9.5Hz, H -l and H-5), 3.68-3.71 (2H, m, C //2OH), 
3.73 (6H, s, O C H 3), 4.27 (1H, t, J  5.2Hz, C H 2Ofl), 4.72 (4H, s, C H 2), 4.74 (2H, d, J  5.8, OH- 
1 and OH-5), 4.92 (1H, d, OH-3 J  5.5), 6.85-6.88 (4H, m, P h ) 7.34-7.36 (4H, m, Ph).
DL- (1,3,5 /  2,4 ,6) -1,7- 0-Benzylidene-6-hydroxymethyl-2,4-di-0-(4-methoxybenzyl) - 
cyclohexane-l,2,3,4,5-pentol (82)
To the tetrol 79 (2.78g, 6.39mmol) in DM F (15ml) was added benzaldehyde dimethyl acetal 
(1.2g, 7.88mmol) and PTSA (50mg). The flask was fitted with a  25cm air condenser connected 
to a  water pump and the solution was stirred at 70°C under reduced pressure. After 50min, the 
mixture was cooled to room temperature and triethylamine (2ml) was added. After lh, the 
solvents were evaporated and the residue dissolved in CH 2CI2 then washed with water (80ml), 
brine (80ml) then dried with MgS0 4 . Evaporation, then recrystallisation (EtOAc/hexane) gave 
the title compound (2.76g, 82%) as a white solid: mp 160-161°C (lit. [Riley etal, 1998] mp 158-
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160°C); 8h (400 MHz; CDCI3; ) 1.93 (1H, dddd, J  10.7, 10.7, 10.7, 4.5Hz, H-6), 2.34 (1H, d, J
I.8Hz, OH), 2.66 (1H, d, J  1.8Hz, OH), 3.23 (1H, ddd, J  1.8, 8.9, 11.0Hz, DsO ex. gives dd, J
8.9, 11.0Hz, H-3), 3.33 (1H, dd, J  8.9, 11.0Hz, H-4), 3.51-3.71 (4H, m, H -l, H-2, H-5 and 
C H 2), 3.78 (6H, br s, O C H 3), 4.50 (1H, dd, J  4.3, 11.0Hz, C H 2), 4.60 (1H, d, J  11.0Hz, C H 2), 
4.63 (1H, d, J  11.0Hz, C H 2), 4.96 (1H, d, J  11.3Hz, C H 2,), 4.97 (1H, d, J  11.3Hz, C H 2), 5.52 
(1H, s, C /ffh), 6.84-6.90 (4H, m, Ph H), 7.24-7.30 (4H, m, Ph H), 7.33-7.52 (5H, m, Ph H).
DL- (1,3,5 /  2,4,6) -1,3-Di-0-benzyl-5,7- O-benzyHdene-6-hydroxy methyl-2,4-di-O- (4- 
methoxybenzyl)cyclohexane 1,2,3,4,5-pentoi (70)
To the diol 82 (lOOmg, 0 .19mmol) in dry DM F (10ml) was added sodium hydride (25mg of a 
60% dispersion in mineral oil, 0.625mmol) at room temperature. After 30min, benzyl bromide 
(0.05ml, 0.46mmol) was added and the mixture was stirred overnight. W ater (5ml) was added 
then the solvents were evaporated. The residue was dissolved in C H 2C12 (20ml) and washed 
with brine (20ml) then dried with MgSO*. Evaporation gave a white solid which was washed 
with pentane then recrystallised (EtOH) to give the title compound (121mg, 90%) as white 
crystals: mp 135-137°C Git. [Riley et al, 1998] mp 135-137°C); 8H (270MHz; C D C I 3 )  1.97-2.00 
(1H, m, H-6), 3.21-3.25 (1H, m, H -l) 3.43-3.71 (5H, m, H-2, H-3, H-4, H-5, and C H 2 axial), 
3.77 (3H, s, OCHs), 3.78 (3H, s, O C H 3), 4.42 (1H, dd, J  11.0, 4.4Hz, C H 2 equatorial), 4.50- 
4.98 (8H, m, PhC H 2), 5.48 (1H, s, CHPh), 6.77-6.84 (4H, m, Ph), 7.20-7.51 (19H, m, Ph).
DL- (1,3,5 /  2,4,6) -1,3-Di-0-benzyl-6-hy droxymethylcyclohexane-1,2,3,4,5-pentol
(83)
To 70 (400mg, 0.57mmol) in E tO H  (20ml) was added lM hydrochloric acid (10ml). The 
mixture was heated to reflux for 3h. Evaporation then chromatography (C H C E/M eO H  9:1) 
gave the tetrol 83 (152mg, 71%) as a white solid: mp 124-125°C (from EtO Ac/hexane); Found: 
C, 67.1; H, 7.1. calc, for C2iH260 6: C, 67.36; H, 7.00%; 8H (400MHz; pHje-DMSO) 1.26 (1H, 
m, H-6), 3.02 (1H, t, J 9 .3 H z , H-3), 3.26-3.37 [3H, m, D 20  ex. gives: 3.21 (1H, t, J 9 .2 H z , H-
4), 3.32 (1H, t, J  10.4Hz, H-5), 3.35 (1H, t, J  10.1Hz, H -l)], 3.44-3.46 (1H, m, D20  ex. gives t, 
J  9.2Hz, H-2), 3.67-3.76 (2H, m, C tf2OH), 4.36 (1H, t, J  4.4Hz, C H 2Ofl), 4.59 (1H, d, J
I I.2Hz, PhCH2), 4.66 (1H, d, J  4.9Hz, OH-5), 4.79 (1H, d, J  11.7Hz, PhCH 2), 4.83 (1H, d, J
11.7Hz, PhCH2), 4.88 (1H, d, J4 .9 H z , OH-4), 4.91 (1H, d, J  11.2Hz, PhC H 2), 5.10 (1H, d, J  
5.8Hz, OH-2), 7.23-7.46 (10H, m, Ph); 8C (100MHz; [2H]6-DMSO) 46.60 (Ins C), 56.29 
(CH2OH), 68.97, 76.67, 76.77, 77.80, 83.19 (Ins C), 73.74 (PhCH2), 127.06, 127.19, 127.69, 
127.95, 128.17 (Ph-CH), 139.65, 139.84 (Ph C).
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DL- (1,3,5 /  2,4,6) -3,5-Di-0-benzyI-6-hydroxymethylcy clohexane-1,2,3,4,5-pentol- 
l,2,4,7-tetrakis(dibenzyl phosphate) (84)
To a solution of bis(benzyloxy)diisopropylaminophosphine (1.1 lg, 3.21mmol) in dry C H 2CI2 
(3ml) was added 1/f-tetrazole (450mg, 6.42mmol). The mixture was stirred at room 
temperature for 30min, then the tetrol 83 (150mg, 0.401mmol) was added. After 40min the 
mixture was cooled to -78°C  and MCPBA (57-86%, l.lg) was added. The mixture was 
allowed to reach room temperature and stirring was continued for 30min, then C H 2CI2 (50ml) 
was added. The solution was washed with 10% Na2SC>3 solution (50ml), saturated NaHCOs 
solution (50ml) and brine (50ml) then dried with MgSC>4. Evaporation then chromatography 
(CHCE/acetone 5:1) gave the title compound (410mg, 72%) as a colourless oil: Found: C, 64.8; 
H , 5.6. calc, for C 77H 78O 18P4: C, 65.34; H , 5.55%; 6P (162MHz; CDCI3) -0 .81, -1.58, -1 .85, -  
2.18; 5h (400MHz; CDCI3) 2.02-2.06 (1H, m, H-6) 3.51-3.64 (2H, m, C //2-OPO(Bn)2), 4.47- 
T50 (2H, m, Ins H), 4.59-5.07 (23H, m, Ins H  and Ph-CH2), 6.97-7.40 (50H, m, Ph-H); m /z  
(FAB+) 1415.4204 (M+H)+ (C77H 79O 18P4 requires 1415.4217); 1416.4235 (M+H)+
(13CiC76H790i8P4 requires 1416.4250).
DL-(1,3,5/ 2 ,4,6)-6-Hydroxymethyl-cyclohexane-1,2,3,4,5 pentol-1,2,4,7- 
tetrakisphosphate (68)
To 84 (150mg) in M eOH (40ml) and water (10ml) was added 10% palladium on activated 
charcoal (200mg). The mixture was treated with hydrogen at 40psi at room temperature 
overnight. The mixture was then filtered through Celite and the solvents were evaporated. The 
residue was dissolved in water(lOOml) and purified by ion-exchange chromatography on Q, 
Sepharose fast flow resin eluting with a  gradient of triethylammonium hydrogencarbonate 
buffer (0-lM). Evaporation gave the tetrakisphosphate 68 (79pmol, 75%) as a colourless glass: 
5p (162MHz; D20 )  0.64, 0.39, 0.47, 0.62; 6H (400MHz; D20 )  1.61 (1H, t, J  10.7Hz, H-6), 3.39 
(1H, t ,J9 .2 H z , H-3 or H-5), 3.52 (1H, t , J  10.1Hz, H-3 or H-5), 3.81 (1H, q ,J 8 .9 H z , H -l or 
H-2 or H-4), 3.92-3.99 (3H, m, H -l or H-2 or H-4 and C H 2), 4.09 (1H, q, J  10.1Hz, H -l or H- 





To propane-1,3-diamine (lO.Og, 0.13mol) in M eO H  (15ml) at 0°C was added acrylonitrile 
(14.3g, 0.27mol) dropwise over 20min. The mixture was stirred for 20min at 0°C, then at room 
temperature overnight. Evaporation gave N,N'-bis(2-cyanoethyl) propane- 1,3-diamine (24.3g, 
quant.) as a colourless liquid. A sample for elemental analysis was distilled using kugelrohr 
apparatus: bpo.3 235°C (lit. [Israel et al, 1964] bpo.5 176°C); found: C, 60.0; H , 9.0; N, 31.2. 
calc, for C9H i6N4: C, 59.96; H , 8.94; N, 31.08%; 8H (400MHz, CDCI3) 1.49 (2H, s, NH), 1.67 
(2H, qn, J  6.7Hz, C //2C H 2N), 2.53 (4H, t, J  6.7Hz, CH 2), 2.73 (4H, t, J  6.4Hz, C H 2), 2.91 
(4H, t, J6 .5 H z , C H 2); 5c (IOOMHz CDCI3) 18.67, 29.77, 45.08, 47.55 (CH2), 118.98 (CN).
N,N/-Bis(3-aminopropyl)propane-l,3-diamine (92)
To N,N'-bis(2-cyanoethyl)propane-1,3-diamine (2.00g, 1 l.lm m ol) in M eOH (20ml) was added 
W-2 Raney nickel (lg, dense slurry in EtOH) in M eOH (10ml). The mixture was cooled to 0°C 
and ammonia was bubbled through for 30min. The mixture was treated with H 2 (50psi) at 
room temperature for 65h. The catalyst was filtered off through Celite. The catalyst and Celite 
pad were washed with E tO H  (300ml). Evaporation of the solvent from the combined filtrate 
and washings, followed by kugelrohr distillation, gave N,N'-bis(3-aminopropyl)propane- 1,3- 
diamine (1.40g, 67%) as a colourless liquid: bpo.os 185°C, (lit. [Israel et al, 1964] bpo.07 97- 
100°C); 5h (270MHz; [2H]6-DMSO) 1.40-1.53 (6H, m, C //2C H 2N), 1.67 (6H, br s, NH and 
NH2), 2.47-2.56 (12H, m, C //2N); m /z  (FAB+) 189 [(M+H)+, 100%].
N,N -Bis(3-formamidopropyl)-N,N'-diformylpropane-1,3-diamine (109)
To N ,N /-bis(3-aminopropyl)propane-1,3-diamine (2.00g, 10.6mmol) was added ethyl formate 
(50ml, 0.6mol) at room temperature. The solution was stirred at room temperature for 24h. 
Evaporation and chromatography (M eO H /C H 2Cl2 2:1) gave the title compound (2.2lg, 85%) 
as a  colourless oil: Found: C, 49.0; H , 8.19; N, 17.2. calc, for C 13H 24N4: C, 51.99; H , 8.05; N, 
18.65%; 8h  (400MHz, pHJe-DMSO) 1.55-1.73 (6H, m, C //2CH 2N), 3.03-3.07 (4H, m, CH 2), 
3.15-3.26 (8H, m, C H 2), 7.99-8.05 (6H, m, CH O, and NH); m /z  (FAB+) 301.1880 (M+H)+ 
(C13H 25N4O 4 requires 301.1876); 302.1910 (M+H)+ (13C iC i2H 25N 4C>4 requires 302.1909).
N,N-Bis(2-cyanoethyl)-N,N'-dimethylpropane-l,3-diamine (120)
To N,N'-dimethyl-1,3-diaminopropane (4.64g, 45.4mmol) in M eOH (10ml) was added 
acrylonitrile (6.9ml, 5.6g, 104mmol) slowly at 0°C with stirring. The mixture was allowed to 
reach room temperature and was stirred for 24h. Evaporation gave the title compound (9.46g,
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quant.) as a  colourless liquid. A sample for elemental analysis was distilled using kugelrohr 
apparatus: bpo.i 215°C, (lit. [Schlogl and Schlogl, 1964] bpi.o 155-160°C); found: C, 64.1; H, 
9.69; N, 27.0. calc, for C 11H 20N 4: C, 63.43; H , 9.68; N, 26.90%; 6H (400MHz, CDCI3) 1.61 
(2H, qn, J  7.0Hz, C //2C H 2N), 2.26 (6H, s, C H 3), 2.44 (4H, t, J  7.0Hz, C H 2), 2.50 (4H, t, J  
7.0Hz, C H 2) 2.68 (4H, t, J  6.7Hz, C H 2); 8C (100MHz; CDCI3) 16.11, 25.02, 52.72, 54.30 
(CH2), 41.62 (CHs), 119.17 (CN); m /z  (EI+) 209.1722 M+ (13C iC i0H 20N4 requires 209.1722); 
208.1695 M + (CiiH2oN4 requires 208.1688).
N,N -Bis(3-aminopropyl)-N,N -dimethylpropane-1,3-diamine (121) 
Method A
To N,N'-bis(2-cyanoethyl)-N,N'-dimethylpropane-1,3-diamine (1.184g, 5.69mmol) was added 
saturated N aO H  solution in 95% E tO H  (10ml) and W-2 Raney nickel (500mg, dense slurry in 
EtOH). The mixture was treated with H 2 (50psi) at 35°C for 48h. The catalyst was filtered off 
through Celite. The Celite pad and catalyst were washed with EtO H  (150ml). The combined 
organic fractions were concentrated to low volume (about 5ml) and water (10ml) was added. 
Aqueous N aO H  (ca. 75%) was added until the amine began to oil out. The amine was extracted 
with CHCI3 (3x 100ml). The pooled organic phases were dried with MgS0 4 . Evaporation and 
kugelrohr distillation gave the title compound (440mg, 36%) as a colourless liquid: bpo.os 
145°C, (lit. [Schloegl and Schloegl, 1964] bpo.e 92-94°C); 6H (270MHz, pH ]6-DMSO) 1.36 
(4H, s, N H 2), 1.59 (6H, qn, J  7.0Hz, C tf2C H 2N), 2.19 (6H, s, CHs), 2.33 (4H, t, J  7.6Hz, 
CH 2N), 2.37 (4H, t, J  7.0Hz, C H 2N), 2.71 (4H, t, J  7.0Hz, C H 2N).
Method B (tetrahydrochloride)
To N ,N /-bis(2-cyanoethyl)-N,N/-dimethylpropane-1,3-diamine (1.350g, 6.5mmol) in absolute 
EtO H  (20ml) was added W-2 Raney nickel (lg, dense slurry in EtOH). The mixture was cooled 
to 0°C and ammonia was bubbled through for 20min. The mixture was treated with H 2 (50psi) 
at room temperature for 90h. The catalyst was filtered off through Celite. The Celite pad and 
catalyst were washed with E tO H  (150ml). Evaporation of the solvent from the combined filtrate 
and washings gave a blue oil which was dissolved in 95% EtO H  (30ml). H 2S (generated by the 
addition of concentrated hydrochloric acid to FeS) was bubbled through for 5min, then N2 for 
30min. The black precipitate was removed by filtration through Celite. Evaporation gave a pale 
brown oil. Excess concentrated hydrochloric acid was added then evaporated. The solid was 
washed with absolute E tO H  (10ml) to yield the title compound as its tetrahydrochloride (2.4g, 
quant.) as a pale yellow solid: mp 184-188°C; 8 h  (270MHz, D20 )  2.15-2.32 (6H, m, 
C //2CH 2N), 2.96 (6H, s, C H 3), 3.15 (4H, t, J  7.7Hz, C H 2N), 3.29-3.36 (8H, m, C //2N C H 3); 





To 121 (400mg, 1.85mmol) in M eOH (2ml) was added ethyl trifluoroacetate (1.5ml, 8.85mmol) 
at room temperature. The mixture was stirred for 8h. Evaporation and chromatography 
(CH2Cl2/M eO H /conc. aqueous NH 3 40:10:0.2) gave the title compound (731 mg, 97%) as a 
colourless oil: 6H (400MHz; [2H]6-DMSO) 1.91 (6H, qn, J  7.0Hz, C //2C H 2N), 2.57 (6H, s, 
CHs), 2.82 (8H, br t, J  6.4Hz, C //2N C H 3), 3.41 (4H, q, J  6.4Hz, CH 2N CO CF3), 9.72 (2H, s, 
NH); m /z  (FAB+) 409.2039 (M+H)+ (Ci5H 27F6N4 0 2 requires 409.2038); 313 [(M-F3CCO 
+H)+, 100%]; 217 [(M -2xF3CC O  +H)+, 79%].
fc-Butyl N-methyl-N-(3-methylaminopropyl)carbamate (126)
To a solution of N,N'-dimethylpropane-1,3-diamine (1.53g, 15.0mmol) in dry TH F (10ml) at 
0°C was added di-2-butyl dicarbonate (1.1 Og, 5.0mmol) in dry TH F (10ml) dropwise over 40 
min with stirring. When addition was complete, the mixture was stirred at 0°C for a  further lh, 
then at room temperature for 20h. Evaporation and chromatography (CH2Cl2/M eO H /conc. 
aqueous N H 3 30:10:0.5) gave the title compound (723mg, 71%) as a colourless liquid: 5h 
(270MHz; CDC13) 1.46 (9H, s, BuO, 1.69-1.82 (2H, m, C/72C H 2N), 2.46 (3H, s, N C H 3), 2.61 
(2H, t, J  7.0Hz, C H 2N), 2.85 (3H, s, C //3NBoc), 3.17 (1H, br s, NH), 3.26-3.35 (2H, m, 
C H 2N B oc); m /Z (FAB+) 204.1795 (M+H)+ (i3CiC9H 23N20 2 requires 204.1793); 203.1763 
(M+H)+ (C ioH 23N 20 2 requires 203.1760).
N,N -Bis(3-(N-t-butoxycarbonyl-N-methylamino)propyl)-N,N -dimethylpr opane- 
1,3-diamine (127)
To 126 (277mg, 1.37mmol) in dry DM F (4ml) was added anhydrous K 2C 0 3 (200mg, 
1.45mmol) and 1,3-dibromopropane (138mg, 0.68mmol). The mixture was heated at 80°C for 
16h, then the DM F was evaporated. The residue was extracted with C H 2C12 (4x 30ml). 
Evaporation and chromatography (CH2Cl2/M eO H /conc. aqueous N H 3 70:10:1) gave the title 
compound (160mg, 52%) as a pale yellow oil: 5h (270MHz, CDC13) 1.45 (18H, s, Bu*), 1.63- 
1.71 (6H, m, C //2C H 2N), 2.21 (6H, s, N C H 3), 2.30-2.37 (8H, m, C //2N C H 3), 2.85 (6H, s, 
BocNCZ/s), 3.22 (4H, t, C H 2NBoc, J  7.0Hz).
This material was used immediately without further characterisation.
N,N-Bis(3-methylaminopropyl)-N,N-dimethylpropane-1,3-diamine 
tetrahydrochloride (110)
To 127 (115mg, 0.26mmol) was added 5M hydrochloric acid (5ml) and the mixture was stirred 
overnight at room temperature. Evaporation gave a pale brown solid which was washed with 
CH 2C12 (20ml) to give the title compound (lOOmg, quant.) as an off white solid: mp 217-220°C; 
8h (270MHz; D 20 )  2.15-2.30 (6H, m, C/72C H 2N), 2.75 (6H, s, CHs), 2.94 (6H, s, CHs), 3.15
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(4H, t, J  7.9Hz, C H 2), 3.27-3.35 (8H, m, C H 2); m /z  (FAB+) 317 [(M+3H + 2x 35CF)+, 9%], 
281 [(M+2H + 35C n +, 45%], 246.2729 (M+H)+ (13CiCi2H 33N4 requires 246.2739), 245.2709 
(M+H)+ (Ci3H 33N4 requires 245.2705).
N,N -Bis(2-hydroxy-3-(oo-methoxyPEG 550)propyl-(3-methylaminopropyl))-N,N - 
dimethylpropane-1,3-diamine tetrahydrochloride (150)
To 110 (83mg, 0.21mmol) in iropropanol (1ml) was added 5M aqueous N aO H  (213pl, 
1.1 mmol) and the mixture was stirred for 5min at room temperature. mPEG 550 
oxiranylmethyl ether (255mg, 0.4mmol) in uopropanol (1ml) was added and the mixture was 
heated to 75°G for 24h. Evaporation gave a pale brown residue. The product was extracted 
with CH 2C12 (3x 10ml). Evaporation then chromatography (CH2Cl2/M eO H /conc. aqueous 
N H 3 50:10:1 then, 40:10:1) gave a colourless oil (98mg, 32%). The sample was converted to its 
tetrahydrochloride salt by the addition of 5M hydrochloric acid (2ml). The acid was evaporated 
then the sample was lyophilised to yield an off-white wax (105mg): 8 h  (free amine, 400MHz; 
CDC13) 1.80-1.90 (6H, m, CH2CH 2N), 2.40-2.49 (12H, m, CHs), 2.57-2.70 (16H, m, C H 2N), 
3.38 (6H, s, OGHs), 3.49-3.51 (4H, m, C H 20 ), 3.54-3.56 (4H, m, C H 20 ), 3.64-3.66 (Co. 96H, 
m, CH 20 ), 3.97-4.03 (2H, m, C //O H ) m /z  (FAB+) i2C /13C peak cluster centred at: 1390 (7%), 
1346 (5%), 1302 (7%), 1258 (7%), 1214 (5%), 1170 (6%), 1126 (4%), all (M+H)+.
N,N -Di-(M>utoxycarbonyl)-N,N -bis(2-cyanoethyl)propane-1,3-diamine (129)
To N,N'-bis(2-cyanoethyl)propane- 1,3-diamine (2.50g, 13.9mmol) in C H 2G12 (25ml) was added 
di-£-butyl dicarbonate (6.06g, 27.8mmol) in C H 2C12 (10ml) slowly in 10 portions at 0°C. After 
15min, the stirred solution was allowed to reach room temperature and was stirred for a  further 
5h. Evaporation gave the title compound (5.3g, quant.) as a colourless oil: 8 h  (400MHz, CDC13) 
1.48 (18H, s, BuO, 1.81 (2H, qn, J  7.3Hz, C tf2C H 2N), 2.62 (4H, m, C H 2CN), 3.29 (4H, t, J  
7.3Hz, C H 2N B oc), 3.48 (4H, t, J6 .5 H z , N C C H 2C i/2NBoc).
This material was used immediately without further characterisation.
N,N -Bis(3-aminopropyI)-N,N -di(-t-butoxycarbonyl)propane-1,3-diamine (130) 
Method A
Lithium aluminium hydride (2.60g, 69mmol) was suspended in dry Et20  (200ml) under N2. 
The suspension was added to 129 (3.58g, 9.4mmol) in dry T H F (40ml) dropwise at 0°C under 
N2. The mixture was stirred for 2h at 0°G under N2. Excess hydride was quenched by the 
dropwise addition of aqueous lM N aO H  to yield a white precipitate. The solvents were 
decanted and the residue was extracted with Et20  (3x 50ml). Evaporation of the pooled organic 
phases, then chromatography (CH2Cl2/M eO H /conc. aqueous N H 3 20:10:1) gave the title 
compound (790mg, 22%) as a colourless oil: 8 h  (400M H z , [2H]6-DMSO) 1.39 (18H, s, Bu*),
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1.48-1.68 (10H, m, CH2C H 2N  and NH2), 2.50 (4H, t, C H 2N, 7.0Hz), 3.10 (4H, t, CH 2NBoc, J  
7.0Hz), 3.17 (4H, t, C H 2NBoc, J  6.8Hz) m /z  (FAB+) 389 [(M+H)+ 39%], 189 [(M- 2x Boc 
+H)+ 47%]; and a by-product, N-(3-aminopropyl)-N,N'-di(-£-butoxycarbonyl)propane-1,3- 
diamine 133, (1.15g, 37%) as a colourless oil: 5h (270MHz, CDCI3) 1.44 (9H, s, Bu% 1.46 (9H, 
s, Bu% 1.67 (4H, m, CH2CH 2N), 2.74 (2H, m, C tf2N H 2), 3.13-3.35 (8H, m, C H 2NBoc and 
N H 2), 3.67 (1H, m, NH); m /z  (FAB+) 332 [(M+H)+, 100%], 232 [(M-Boc +H)+, 20%], 132 
[(M -2x Boc+H)+, 28%].
Method B
To 129 (2.74g, 7.2mmol) in M eOH (20ml) was added W-2 Raney nickel (lg, dense slurry in 
water) with M eO H  (10ml). The mixture was cooled to 0°C and ammonia was bubbled through 
for 30min. The mixture was treated with H 2 (50psi) for 72h. The catalyst was filtered off 
through Celite. The Celite pad and catalyst were washed with E tO H  (400ml). Evaporation of 
the solvent from the combined filtrate and washings, followed by chromatography 
(CH2Cl2/M eO H /conc. aqueous N H 3 20:10:1) gave the title compound (1.93g, 69%) as a 
colourless oil with properties as above.
Method C
To 129 (1.120g, 1.93mmol) in M eOH (10ml) was added concentrated aqueous ammonia (8ml). 
Ammonia was bubbled through the mixture for 10 min at 0°C. The mixture was heated in a 
sealed vessel, with stirring, at 60°C for 7h, then at room temperature overnight. Evaporation 
and chromatography (CH2Cl2/M eO H /conc. aqueous N H 3 20:10:1) gave the title compound 
(418mg, 56%) as a colourless oil with properties as above.
N,N -Bis (3-trifluoroacetamidopropyl) propane-1,3-diamine (134)
To thermine (5.lg, 27mmol) in M eOH (10ml) was added ethyl trifluoroacetate (7.9g, 56mmol) 
slowly at 0°C. After 5min the ice bath was removed and stirring was continued for 150min. 
Evaporation gave the title compound (10.4g, quant.) as a colourless oil: 5h (400M H z, CDCI3) 
1.67 (2H, qn, J  7.0Hz, C i/2CH 2N), 1.73 (4H, qn, J  6.1Hz, C //2C H 2NCO), 2.66 (4H, t, J  
7.0Hz, C H 2N), 2.79 (4H, t,J5 .9 H z , C H 2N), 3.44 (4H, t, J 6 .1 H z , C H 2NCO), 6.8-10.2 (4H, br 
signal, NH); 6C (100MHz, CDCI3) 27.12 (CH2), 30.03 (CH2), 40.23 (CH2), 48.02 (CH2), 48.77 
(CH2), 116.2 (q ,J288H z, CF3), 157.2 (q ,J3 7 H z , COCF3).
This material was used immediately without further characterisation.
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N,N -Bis(3-trifluoroacetamidopropyl)-N,N -di-(<-butoxycarbonyl)propane-1,3- 
diamine (131)
M ethod A
To 134 (180mg, 0.47mmol) in dry T H F (2ml) was added di-i-butyl dicarbonate (215mg, 
0.99mmol) in dry T H F (2ml) dropwise at 0°C. After 5min, the ice bath was removed and the 
mixture was stirred at room temperature overnight. Evaporation and chromatography 
(EtOAc/hexane 1:1) gave the title compound (254mg, 93%) as a  white solid. A sample for 
elemental analysis was recrystallised from EtOAc/hexane: mp 70-71°C; Found: C, 47.7; H, 
6.7; N, 9.6. calc, for C23H 38N 4 0 6F6: C, 47.58; H, 6.60; N, 9.65%; 5H (400MHz, CDCls) 1.47 
(18H, s, Bu% 1.74-1.80 (6H, m, C i/2C H 2N), 3.11-3.19 (4H, m, C H 2N C O C F3), 3.21-3.40 (8H, 
m, C H 2NBoc), 8.29 (2H, br s, NH); 8c (100MHz, CDCI3) 27.14 (CH2), 27.67 (CH2), 28.37 
(CH3), 35.95 (CH2), 43.11 (CH2), 44.86 (CH2), 80.61 (Boc C), 116.0 (q, J  287Hz, CF3), 156.8 
(q, J  37Hz, COCF3); m /z  (FAB-) 579 [(M-H)~ 100%]; (FAB+) 603 [(M+Na)+, 38%], 581 
[(M+H)+, 26%], 481 [(M-Boc +H)+, 52%], 381 [(M -2x Boc +H)+, 14%].
Method B
To 130 (620mg, 1.60mmol) in M eO H  (10ml) was added ethyl trifluoroacetate (lml, 8mmol). 
The mixture was stirred at room temperature overnight. Evaporation and chromatography 




To 131 (712mg, 1.23mmol) in dry T H F (20ml) was added potassium £-butoxide (2.6ml, 1.0M 
solution in THF, 2.6mmol), then further dry TH F (5ml) at room temperature under N 2. After 
5min, methyl iodide (0.2ml, 456mg, 3mmol) was added and the mixture was stirred at room 
temperature for 20min, under N2. The mixture was concentrated to low volume, diluted with 
EtOAc (200ml), washed with water (200ml), then brine (200ml) and then dried with MgSCH. 
Evaporation gave the title compound (730mg, 98%) as a colourless oil: 8 f  (376MHz, [2H]6- 
DMSO) -68.17 (2F, s), -69.11 (4F, s); SH (400MHz, pHJe-DMSO, 22°C) 1.37 (18H, s, BuO, 
1.65-1.77 (6H, m, O tf2C H 2N), 2.95 (2H, s, C H 3N), 3.09-3.15 (11H, m, C H 2NCO and C H 3N), 
3.32-3.44 (5H, m, C H 2NCO); 8H (400MHz, [2H]6-DMSO, 100°C) 1.42 (18H, s, Bu% 1.68-1.80 
(6H, m, C //2C H 2N), 2.96 (6H, s, C H 3N), 3.10-3.20 (8H, m, C H 2NBoc), 3.41 (4H, t, J  7.6Hz, 
C H 2N CO CF3); m /z  (FAB+) 610.3122 (M+H)+ (^ C iC ^ sF eN + O e  requires 610.3120), 





To 132 (144mg, 0.24mmol) in M eOH (8ml) was added concentrated aqueous ammonia 
solution (2ml). The mixture was stirred at 55°C in a sealed bottle for 3V2h. Evaporation and 
chromatography (CH2Cl2/M eO H /conc. aqueous N H 3 40:20:2.5) gave the title compound 
(78mg, 79%) as a pale yellow oil: 5H (400MHz, CDCI3) 1.45 (18H, s, 1.72-1.74 (6H, m, 
CH 2C H 2N ), 2.39 (6H, s, C H 3N), 2.58 (4H, t, J  7.0Hz, C H 2NHMe), 2.76 (2H, s, NH), 3.12-3.20 
(4H, m, C H 2NBoc), 3.22-3.28 (4H, m, C H 2NBoc); m /z  (FAB+) 418.3473 (M+H)+ 
(13C iC 20H 4-5N 4O 4 requires 418.3474), 417.3443 (M+H)+ (CNH45N 4O 4 requires 417.3441), 317 
[(M-Boc +H)+, 15%], 217 [(M - 2x Boc + H +), 38%].
N,N-Bis(3-methylaminopropyl)propane-l,3-diamine tetrahydrochloride (159)
HC1 was bubbled through a solution of 128 (75mg, 0.18mmol) in C H 2C12 (10ml) for lOmin. 
Evaporation and lyophilisation gave the title compound (61 mg, 96%) as a hygroscopic white 
solid: 6 h  (400MHz, D 20 )  2.08-2.20 (6H, m, C //2CH 2N), 2.75 (6H, s, C H 3), 3.12-3.24 (12H, m, 
CH 2N); m /z  (FAB+) 217 [(M+H)+, 76%].
(±)-N,N -Bis(3-(N-(2-hydroxy-3-phenoxypropyl)-N-methylamino)propyl)-N,N -di- 
(fc-butoxycarbonyl)propane-l ,3-diamine (136)
To 128 (45mg, O.llmmol) in wopropanol (1ml) was added phenoxymethyloxirane (33mg, 
0.22mmol) and the mixture was heated to reflux with stirring for lOh. Evaporation and 
preparative TLC (CH2Cl2/M eO H /conc. aqueous N H 3 70:10:0.5) gave the title compound 
(20mg, 26%) as a colourless oil: 8 h  (270MHz, CDCI3) 1.45 (18H, s, Bu*), 1.65-1.80 (6H, m, 
CH 2C H 2N), 2.32 (6H, s, C H 3N), 2.44-2.60 (8H, m, C H 2N), 3.10-3.35 (10H, m, C H 2NBoc and 
OH), 3.95-3.99 (4H, m, C H 20 ), 4.05-4.11 (2H, m, CH O H ), 6.90-6.98 (6H, m, ArH), 7.25-7.31 
(4H, m, ArH); m /z  (FAB+) 718.4853 (M+H)+ (isCiCssHejtf^Oa requires 718.4836); 717.4811 
(M+H)+ (C39H 65N 4O 8 requires 717.4802).
N,N'-Bis-(3-(N-(2-hydroxy-3-(co-methoxyPEG 2000)propyl)-N- 
methylamino) propyl) -N,N -di- (f-butoxycarbonyl) propane-1,3-diamine (137)
To 128 (43mg, 0.103mmol) in wopropanol (1ml) was added mPEG 2000 oxiranylmethyl ether 
(410mg, 0.21 mmol) in wopropanol (2ml) and the mixture was heated to reflux with stirring for 
27h. Evaporation gave the title compound (450mg, quant.) as a pale yellow wax: 5 h  (400MHz, 
CDCI3) 1.45 (18H, s, Bu% 1.66-1.75 (6H, m, C //2C H 2N), 2.25 (6H, s, C H 3N), 2.31-2.45 (8H, 
m, CH 2N), 3.15-3.20 (8H, m, C H 2NBoc), 3.38 (6H, s, O C H 3), 3.42-3.60 {ecu 12H, GH20),
3.60-3.77 (ca. 360H, CH 2Q), 3.81-3.88 {ecu 4H, m, C H 2Q and G//OH).
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N,N -Bis(3-(N-(2-hydroxy-3-(co-methoxyPEG 2000)propyl)-N- 
methylamino)propyl)propane-l,3-diamine tetrahydrochloride (152)
HC1 was bubbled through a stirred solution of 137 (lOOmg, 0.02mmol) in C H 2CI2 (10ml) for 
lOmin. Evaporation and lyophilisation gave the title compound (lOOmg, quant.) as a white wax: 
8h (4-OOMHz, CDCI3) 2.43 (6H, m, C/72C H 2N), 2.98 (6H, s, C H 3N), 3.31-3.36 (16H, m, 
CH 2N), 3.38 (6H, s, CHsO), 3.48-3.83 (ca. 370H, m, C H 20 ), 4.33 (2H, m, CtfOH).
co-Methoxy PEG 550 oxiranylmethyl ether
To mPEG 550 (lO.Og, 0.018mol, previously dried by azeotropic removal of water with toluene) 
was added N aO H  (2.18g, 0.054mol), water (0.3ml) and epichlorohydrin (17ml, O.22mol). The 
mixture was stirred vigorously at 60°G for 3h. The mixture was diluted with CH 2CI2 (100ml) 
and the solid was filtered off and washed with C H 2CI2 (250ml). The combined organic fractions 
were dried with MgSO*. Evaporation under high vacuum for 6h gave the title compound 
(10.8g, 98%) as a colourless oil: 8H (270MHz, pHJe-DMSO) 2.53 (1H, dd, J  5.1, 2.5Hz, 
oxirane C H 2), 2.72 (1H, t, J  5.0Hz, oxirane C H 2), 3.06-3.12 (1H, m, oxirane CH), 3.22-3.31 
(2H, m, C H C //2O), 3.24 (3H, s, GH30 ), 3.41-3.73 (ca. 45H, m, C H 20); m /z  (ES+) 771 (20%), 
727 (36%), 683 (56%), 639 (74%), 595 (92%), 551 (100%), 507 (92%), 463 (80%), 419 (58%), 
375 (46%) all (M+Na)+.
N,N -Bis(3- (N-(2-hydroxy-3- (co-methoxyPEG 550) propyl) -N-methylamino) propyl) - 
N,N -di-(f-butoxycarbonyl)propane-1,3-diamine
To 128 (36mg, 0.086mmol) in wopropanol (2ml) was added mPEG 550 oxiranylmethyl ether 
(104mg, 0 .17mmol) and the mixture was heated to reflux with stirring for 24h. Further amine 
(15mg) in uopropanol (2ml) was added and the mixture was heated to reflux with stirring for a 
further 5h. Evaporation gave the title compound (143mg, quant.) as a colourless oil: 8h  
(400MHz, CDC13) 1.45 (18H, s, Bu% 1.61-1.69 (6H, m, C tf2C H 2N), 2.25 (6H, s, C H 3N), 2.29-
2.46 (8H, m, C H 2N), 3.17-3.21 (8H, m, GH2NBoc), 3.38 (6H, s, C H sO), 3.42-3.61 (ca. 10H, 
C H 2O) 3.63-3.66 (ca. 90H, C H 20 ), 3.83-3.86 (2H, m, C//OH); m /z  (FAB+) U C /'3C peak 
cluster centred at: 1474 (1%), 1430 (1%), 1386 (1%), 1342 (1%) all (M+H)+.
N,N-Bis(3-(N-(2-hydroxy-3-(co-methoxyPEG 550)propyl)-N-methylamino) 
propyl)propane-l,3-diamine tetrahydrochloride (151)
HG1 was bubbled through a  stirred solution of the Boc-protected diPEG 550 conjugate (90mg, 
0.06mmol) in C H 2CI2 (3ml) for lOmin. Evaporation and lyophilisation gave the title compound 
(90mg, quant.) as a off white semi-solid: 5h  (400M H z, CDC13) 2.47 (6H, m, C //2CH 2N), 3.02 
(6H, br s, C H 3N), 3.30-3.45 (16H, m, C H 2N), 3.38 (6H, s, CH 3Q), 3.47-3.82 (ca. 100H,
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C H 20 ), 4.33 (2H, m, C //O H ); m /z  (FAB+) 1406 (2%), 1362 (2.5%), 1318 (3%), 1274 (3%), 




To 130 (82mg, 0.21 mmol) in uopropanol (2ml) was added mPEG 550 oxiranylmethyl ether 
(253mg, 0.42mmol) in uopropanol (1ml). The mixture was heated to reflux, with stirring, for 
24h. Evaporation gave the crude diPEGylated conjugate (330mg, quant.) as a pale yellow oil: 
5h (400MHz, CDGI3), crude, 1.41 (18H, s, Bu% 1.62-1.95 (6H, m, C tf2C H 2N), 2.51-2.59 (8H, 
m, C H 2N), 3.15-3.25 (8H, m, C H 2NBoc), 3.35 (6H, s, C H 3O), 3.41-3.53 (ca. 12H, C H 20), 
3.60-3.78 (ca. 106H, GH20 ), 3.80-3.83 (4H, m, C H 20  and G7/OH); m /z  (FAB+) is q / is g  peak 





To 130 (1.75g, 4.51mmol) in wopropanol (20ml) was added mPEG 550 oxiranylmethyl ether 
(5.4g, 9mmol) in wopropanol (20ml). The mixture was heated, with stirring, at 80°G for 38h. 
Evaporation and chromatography (CH2Cl2/M eO H  6:1) gave the tetraPEGylated conjugate 
(1.40g, 11%) as a  pale yellow oil: 8H (400MHz, CDCI3): 1.45 (18H, s, Bu% 1.60-1.70 (6H, m, 
CH 2CH 2N}, 2.50-2.55 (12H, m, C H 2N), 3.15-3.26 (8H, m, CH 2NBoc), 3.38 (12H, s, C H 3O), 
3.41-3.49 (ca. 6H, m, C H 20 ), 3.51-3.56 (ca. 8H, m, C H 20), 3.56-3.68 (ca. 180H, m, C H 20), 
3.80-3.84 (4H, C H 20  and Ci/O H ); m /z  (ES+) 12C / 13C peak cluster centred at: 1339 (82%), 
1318 (95%), 1296 (90%), 1274 (100%), 1252 (95%), 1230 (90%), 1208 (80%) all (M+H)2+; and 
the triPEGylated conjugate (560mg, 24%) as a pale yellow oil: 1.47 (18H, s, Bu1), 1.60-1.70 (4H, 
m, C //2CH 2N), 1.95-2.05 (2H, m, CH2C H 2N), 2.48-2.60 (6H, m, C H 2N), 2.95-3.05 (4H, m, 
C H 2N), 3.15-3.25 (8H, m, C H 2NBoc), 3.41 (9H, s, C H sO), 3.44-3.50 (ca. 4H, m, CH 20 ), 3.54- 
3.58 (ca. 6H, m, C H 20 ), 3.58-3.80 (ca. 130H, m, C H 20 ), 3.80-3.94 (3H, m, CtfOH) m /z  (ES+) 
12C / 13C peak cluster centred at: 1098 (85%), 1076 (90%), 1054 (100%), 1031 (96%), 1009 





HC1 was bubbled through a stirred solution of 140 (2.27g, l.lm m ol) in C H 2CI2 (40ml) for 
30min. Evaporation and lyophilisation gave the title compound (2.07g, quant.) as an off white 
foam: 5H (400MHz, D 20 )  2.13 (6H, m, CH2CH 2N), 3.11-3.27 (18H, m, C H 2N), 3.39 (9H, s, 
CHsO), 3.53-3.64 (ca. 16H, m, C H 20 ), 3.68-3.88 (ca. 120H, m, C H 20), 4.14 (3H, m, CtfOH). 
N,N,N',N-Tetrakis(3-(N-2-hydroxy-3-(o)-methoxyPEG550)propyl)ammo)propyl- 
propane-1,3-diamine tetrahydrochloride (154)
HC1 was bubbled through a stirred solution of 141 (1.34g, 0.52mmol) in C H 2CI2 (25ml) for 
30min. Evaporation and lyophilisation gave the title compound (1.30g, quant.) as an off white 
foam: 8h  (400MHz, D20 )  2.10 (6H, m, CH2C H 2N), 2.97-3.22 (20H, m, C H 2N), 3.39 (12H, s, 
CHsO), 3.53-3.64 (ca. 20H, m, C H 20 ), 3.66-3.72 (ca. 164H, m, C H 20 ), 4.17 (4H, m, C //O H ).
N-(3-Aminopropyl)-N - (3-t-butoxycarbonylaminopropyl)-N ,N -d i-( 
butoxycarbonyl)propane-l,3-diamine (145) 
M ethod A
To thermine (2.09g, 1 l.lm m ol) in absolute E tO H  (50ml) was added ethyl trifluoroacetate 
(1.74g, 12.3mmol) in absolute E tO H  (50ml) dropwise over 40min, with stirring, at -78°C . The 
mixture was then stirred for a  further 30min at 0°C. Di-^-butyl dicarbonate (9.7g, 44.5mmol) in 
absolute E tO H  (20ml) was added dropwise over lOmin, stirring was continued at 0°C for 
30min then at room temperature overnight. Evaporation gave a yellow oil which was dissolved 
in M eOH (100ml), to which concentrated aqueous ammonia solution was added (70ml), then 
ammonia gas was bubbled through the solution for 30min, with stirring, at 0°C. The mixture 
was stirred in a sealed bottle for 20h. Evaporation then chromatography 
(CH2Cl2/M eO H /conc. aqueous N H 3 70:10:1, then 50:10:1, then 30:10:1) gave the title 
compound (2.76g, 51%) as a colourless oil: 8h  (400MHz, CDCI3) 1.44 (9H, s, Bu'), 1.46 (9H, s, 
BuO, 1.47 (9H, s, BuO, 1.60-1.67 (2H, m, C //2C H 2N), 1.73-1.78 (4H, m, C //2C H 2N), 1.97 (2H, 
s, NH 2), 2.71 (2H, t, J 6 .7 H z , C H 2N H 2), 3.10-3.28 (10H, m, C H 2NBoc), 4.85 (0.5H, br s, NH),
5.30 (0.5H, br s, NH); m /z  (FAB+) 490.3678 (M+H)+ (13CiC23H49N406 requires 490.3686); 
489.3651 (M+H)+ (C24H 49N 4O 6 requires 489.3652).
Method B
To thermine (1.118g, 5.95mmol) in TH F (100ml) was added ethyl trifluoroacetate (844mg, 
5.95mmol) in TH F (20ml) slowly over 5min, with stirring, at 0°C. The mixture was stirred for 
lOmin at 0°C then di-^-butyl dicarbonate (5.2g, 23.9mmol) in TH F (25ml) was added slowly 
over 40min at 0°C. The mixture was allowed to reach room temperature and stirred for 2h.
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Evaporation gave a colourless oil which was dissolved in propylamine (50ml) and heated to 
reflux, with stirring, for 16h. Evaporation and chromatography (CH2Cl2/M eO H /conc. 
aqueous NH 3 70:10:1, then 50:10:1, then 30:10:1) gave the title compound (1.184g, 40%) as a 
colourless oil with spectroscopic properties as above.
N- (3- (N- (2-Hydroxy-3- (co-methoxyPEG 550) propyl) amino) propyl) -N - (3-f-butoxy
carbonylaminopropyl)-N,N-di-(t-butoxycarbonyl)propane-l,3-diamine (146) and 
N,N-Bis(3-(N-(2-hydroxy-3-(co-methoxyPEG 550)propyl) amino)propyl)-N -(3-f- 
butoxycarbonylaminopropyl)-N,N'-di-(£-butoxycarbonyl)propane-l,3-diamine 
(148)
To 145 (959mg, 1.97mmol) in wopropanol (5ml) was added mPEG 550 oxiranylmethyl ether 
(1.19g, 1.97mmol) in wopropanol (5ml). The mixture was heated to reflux, with stirring, for 48h. 
Evaporation and chromatography (CH2Cl2/M eO H  7:1) gave the diPEGylated conjugate 
(315mg, 9%) as a colourless oil: 5h (400M H z, CDCI3) 1.44 (9H, s, Bu*), 1.45 (9H, s, Bu*), 1.46 
(9H, s, Bu% 1.62-1.74 (6H, m, C //2C H 2N), 2.48-2.60 (6H, m, C H 2N), 3.15-3.24 (10H, m, 
C H 2NBoc), 3.38 (6H, s, C H sO), 3.50-3.57 (ca. 12H, m, C H 20 ), 3.60-3.73 (ca. 90H, m, C H 20 ), 
3.81-3.85 (2H, m, CtfOH); m /z  (FAB+) 1590 (16%), 1546 (21%), 1501 (21%), 1457 (20%), 
1413 (20%), 1369 (19%) all (M+H)+; and the monoPEGylated conjugate (460mg, 21%) as a 
colourless oil: 5H (400MHz, CDCI3) 1.44 (9H, s, Bu*), 1.45 (9H, s, Bu% 1.46 (9H, s, Bu% 1.65-
1.78 (6H, m, C //2C H 2N), 2.90-2.98 (4H, m, C H 2N), 3.14-3.27 (10H, m, C H 2NBoc), 3.38 (3H, 
s, CHsO), 3.54-3.58 (ca. 6H, m, C H 20 ), 3.62-3.66 (ca. 44H, m, C H 20 ), 3.80-3.84 (1H, m, 
C//OH); m /z  (FAB+) 1149 (10%), 1105 (18%), 1061 (20%), 1017 (25%), 973 (24%), 929 (20%) 
all (M+H)+; (FAB+) 1061.7005 (M+H)+ (C50H 101N 4O 19 requires 1061.7060), 1017.6772 
(M+H)+ (C48H 97N4O 18 requires 1017.6798), 973.6511 (M+H)+ (C46H 93N 4O 17 requires 
973.6536).
N,N-Bis(3-(N-(2-hydroxy-3-(co-methoxyPEG 550)propyl) amino)propyl)-N -(3 -t  
butoxycarbonylaminopropyl)-N,N-di-(t-butoxycarbonyl)propane-l, 3-diamine
(148)
To 145 (188mg, 0.39mmol) in uopropanol (1ml) was added mPEG 550 oxiranylmethyl ether 
(462mg, O.77mmol) in uopropanol (1ml). The mixture was heated at 75°G, with stirring, for 
24h. Evaporation and chromatography (CH2Cl2/M eO H  8:1 then 7:1) gave the title compound 
(398mg, 61%) as a colourless oil with spectroscopic properties as above.
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N- (3- (N- (2-Hydroxy-3- (©-methoxyPEG 550) propyl) amino) propyl) -N - (3-
aminopropyl)propane-1,3-diamine tetrahydrochloride (155)
HC1 was bubbled through a stirred solution of 146 (372mg, 0.34mmol) in CH 2C H 2 (30ml) for 
20min at room temperature. Evaporation and lyophilisation gave the title compound (330mg, 
quant.) as a white wax: 8h  (270M H z, D 2O) 2.12 (6 H, m, C //2C H 2N), 3.10-3.20 (14H, m, 
C H 2N), 3.38 (3H, s, C H 3O), 3.64-3.72 (ca. 45H, C H 20 ), 4.05 (1H, m, C //O H ); m /z  (FAB+) 
849 (45%), 805 (55%), 761 (64%), 717 (60%), 673 (50%), 630 (40%) all (M+H)+.
N,N-Bis(3-(N-(2-hydroxy-3-(co-methoxyPEG 550)propyl) amino)propyl)-N -(3- 
aminopropyl)propane-l,3-diamine tetrahydrochloride (157)
HC1 was bubbled through a stirred solution of 148 (450mg, 0.28mmol) in C H 2C H 2 (1 0 ml) for 
20min at room temperature. Evaporation and lyophilisation gave the title compound (408mg, 
quant.) as a  pale yellow wax: 8h  (400M H z, D 2O) 2.14-2.23 (6 H, m, C //2C H 2N), 3.10-3.25 
(10H, m, C H 2N), 3.35-3.46 (12H, s, C H 2N and CHsO), 3.62-3.85 (ca. 100H, C H 20 ), 4.23 (2H, 
m, C //O H ); m /z  (FAB+) 12C / 13C peak cluster centred at 1334 (3%), 1290 (4%), 1246 (4%), 




N,N-Bis(3-[N-(2-hydroxy-3-(©-methoxyPEG 2000)propyl) amino)propyl)-N'-(3-1- 
butoxycarbonylaminopropyl)-N,N-di-(t-butoxycarbonyl)propane-l,3-diamine
(149)
To 145 (986mg, 2.02mmol) in wopropanol (20ml) was added mPEG 2000 oxiranylmethyl ether 
(4.15g, 2.02mmol) in wopropanol (1ml). The mixture was heated to reflux, with stirring, for 
lOOh. Evaporation and chromatography (CH2Cl2/M eO H  8:1 and then 7:1) gave the 
diPEGylated conjugate (2.53g, 28%) as a pale yellow wax: 8h  (400M H z, CDCI3) 1.44 (9H, s, 
BuO, 1.45 (9H, s, BuO, 1.47 (9H, s, Bu% 1.65-1.75 (6H, m, C tf2C H 2N), 2.48-2.59 (6H, m, 
CH 2N), 3.08-3.26 (10H, m, C H 2NBoc), 3.39 (6H, s, C H 3O), 3.45-3.49 (ca. 8H, m, C H 20 ), 
3.55-3.72 (ca. 360H, m, C H 2O), 3.82 (2H, m, C//OH); and the monoPEGylated conjugate 
(1.80g, 35%) as a pale yellow wax: 5h (400M H z, CDGI3) 1.44 (9H, s, Bu )^, 1.45 (9H, s, Bu )^,
1.46 (9H, s, Bu% 1.66-1.75 (6H, m, G //2GH2N), 2.85-2.91 (4H, m, CH 2N), 3.10-3.25 (10H, m, 
C H 2N B oc), 3.38 (3H, s, C H 3O), 3.54-3.56 (ca. 8H, m, C H 20 ), 3.64-3.70 (ca. 186H, m, C H 20 ),
3.82 (1H, m, C//OH); m /z  (FAB+) ^ C / ^ C  peak cluster centred at 2416 (1%), 2374 (2%), 2324 
(5%), 2288 (5%), 2239 (4%) all (M+H)+.
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N- (3- (N- (2-Hydroxy-3- (co-methoxyPEG 2000) propyl) amino) propyl) -N - (3- 
aminopropyl)propane-1,3-diamine tetrahydrochloride (156)
HC1 was bubbled through a stirred solution of 147 (783mg, 0.31mmol) in C H 2CH 2 (20ml) for 
15min at room temperature. Evaporation and lyophilisation gave the title compound (694mg, 
quant.) as a white wax: 8h (270MHz, D 2O) 2.15 (6H, m, C //2CH 2N), 3.15-3.28 (14H, m, 
C H 2N), 3.39 (3H, s, C H 3O), 3.65-3.76 (ca. 185H, C H 20), 4.10 (1H, m, C7/OH).
N,N-Bis(3-(N-(2-hydroxy-3-(<o-methoxyPEG 2000)propyl)amino)propyl)-N'-(3- 
aminopropyl)propane-l,3-diamine tetrahydrochloride (158)
HC1 was bubbled through a stirred solution of 149 (1.305g, 0.28mmol) in C H 2CI2 (20ml) for 
20min at room temperature. Evaporation and lyophilisation gave the title compound (1.096g, 
quant.) as a white wax: 8h (400MHz, D 2O) 1.97-2.13 (6H, m, C //2C H 2N), 3.07-3.33 (ca. 12H, 
m, C H 2N), 3.35-3.46 (ca. 4H, m, C H 2N), 3.37 (6H, s, C H 3O), 3.61-3.73 (ca. 370H, C H 2C>), 
4.23 (2H, m, C i/O H ).
N,N'-Bis(3-(2-cyanoethyIamino)propyl)-N,N-di-(Mmtoxycarbonyl)propane-l,3- 
diamine (161)
To 130 (2.43g, 6.3mmol) in M eOH (20ml) was added acrylonitrile (0.86ml, 693mg, 13mmol) 
slowly at 0°C with stirring. After lh  the ice bath was removed and the mixture was stirred at 
room temperature overnight. Evaporation gave the title compound (3.03g, 98%) as a colourless 
oil: 5h (400MHz, CDCI3) 1.45 (18H, s, Bu% 1.70 (4H, qn, J6 .7 H z , C //2C H 2N), 1.73-1.79 (4H, 
m, C //2GH 2NB0 C and 2x NH), 2.51 (4H, t, J  6.7Hz, C H 2CN), 2.62 (4H, t, J  6.7Hz, 
CH 2CH 2C //2N), 2.91 (4H, t, J  6.7Hz, C/72GH2CN), 3.16-3.43 (8H, m, GH2NBoc); m /z  
(FAB+) 496.3704 (M+H)+ (^ C ^ H iy N e O *  requires 496.3692) 495.3676 (M+H)+ 
(C25H 47N 6O 4. requires 495.3659).
N,N-Bis(3-(N-t-butoxycarbonyl)-N-(2-cyanoethyl)amino)propyi)-N,N-di(t* 
butoxycarbony!)propane-l,3-diamine (162)
To 161 (2.92g, 5.9mmol) in C H 2CI2 (30ml) was added di-i-butyl dicarbonate (2.64g, 12mmol) 
in C H 2CI2 (10ml) slowly, with stirring, at 0°G. After 90min, the ice bath was removed and the 
mixture was stirred at room temperature overnight. Evaporation gave the crude title compound 
(4.lg, quant.) as a colourless oil: 5h  (400MHz, CDCI3) 1.46 (18H, s, Bu% 1.47 (18H, s, Bu% 
1.69-1.88 (6H, m, C tf2C H 2N), 2.55-2.70 (4H, m, C H 2CN), 3.17-3.29 (12H, m, GH2NBoc), 
3.48 (4H, t, J6 .9 H z , C //2C H 2CN).
This material was used immediately without further characterisation.
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N,N -Bis(3-(N-(3-aminopropyl)-N-(t-butoxycarbonyl) amino)propyl)-N,N -di(-t- 
butoxycarbonyl)propane-l ,3-diamine (163)
To 162 (2.580g, 3.72mmol) in M eOH (30ml) was added W-2 Raney Nickel (2g, dense slurry in 
water) in M eO H  (10ml). The mixture was cooled to 0°C and ammonia was bubbled through 
for 30min. The mixture was treated with H 2 (60psi) at room temperature for 65h. The catalyst 
was filtered off through Celite. The catalyst and Celite pad were washed with M eOH (400ml). 
Evaporation of the solvent from the combined filtrate and washings, followed by 
chromatography (C ^ C b /M eO H /c o n c . aqueous N H 3 70:10:1, then 60:10:1, then 50:10:1) 
gave the title compound (2.286g, 88%) as a colourless oil: 8h  (400MHz, CDCI3) 1.45 (36H, s, 
Bu% 1.66 (4H, qn, J6 .7 H z , C //2C H 2N), 1.71-1.78 (6H, m, C/72GH2NBoc), 1.88 (4H, s, N H 2), 
2.70 (4H, t, J 6 .7 H z , C //2N H 2), 3.17-3.43 (16H, m, GH2NBoc); m /z  (FAB+) 704.5381 (M+H)+ 
(13CiC34H7iN608 requires 704.5367), 703.5348 (M+H)+ (CssHyiNeOs requires 703.5333).
N,N-Bis(3-(3-aminopropylamino)propyI)propane-l,3-diamine hexahydrochloride 
(169)
HC1 gas was bubbled through a stirred solution of 163 (35mg, 0.05mmol) in C H 2CI2 (10ml) for 
20 min. Evaporation, then lyophilisation gave the title compound as a  hygroscopic off-white 
solid (25mg, quant.): 8h  (270M H z, D 2O) 2.05-2.20 (10H, m, C //2CH 2N), 3.08-3.26 (20H, m, 
GH2N).
N - (3-(3-Aminopropyl)-N-(t-butoxycarbonyl) amino) propyl-N-(3-(N-(3-(2-hydroxy- 
3- (oo-methoxyPEG 550) propylamino) propyl) -N-(t-butoxycarbonyl) amino)propyl) - 
N,N-di(-t-butyloxycarbonyl)propane-l,3-diamine (164)
To 163 (537mg, 0.76mmol) in uopropanol (8ml) was added mPEG 550 oxiranylmethyl ether 
(465mg, 0.75mmol) in uopropanol (2ml). The mixture was stirred at 80-90°C for 48h. 
Chromatography (CH2Cl2/M eO H /conc. aqueous N H 3 80:10:1) gave the title compound 
(302mg 32%) as a pale yellow oil; 8H (400MHz; GDGI3) 1.45 (36H, s, Bu% 1.72-1.81 (10H, m, 
C //2C H 2N), 2.67-2.72 (6H, m, C H 2N), 3.14-3.30 (16H, m, C H 2NBoc), 3.38 (3H, s, C H 3O), 
3.45-3.58 {ca. 8H, m, GH20 )  3.62-3.70 {ca. 50H, m, C H 20 ), 3.82 (1H, m, G/fOH); m /z  (FAB+) 
1320 (1%), 1276 (1%), 1232 (1.5%), 1188 (1.5%), 1144 (1%) all (M+H)+.
N - (3- (3-Aminopropylamino) propyl) -N- (3- (3- (3- (2-hydroxy-3- (co-methoxyPEG 
550)propylamino)propylamino)propylamino)propyl)propane-l,3-diamine 
hexahydrochloride (167)
HC1 was bubbled through a stirred solution of 164 (302mg, 0.33mmol) in C H 2CI2 (25ml) for 
20min at room temperature. Evaporation gave an oil which was lyophilised to give the title 
compound (210mg 86%) as a  white wax: 8h  (400MHz; D 2O) 1.93-2.08 (10H, m, C //2CH 2N)
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3.01-3.10 (22H, m, C H 2N), 3.24 (3H, s, CHsO), 3.44-3.52 {ca. 8H, m, C H 20 ), 3.52-3.60 {ca. 








To 163 (845mg, 1.20mmol) in iwpropanol (25ml) was added mPEG 550 oxiranylmethyl ether 
(1.45g, 2.4mmol) in uopropanol (10ml). The mixture was stirred at 65°G for 44h. Evaporation 
and chromatography (CH2Cl2/M eO H  6:1) gave the triPEGylated conjugate^ 6 7mg, 6%) as a 
colourless oil: SH (400MHz, CDC13) 1.45 (36H, s, Bu% 1.73 (10H, m, C //2C H 2N) 2.54 (10H, m, 
C H 2N), 3.15-3.19 (16H, m, C H 2NBoc), 3.38 (9H, s, CHsO), 3.54-3.60 {ca. 20H, m, C H 20 ),
3.60-3.70 {ca. 140H, m, C H 20 ), 3.83 (3H, m, C //O H ); m /z  (MALDI-TOF) 2685 (99%), 2640 
(99%), 2596 (100%), 2551 (100%), 2507 (100%), 2463 (100%), 2419 (99%) all (M+H)+; and the 
diPEGylated conjugate (262mg 12%) as a colourless oil: 5h (400M H z; CDCl3) 1.45 (36H, s, 
BuO, 1.73 (10H, m, G i/2C H 2N), 2.48 (8H, m, C H 2N), 3.10-3.20 (16H, m, C H 2NBoc), 3.38 (6H, 
s, CHsO), 3.45-3.60 {ca. 10H, m, C H 20), 3.61-3.70 {ca. 100H, m, C H 20 ), 3.85 (2H, m, 
C//OH).
N ,N -Bis(3- (3- (2-hydroxy-3- (©-methoxyPEG550) propylamino) 
propylamino) propyl)-propane-1,3-diamine hexahydrochloride (168)
HC1 was bubbled through a stirred solution of 165 (243mg, 0.13mmol) in C H 2C12 (5ml) for 
15min at room temperature. Evaporation gave an oil which was dissolved in water and 
lyophilised to give an off-white foamy solid (220mg, quant.): Sh (400M H z; D20 ) 1.95-2.03 
(10H, m, C //2C H 2N), 3.04 (24H, t, J  7.6Hz, C H 2N), 3.22 (6H, s, CHsO), 3.43-3.48 {ca. 14H, 




To bis(3-aminopropyl)amine (1.40g, 10.7mmol) in dry TH F (20ml) was added 2-(t- 
butoxycarbonyloxyimino)-2-phenylacetonitrile (5.78g, 23.5mmol) in dry T H F (50ml) dropwise 
over 90min, with stirring, at 0°C. The mixture was allowed to warm to room temperature and 
stirred for 40min. Evaporation and chromatography (EtOAc/M eOH 4:1) gave the title 
compound (1.874g, 54%) as a pale yellow solid: mp 70-71°C (lit. [Hu and Hesse, 1996] mp 
82°C); 5h (270M H z, CDCIs) 1.44 (18H, s, Bu% 1.64 (5H, qn, J6 .4 H z , CH2C H 2 and NH), 2.65 
(4H, t, J 6 .4 H z , C H 2N), 3.18-3.27 (4H, m, C H 2NBoc), 5.28 (2H, s, NH); m /z  (FAB+) 333.2580 
(M+H)+ (13C iC i5H 34N 30 4 : requires 333.2583); 332.2548 (M+H)+ (Ci6H 34N 3C>4 requires 
332.2549).
N,N-Bis(3-t-butoxycarbonylaminopropyl)-2-cyanoethylamine (171)
To bis(3-£-butoxycarbonylaminopropyl)amine (1.115g, 3.39mmol) in TH F (10ml) was added 
acrylonitrile (0.5ml, 403mg, 7mmol) and the mixture was stirred at room temperature 
overnight. Acrylonitrile (lml, 806mg,14mmol) was added and the mixture was heated to reflux 
for 60h. Evaporation and chromatography (EtOAc) gave the title compound (1.042g, 80%) as a 
pale yellow oil: 5H (270MHz, CDCIs) 1.44 (18H, s, Bu), 1.64 (4H, qn, J  6.6Hz, C //2C H 2N),
2.45 (2H, t, J  6.9Hz, C H 2CN), 2.48 (4H, t, J  6.7Hz, C H 2N), 2.76 (2H, t, J  7.0Hz, C H 2N), 
3.15-3.22 (4H, m, C H 2NBoc), 5.12 (2H, s, NH); m /z  (FAB+) 386.2853 (M+H)+ 
(13C iC i8H 37N404 requires 386.2848); 385.2818 (M+H)+ (Ci9H 37N 4 0 4  requires 385.2815).
3-Amino-N,N-bis(3-t-butoxycarbonylaminopropyl)propylamine (172)
To 171 (971mg, 2.54mmol) in M eO H  (25ml) was added W-2 Raney nickel (lg, dense slurry in 
water) with M eO H  (10ml). The mixture was cooled to 0°C and ammonia was bubbled through 
for 30min. The mixture was treated with H 2 (60psi) at room temperature for 72h. The catalyst 
was filtered off through Celite. The catalyst and Celite pad were washed with E tO H  (300ml). 
Evaporation of the solvent from the combined filtrate and washings gave a blue-green oil (ca. lg) 
which was used immediately for the next step: 8h (400M H z, CDC13) 1.43 (20H, s, Bu* and 
N H 2), 1.63-1.66 (6H, m, CH2C H 2N), 2.44-2.75 (8H, br m, C H 2N), 3.12-3.20 (4H, br m, 
C H 2NBoc) 5.28 (2H, br s, NH); m /z  (FAB+) 390.3160 (M+H)+ (13C 1C 18H 41N4O 4 requires 
390.3161); 389.3126 (M+H)+ (C19H 41N4O 4 requires 389.3128).
Benzyl N-(3-(N,N-bis(3-t>butoxycarbonylaminopropyI)amino)propyl)carbamate
(176)
To 172 (789mg, 2.04mmol) in C H 2C12 (10ml) was added NEt3 (0.6ml, 436mg). The mixture 
was cooled to 0°C and benzyl chloroformate (0.5ml, 2.5mmol) was added slowly in 4 portions 
with stirring. The mixture was stirred at 0°C for lOmin then at room temperature overnight.
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The mixture was diluted with C H 2CI2 (150ml), washed with water (100ml), then brine (100ml) 
and then dried with MgSCb. Evaporation and chromatography (CH2CI2 then C H ^C b/M eO H  
10:1 then 7:1) gave the title compound (301 mg, 29%) as a colourless oil: 5h  (270M H z, CDCI3) 
1.42 (18H, s, Bu% 1.58-1.65 (6H, m, C //2GH2N), 2.41 (6H, t, J  6.5Hz, C H 2N), 3.12-3.25 (6H, 
m, C H 2NCO), 5.08 (2H, s, PhC H 2), 5.29 (2H, m, NH), 5.90 (1H, br s, NH), 7.30-7.34 (5H, m, 
Ar); m /Z (FAB+) 524.3529 (M+H)+ (13C iC 26H 47N 4 0 6 requires 524.3529); 523.3497 (M+H)+ 
(C27H 47N 4O 6 requires 523.3496).
Benzyl N-(3-(N,N-bis(3-aminopropyl) amino)propyl)carbamate trihydrochloride
(177)
HC1 was bubbled through a solution of 176 (245mg, 0.47mmol) in C H 2CI2 (15ml) at room 
temperature for 30min. Evaporation then lyophilisation gave the title compound (191 mg, 98%) 
as a colourless glass: 8h  (270M H z, D 2O) 1.90-2.00 (2H, m, C //2CH 2N), 2.00-2.21 (4H, m, 
C //2C H 2N), 3.02-3.15 (4H, m, C H 2N), 3.19-3.45 (8H, m, C H 2N), 5.12 (2H, s, PhC H 2), 7.41-
7.45 (5H, m, Ar); m /Z (FAB+) 324.2486 (M+H)+ (^C iC ieH sM C b requires 324.2481); 
323.2454 (M+H)+ (C17H 31N 4O 2 requires 323.2447).
Benzyl N- (3- (N,N-bis(3- (N ,N-bis (2-cyanoethyl) amino) propyl) amino) propyl) 
carbamate (179)
To 177 (181mg, 0.56mmol) in M eO H  (10ml) was added NEt3 (0.24ml, 174mg, 1.7mmol) then 
acrylonitrile (0.06ml, 48mg, 0.9mmol). The mixture was stirred at room temperature overnight. 
Acrylonitrile (0.06ml, 48mg, 0.9mmol) was added and the mixture was stirred at room 
temperature for 48h. Evaporation and chromatography (C ^ C b /M e O H  7:1) gave the title 
compound (80mg, 26%) as a  colourless oil: 8h  (270M H z, CDCI3) 1.68 (6H, qn, J  7.0Hz, 
C //2C H 2N), 2.44 (8H, t, J  6.6Hz, C H 2), 2.55 (10H, t, J  6.8Hz, C H 2), 2.79 (8H, t, J  6.5Hz, 
C H 2), 3.23-3.30 (2H, m, C H 2NCO), 5.09 (2H, s, PhCH 2), 5.81 (1H, m, NH), 7.30-7.37 (5H, m, 
Ar); m /z  (FAB+) 557 [(M+Na)+, 10%], 535 [(M+H)+, 100%] 91 [(C7H 7)+, 40%].
o-Methoxy PEG 550 chloroformate
To mPEG 550 (lO.Og, 0.018mol, previously dried by azeotropic removal of water) in C H 2CI2 
(150ml) was added phosgene {CAUTION! highly toxic, 100ml, 20% solution in toluene). The 
mixture was stirred at room temperature for 48h and then stored in solution in the 
CH 2CI2/toluene/phosgene mixture. An aliquot was removed when required and the solvents 
evaporated to yield a colourless oil: 5h (270M H z , CDCI3) 3.38 (3H, s, C H 3O), 3.54 (2H, m, 
CH 20 ), 3.60-3.70 {ca. 45H, m, GH20 ), 3.78 (2H, m, GH20 ), 4.46 (2H, m, C H 2OCO); m /z  
(FAB+) 777 (8%), 733 (10%), 689 (12%), 645 (14%), 601 (14%), 557 (12%), 513 (8%) all 





To 172 (94mg, 0.24mmol) in C H 2CI2 (5ml) was added NEt3 (0.07ml, 51mg, 0.5mmol) followed 
by mPEG 550 chloroformate (192mg, 0.3mmol). The mixture was stirred at room temperature 
overnight. Evaporation and chromatography (CH^Cb/M eOH 7:1) gave the title compound 
(65mg, 28%) as a colourless oil: 8h  (400MHz, CDCI3) 1.44 (18H, s, Bu% 1.63-1.66 (6H, m, 
C //2CH 2N), 2.44-2.50 (6H, m, C H 2N), 3.12-3.25 (6H, m, C H 2NGO), 3.38 (3H, s, C H 3O), 
3.54-3.56 (2H, m, GH20 ), 3.62-3.70 {ca. 40H, m, C H 20 ), 4.19-4.21 (2H, m, C H 2OCON), 5.27 
(2H, br s, HNBoc), 5.64 (1H, br s, NH); m /Z (FAB+) 1019 (25%), 975 (40%), 931 (46%), 887 
(55%), 843 (57%), 799 (50%), 755 (44%), 711 (30%) all (M+H)+.
co-MethoxyPEG550yl N-(3-(N,N-bis(3-t-butoxycarbonylaminopropyl) 
amino) propyl) carbamate trihydrochloride (175)
HC1 was bubbled through a solution of 174 (38mg, 0.04mmol) in C H 2CI2 (3ml) for 15min. 
Evaporation and lyophilisation gave the title compound (29mg, quant.) as a colourless oil: 8h  
(400MHz, D 20 )  1.75-1.81 (2H, m, CH2CH 2N), 1.92-2.02 (4 H, m, G /f2C H 2N), 2.94 (4H, t, J  
7.7Hz, C H 2N), 3.07-3.16 (8H, m, GH2N), 3.22 (3H, s, C H 3O), 3.46-3.48 (2H, m, GH20 ), 3.54- 
3.61 {ca. 40H, m, GH20 ), 4.06 (2H, m, C H 2CON); m /z  (FAB+) 863 (40%), 819 (54%), 775 
(66%), 732 (81%), 687 (84%), 643 (86%), 599 (72%), 555 (52%), 511 (35%) all (M+H)+.
Bis(3-trifluoroacetamidopropyl) amine (182)
To a solution of bis(3-aminopropyl)amine (15.0g, 0.115mol) in absolute E tO H  (100ml) was 
added ethyl trifluoroacetate (33.4g, 0.235mol) slowly, with stirring, at 0°C. After 20min the 
mixture was allowed to reach room temperature and stirred for a  further 60h. The solvents 
were evaporated and the residue dissolved in EtOAc (500ml) and washed with water (200ml), 
then brine (200ml), then dried with MgSO*. Evaporation gave the title compound (37g, quant.) 
as a pale yellow solid: mp 168-171°C; 8h  (270MHz, CDCI3) 1.74 (4H, qn, J  6.3Hz, 
CH 2CH 2N), 2.73 (4H, t, J  6.3Hz, C H 2N), 3.44 (4H, t, J  6.3Hz, C H 2NCO), 8.67 (2H, br s, 
NH); 8c (68MHz, GDCI3) 27.85 (CH2C H 2N), 39.26 (GH2N), 47.87 (CH2NGO), 116.11 (q, J  
288Hz, CF3), 157.30 (q, J  37Hz, CO); m /z  (FAB+) 325.1192 (M+H)+ (13CiC9Hi6F6N302 
requires 325.1180); 324.1162 (M+H)+ (G10H 16F6N3O 2 requires 324.1146).
Ethyl 6-bromohexanoate (184)
To 6-bromohexanoic acid (lO.Og, 0.05mol) in ethanol (500ml) was added concentrated H 2SO 4 
(4ml). The mixture was heated to reflux for 24h. The solvents were evaporated to low volume 
{ca. 70ml) then diluted with C H 2CI2 (200ml). The solution was washed with water (200ml) and 
then the water layer was extracted with C H 2CI2 (100ml). The pooled organic phases were
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washed with 8% aqueous NaHCC>3 solution (200ml), then with brine (200ml), then dried with 
MgSC>4 . Evaporation followed by kugelrohr distillation gave the title compound (9.95g, 87%) as 
a colourless liquid: bpo.os 125°C (lit. [McHintosh et al, 1983] bpo.13 69-72°C); 8h  (400MHz, 
CDCIs) 1.25 (3H, t, J  7.0Hz, C H 3), 1.48 (2H, qn, J  7.0Hz, C H 2), 1.66 (2H, qn, J  7.0Hz, C H 2), 
1.89 (2H, qn, J  7.0Hz, C H 2), 2.32 (2H, t, J  7.0Hz, C H 2CO), 3.41 (2H, t, J  7.0Hz, C H 2Br), 
4.12 (2H, q, J  7.0Hz, C //2C H 3).
Ethyl 6-(bis(3-trifluoroacetamidopropyl)amino)hexanoate (185)
To bis(3-trifluoroacetamidopropyl)amine (5.00g, 15mmol) in DM F (10ml) was added 
anhydrous K 2CC>3 (2.5g, 18mmol) and ethyl 6-bromohexanoate (3.79g,17mmol). The mixture 
was stirred at 80°C overnight. The solvents were evaporated and the residue taken up in water 
and extracted with C H 2C12 (3x 100ml). The pooled organic phases were washed with brine 
(200ml) then dried with MgSC>4 . Evaporation and chromatography (EtOAc/hexane 10:1) gave 
the title compound (3.03g, 42%) as a colourless oil: 5h  (270MHz, CDCI3) 1.23-1.33 (5H, m, 
C H 3 and C i/2C H 2C H 2N), 1.41-1.52 (2H, m, C //2C H 2CO), 1.58-1.79 (6H, m, C tf2C H 2N),
2.30 (2H, t, J  7.3Hz, C H 2CO), 2.43 (2H, t, J  7.1Hz, C H 2N), 2.54 (4H, t, J  6.4Hz, C H 2N), 
3.40-3.49 (4H, m, C H 2NCO), 4.12 (2H, q, J  7.2Hz, C H 20 ), 8.54 (2H, s, NH); m /z  (FAB-) 464 
[(M-H)~, 100%]; (FAB+) 488 [(M+Na)+, 20%], 467.2175 (M+H)+ (13C iC i7H3oF6N304 requires 
467.2174); 466.2141 (M+H)+ (C18H 30F6N3O 4 requires 466.2141).
t-Butyl N-(2-aminoethyl)carbamate (193)
To ethane-1,2-diamine (3.1ml, 46mmol) in TH F (20ml) was added di-^-butyl dicarbonate 
(500mg, 2.3mmol) in TH F (20ml) dropwise over 15min, with stirring, at room temperature. 
The mixture was stirred at room temperature for a further 3h, then the solvents were 
evaporated. The residue was dissolved in chloroform /M eOH (200ml/3ml) and washed with 
water (2x 200ml) then brine (200ml), then dried with MgSC>4. Evaporation gave the title 
compound (210mg, 57%) as a colourless oil: 5h  (400M H z CDCI3) 1.45 (11H, m, Bul and N H 2), 
2.80 (2H, t, J5 .8 H z , C H 2N), 3.15-3.18 (2H, m, C H 2NBoc), 4.95 (1H, s, NH); m /z  (FAB+) 161 
[(M+H)+, 95%].
6-Bromo-N-(2~ (t-butoxycarbonylamino) ethyl) hexanamide (195)
To 6-bromohexanoic acid (1.535g, 7.87mmoI) in dry C H 2C12 (15ml) was added oxalyl chloride 
(5.0g, 39mmol). The mixture was cooled to 0°C and DM F (2 drops) was added {CAUTION! 
rapid evolution o f gas). The mixture was stirred at 0°C for 30min then at room temperature for 
lOOmin. The solvents were evaporated and dry C H 2C12 (5ml) was added then evaporated. Dry 
C H 2C12 (20ml) was added, then 193 (2.04g, 12.5mmol) and NEt3 (2.5ml, 1.82g) slowly at 0°C. 
The mixture was stirred at 0°C for 30min then at room temperature for 90min. The mixture
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was diluted with C H 2CI2 (100ml) then washed with water (100ml) then brine (100ml) then dried 
with MgSC>4. Evaporation then recrystallisation (EtOAc) gave the title compound (1.795g, 68%) 
as white crystals: mp 104-106°C; 8H (270MHz, CDCI3) 1.44 (9H, s, Bu% 1.44-1.51 (2H, m, 
C //2C H 2C H 2CO), 1.66 (2H, qn, J  7.2Hz, C //2C H 2CO), 1.87 (2H, qn, J  7.2Hz, C tf2C H 2Br), 
2.20 (2H, t, J  7.3Hz, C O C H 2), 3.27-3.37 (4H, m, C H 2NCO), 3.41 (2H, t, J  6.8Hz, C H 2Br), 
5.04 (1H, s, NH), 6.38 (1H, s, NH); m /z  (FAB+) 340.1118 (M+H)+ (13CiCi2H2681BrN203 
requires 340.1139); 339.1097 (M+H)+ (Ci3H 2681BrN203 requires 339.1106); 338.1113 (M+H)+ 
(13CiCi2H2679BrN203 requires 338.1160); 337.1121 (M+H)+ (Ci3H2679BrN203 requires 
337.1127).
6 -(B is (3 -tr if lu o ro ac e tam id o p ro p y l)  am in o )-N -(2 -t-b u to x y carb o n y lam in o eth y l)  
h e x a n a m id e  (196)
Compound 195 (557mg, 1.65mmol), bis(3-trifluoroacetamidopropyl)amine (587mg, 1.82mmol) 
and anhydrous K2C 0 3 (340mg, 2.5mmol) in dry DM F (3ml) were heated to 80°C with stirring. 
After 18h, the solvents were evaporated and the was residue taken up in C H 2CI2 (150ml), then 
washed with water (100ml), then brine (100ml) and then dried with MgSC>4. Evaporation and 
chromatography (EtO Ac/M eO H 10:1, then 7:1, then 5:1) gave the title compound (647mg, 
68%) as a colourless oil: SH (270MHz, CDC13) 1.28-1.33 (2H, m, C //2C H 2C H 2CO), 1.44 (11H, 
m, Bu' and C tf2C H 2CO), 1.61-1.75 (6H, m, C //2C H 2N), 2.18 (2H, t, J  7.3Hz, C H 2CO), 2.41 
(2H, t, J  7.0Hz, C H 2N), 2.51 (4H, t, J  6.6Hz, N C //2C H 2C H 2CO CF3), 3.27-3.43 (8H, m, 
C H 2NCO), 5.06 (1H, s, NH), 6.45 (1H, s, NH), 8.27 (2H, s, N H CO CF3); m /z  (FAB+) 602 
[(M+Na)+, 20%], 581.2970 (M+H)+ (l3C iC 22H 4oF6N 50 5  requires 581.2967), 580.2940 (M+H)+ 
(C23H40F6N5O5 requires 580.2934), (FAB-) 578 [(M-H)‘ , 100%].
<-Butyl N ,N /-b is (3 - tr if lu o ro a c e ta m id o p ro p y l)c a rb a m a te  (200)
To bis(3-trifluoroacetamidopropyl)amine (270mg, 0.84mmol) in CH 2CI2 (5ml) was added di-2- 
butyl dicarbonate (182mg, 0.84mmol) in C H 2CI2 (5ml) slowly, with stirring, at 0°C. The 
mixture was stirred at 0°C for lOmin, then at room temperature for 48h. Evaporation gave the 
title compound (360mg, quant.) as a  colourless oil: 8 h  (400MHz, CDC13, 23°C) 1.47 (9H, s, 
Bu% 1.68-1.86 (4H, m, C /f2C H 2N), 3.25-3.20 (8H, m, C H 2NCO), 6.90 (1H, br s, NH), 8.24 
(1H, br s, NH); 5H (400MHz, CDCIs, -40°C) 1.47 (9H, s, Bu% 1.58-1.63 (2H, m, C //2C H 2N),
1.83 (2H, qn, J  7.4Hz, C //2C H 2N), 3.22 (2H, t, J  7.0Hz, C H 2NBoc), 3.28-3.35 (4H, m, 
C H 2NCO), 3.37 (2H, dt, J 5 .4 ,  7.0Hz, C H 2N H CO CF3), 7.52-7.59 (1H, m, NH), 8.69 (1H, t, J  




t-B uty l N ,N -b is (3 -a m in o p ro p y l)c a rb a m a te  (201)
To 200 (310mg, 0.73mmol) in M eOH (6ml) was added concentrated aqueous ammonia 
solution (3ml). Ammonia was bubbled through the solution for 5min at 0°C, then the mixture 
was heated at 60°C in a sealed bottle for 5h. Evaporation and chromatography 
(CH2Cl2/M eO H /conc. aqueous N H 3 10:5:1) gave the title compound (155mg, 91%) as a 
colourless oil: 8H (400MHz, [2H]6-DMSO) 1.41 (9H, s, Bu), 1.75 (4H, qn, J  7.0Hz, C //2C H 2N), 
2.76 (4H, t, J  7.3Hz, C H 2N), 3.18 (4H, t, J  6.8Hz, C H 2NBoc), 3.38 (4H, br s, N H 2); m /z  
(FAB+) 254 [(M+Na)+, 8%], 232 [(M+H)+, 100%], 132 [(M-Boc +H)+, 64%].
t-B utyl N ,N -b is (3 -(2 -c y a n o e th y lam in o )p ro p y l)c a rb a m a te  (202)
To bis(3-trifluoroacetamidopropyl)amine (3.36g, 10.4mmol) in TH F (50ml) was added di-t- 
butyl dicarbonate (2.27g, 10.4mmol) in TH F (50ml) slowly over 15min at room temperature. 
The mixture was stirred at room temperature for 24h, then the solvents were evaporated. To 
the residue in M eOH (100ml) was added concentrated aqueous ammonia solution (50ml), then 
ammonia was bubbled through the solution for 30min at 0°C. The mixture was stirred at room 
temperature in a sealed bottle for 72h. Evaporation and chromatography (CH2CI2/  
M eO H /conc. aqueous N H 3  10:5:1) gave a colourless oil {ca. 2.4g) which was dissolved in 
M eOH (50ml). Acrylonitrile (1.5ml, 1.21 g, 23mmol) in M eO H  (10ml) was added slowly at 
room temperature. The mixture was stirred at room temperature for 40h. The solvents were 
evaporated and the residue was dissolved in CH 2CI2 (200ml) and washed with water (100ml), 
then brine (100ml), then dried with MgS0 4 . Evaporation gave a colourless oil (800mg), fraction
A.
Evaporation of the water from the aqueous layer gave an oily residue {ca. 2g), to this, in M eOH 
(30ml), was added acrylonitrile (0.6ml, 484mg, 9 .lmmol) in M eOH (10ml). The mixture was 
stirred at room temperature for 40h then acrylonitrile (1.2ml, 967mg, 18.2mmol) was added 
and stirring was continued for a further 48h. Anhydrous K 2C O 3 (1.5g, 10.9mmol) was added 
and the mixture was stirred at room temperature for 14h. The solvents were evaporated and the 
residue was taken up in C H 2CI2 (200ml), washed with water (150ml), then brine (150ml) and 
then dried with MgSO*. Evaporation gave a pale brown oil (ca 1.2g) fraction B.
Fraction A and fraction B were combined. Chromatography (C ^ C b /M e O H  4:1 then 3:1) 
gave the title compound (1.04g, 30%) as a pale yellow oil: 8 h  (270MHz, CDCI3) 1.46 (9H, s, 
BuO,1.71-1.73 (6H, m, C //2C H 2N and NH), 2.50 (4H, t, J  6.5Hz, C H 2CN), 2.63 (4H, t, J  
6.6Hz, N C //2C H 2CN), 2.89 (4H, t, J  6.6Hz, C H 2N), 3.20-3.32 (4H, m, C H 2NBoc); m /z  
(FAB+) 339.2588 (M+H)+ pC iC ie lfeN sC b  requires 339.2589); 338.2566 (M+H)+ 
(C17H 32N 5O 2 requires 338.2556); 238 [(M-Boc +H)+ 56%].
180
Chapter 9: Experimental
t-B utyl N ,N -b is (3 -(3 -a m in o p ro p y la m in o )p ro p y l)c a rb a m a te  (203)
To 202 (l.OOg, 3.0mmol) in M eOH (20ml) was added W-2 Raney nickel (lg, dense slurry in 
water). Ammonia was bubbled through the mixture for 30min at 0°C. The mixture was treated 
with H 2 (60psi) at room temperature for 60h. The catalyst was filtered off through Celite. The 
Celite pad and catalyst were washed with M eOH (300ml). Evaporation of the combined filtrate 
and washings gave a blue oil {ca. lg) which was used in the next step without purification.
t-B uty! N ,N -b is(3 -(N -benzy loxycarbony l-N -(3 -benzy loxycarbony lam inop ropy l) 
a m in o p ro p y l) )c a rb a m a te  (204)
To 203 {ca. lg) in TH F (20ml) was added dibenzyl dicarbonate (4.23g, 15mmol) in T H F (10ml) 
in 10 portions, with stirring, at 0°C. The mixture was stirred at 0°C for 20min then at room 
temperature for 36h. Evaporation and chromatography (EtOAc/hexane 1:1, then 2:1) gave the 
title compound (1.57g, ~60%) as a colourless oil: § h  (270MHz, CDCI3) 1.40 (9H, s, Bu(), 1.61-
1.78 (8H, m, C //2CH 2N), 3.05-3.38 (16H, m, C H 2NCO), 5.09 (8H, s, PhC H 2), 5.68 (2H, br s, 
NH), 7.28-7.36 (20H, m, Ar); m /z  (FAB+) 904 [(M+Na)+, 16%], 883.4661 (M+H)+ 
(13CiC 48H 64NsOio requires 883.4687); 882.4646 (M+H)+ (C49H 64N 5O 10 requires 882.4653), 
782 [(M -Boc+H )+, 100%].
B is(3 -(N -benzy loxycarbony l-N -(3 -benzy loxycarbony l)am inop ropy l) 
a m in o p ro p y l)  a m in e  (205)
HC1 was bubbled through a solution of 204 (1.327g, 1.51mmol) in CH 2CI2 (40ml) for 30min at 
room temperature. The solvents were evaporated, the residue was dissolved in M eO H  (10ml) 
and aqueous 5M N aO H  (0.9ml) was added. Evaporation gave an oily residue which was taken 
up in C H 2CI2 (200ml), washed with water (100ml), then brine (100ml) and then dried with 
MgS0 4 . Evaporation gave the title compound (1.074g, 91%) as a  colourless oil: 8h (270MHz, 
CDCI3) 1.55-1.77 (8H, m, C //2C H 2N), 2.10 (1H, br s, NH), 2.40-2.58 (4H, m, C H 2N), 3.06- 
3.39 (12H, m, C H 2NCbz), 5.10 (8H, s, PhCH 2), 5.69 (2H, br s, NH), 7.30-7.35 (20H, m, Ar); 
m /z  (FAB+) 783.4168 (M+H)+ (isC ^sH seN sO a requires 783.4162); 782.4139 (M+H)+ 
(C44H 56N 5O 8 requires 782.4129).
B is(3 -(N -benzy loxycarbonyl-N -(3-benzy loxycarbonyl) a m in o p ro p y l)  a m in o p ro p y l)  
am ine-N -(2 - (t-b u to x y c arb o n y la m in o ) ethyl) h e x a n a m id e  (206)
To the amine 205 (1.074g, 1.38mmol) in dry DM F (4ml) was added anhydrous K 2C O 3 (285mg, 
2mmol) and 195 (693mg, 2.1 mmol). The mixture was stirred at 85°C for 20h, then the solvents 
were evaporated. The residue was taken up in C H 2CI2 (200ml), then washed with water( 100ml), 
then brine (100ml) and then dried with MgSC>4. Evaporation then chromatography 
(EtOAc/M eOH 6:1, then 4:1) gave the title compound (965mg, 67%) as a colourless oil: 8 h
181
Chapter 9: Experimental
(400MHz, CDCI3) 1.24-1.42 (4H, m, C //2C tf2C H 2CO), 1.42 (9H, s, Bu% 1.59-1.68 (10H, m, 
C tf2C H 2N), 2.12-2.16 (2H, m, CH2CO ), 2.25-2.40 (6H, m, C H 2N), 3.15-3.29 (16H, m, 
C H 2NCO), 5.10 (8H, s, PhC H 2), 5.74 (1H, m, NH), 6.43 (1H, m, NH), 7.31-7.33 (20H, m, Ar); 
8c (100MHz, CDCI3) 25.24, 25.57, 25.84, 26.10, 26.44, 26.98, 28.10 (CH2), 28.37 (CH3), 
28.91, 36.41, 37.69, 38.28, 40.38, 44.38, 45.24, 46.01, 51.17, 51.28, 53.44 (CH2), 66.50, 67.15 
(PhCH2), 79.52 (Boc C), 127.80, 128.05, 128.31, 128.47 (Ar CH), 136.01, 136.50, 136.74 (Ar 
C), 156.02, 156.58, 156.91 (CO, carbamates), 173.74 (CO, amide); m /z  (FAB+) 1040.5960 
(M+H)+ (13C2C55H8oN?Oii requires 1040.5983); 1039.5912 (M+H)+ (13CiC56HeoN70n requires 
1039.5949); 1038.5893 (M+H)+ (C57H 80N 7OH requires 1038.5915).
B is(3- (N -benzy loxycarbony l-N -(3 -benzy loxycarbony l) a m in o p ro p y l)  a m in o p ro p y l)  
am in e -N - (2 -am inoethy l) h e x a n a m id e  (207)
HC1 was bubbled through a solution of 206 (860mg, 0.83mmol) in C H 2CI2 (25ml) for 30min at 
room temperature. The solvents were evaporated, the residue was dissolved in M eO H  (20ml) 
and aqueous 5M N aO H  (0.66ml) was added. Evaporation gave an oily residue which was taken 
up in C H 2CI2 (200ml), washed with water (100ml), then brine (100ml) and then dried with 
MgSCb. Evaporation gave the title compound (676mg, 87%) as a  colourless oil: 8 h  (400MHz, 
CDCI3) 1.25-1.33 (4H, m, C //2C //2C H 2CO), 1.61-1.68 (10H, m, CJ72C H 2N), 2.03-2.16 (4H, 
m, C //2N H 2 and G tf2CO), 2.25-2.35 (6H, m, C H 2N), 2.78 (2H, s, N H 2), 3.15-3.26 (14H, m, 
C H 2NCO), 5.10 (8H, s, PhCH2), 5.75-5.77 (1H, m, NH), 6.26-6.29 (1H, m, NH), 7.31-7.33 
(20H, m, Ar); m /z  (FAB+) 939.5412 (M+H)+ (i3C iC 5iH 72N 70 9  requires 939.5425); 938.5383 
(M+H)+ (C52H 72N 7O 9 requires 938.5391).
co-M ethoxyPEG 550yl N -(2-(6-(N ,N -bis(3-(N -benzyloxycarbonyl-N -(3- 
b en zy lo x y c a rb o n y la m in o p ro p y l)  am in o ) p ropy l) am in o ) h e x a n a m id o )  ethyl) 
c a rb a m a te  (208)
To 207 (408mg, 0.44mmol) in C H 2CI2 (6ml) was added mPEG 550 chloroformate (320mg, 
0.5mmol) and NEt3 (145pi, 105mg) at 0°C. The mixture was stirred at 0°C for 5min then at 
room temperature for 3h. Further mPEG 550 chloroformate (45mg, 0.07mmol) in CH 2CI2 
(lml) was added and the mixture was stirred at room temperature for 4h. Evaporation and 
chromatography (CH2Cl2/M eO H  20: 1 then 10:1) gave the title compound (274mg, 42%) as a 
colourless oil: SH (400MHz, CDCI3) 1.25-1.38 (4H, m, C7/2C //2C H 2CO), 1.60-1.70 (10H, m, 
C //2C H 2N), 2.13-2.16 (2H, m, C H 2CO), 2.24-2.38 (6H, m, C H 2N), 3.15-3.31 (16H, m, 
C H 2NCO), 3.38 (3H, s, OCHs), 3.53-3.56 (2H, m, C H 2O), 3.62-3.82 (ca. 40H, m, C H 20), 
4.17-4.20 (2H, m, C H 2OCO), 5.10 (8H, s, PhCH 2), 5.51-5.53 (1H, m, NH), 5.71 (1H, m, NH), 
7.32-7.34 (20H, m, Ar); m /z  (FAB+) 13C / 12C peak cluster centred at 1481 (3%), 1438 (4%), 
1393 (5%), 1349 (6%), 1305 (6%), 1261 (5%), 1217 (4%) all (M+H)+.
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co-M ethoxyPEG 550yl N -(2 -(6 -(N ,N -b is(3 -(3 -am inop ropy lam ino ) p ropy l) 
am ino ) h e x a n am id o ) ethyl) c a rb a m a te  p e n ta h y d ro c h lo r id e  (209)
To 208 (75mg) in M eOH (5ml) was added Pearlman’s catalyst (50mg). The mixture was treated 
with H 2 (60psi) at room temperature for 40h. The mixture was diluted with M eOH (10ml) and 
the catalyst was filtered off. Aqueous 5M HC1 (2ml) was added then evaporated. Lyophilisation 
gave the title compound (57mg, quant.) as a colourless foam: 8 h  (400MHz, D 2O) 1.37 (2H, qn, 
J  7.0Hz, C //2C H 2C H 2CO), 1.60-1.71 (4H, m, C H 2), 2.06-2.15 (8H, m, C //2CH 2N), 2.27 (2H, 
t, J  7.0Hz, C H 2CO), 3.09-3.30 (22H, m, C H 2N CO and C H 2N), 3.38 (3H, s, C H sO), 3.62-3.66 
(2H, m, CHsO), 3.70-3.75 {ca. 40H, m, C H 20 ), 4.21-4.23 (2H, m, C H 2OCO); m /z  (FAB+) 944 
(15%), 900 (22%), 856 (32%), 812 (35%), 768 (30%), 724 (30%), 680 (22%) all (M+H)+.
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